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1.General introduction
Hematological malignancies, such as leukemia, are life-threatening diseases that find their 
origin in a derailment of the hematopoietic system. Allogeneic stem cell transplantation (SCT) 
is often the final treatment modality in which the patient is transplanted with hematopoietic 
stem cells (HSCs) from an allogeneic donor that give rise to a new and healthy hematopoietic 
system. After SCT, residing tumor cells are eradicated by donor-derived T cells (GVL reactivity). 
However, these alloreactive T cells may also provoke strong graft-versus-host reactivity against 
healthy host tissues. This often leads to graft-versus-host disease (GVHD), which can result 
in mortality. Although HLA-matching between donor and recipient has strongly decreased the 
occurrence of GVHD, other immunogenic factors may still trigger donor T cell alloreactivity. 
Therefore, immunotherapeutic strategies augmenting GVL reactivity while reducing GVHD are 
urgently needed. Recently, natural killer (NK) cells have been described to provoke efficient GVL 
reactivity without the induction of GVH responses. This makes NK cells important candidates to 
exploit for adoptive immunotherapeutic strategies in leukemia treatment, which is the focus of 
this thesis.
2.The hematopoietic system
2.1 Hematopoiesis
The development of the human blood compartment, termed hematopoiesis, is a highly coordinated 
process by which pluripotent hematopoietic stem cells (HSCs) give rise to the functional mature 
hematopoietic system consisting of red blood cells (i.e. erythrocytes), white blood cells (i.e. 
lymphocytes, granulocytes, monocytes) and platelets. As mature hematopoietic cells have a 
limited life-span, hematopoiesis is a continuous process throughout life.1 Besides giving rise to 
mature functional hematopoietic cells, HSCs are capable of self-renewal to maintain the pool of 
pluripotent progenitors.
Hematopoiesis can be described as a hierarchical process that is tightly regulated and starts 
in the bone marrow (Figure 1). The HSC population consists of long-term HSCs (LT-HSCs) 
which give rise to short-term HSCs (ST-HSCs).2 Both populations are capable of self-renewal. 
ST-HSCs differentiate into a multi-potent progenitor (MPP) population that has no capacity of 
self-renewal. MPPs further develop into two early committed progenitor lineages; the common 
lymphoid progenitor (CLP) and the common myeloid progenitor (CMP). The CLP lineage gives 
rise to the mature lymphocyte population consisting of NK, T and B cells.3 The CMP lineage 
further differentiates into granulocyte/macrophage progenitors (GMPs) and megakaryocyte/ 
erythrocyte progenitors (MEPs).4 However, the hierarchical relationship between MEP and other 
progenitors is now under debate as it has recently been suggested that MEPs may directly arise 
from MPPs.5 MEPs further differentiate into erythrocytes and megakaryocytes, the latter giving 
rise to platelets. The GMP lineage gives rise to mature monocytes, macrophages, dendritic cells
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and granulocytes (i.e. neutrophils, eosinophils and basophils). The hematopoietic progenitor for 
dendritic cells, however, remains controversial as these cells can arise from both myeloid and 
lymphoid progenitors.6;7
o o
LT-HSC ST-HSC MPP
Figure 1. Human hematopoiesis. The hematopoietic system originates from hematopoietic stem cells (HSCs) that 
reside in bone marrow. Long-term HSCs (LT-HSC) and short-term HSCs (ST-HSC) either undergo self-renewal or 
differentiate into multi-potent progenitors (MPP) that give rise to common lymphoid progenitors (CLP) and common 13 
myeloid progenitors (CMP). CLPs differentiate into mature NK, T and B cells. CMPs further differentiate into multi­
lineage progenitors giving rise to granulocytes and macrophages (GMP), and megakaryocytes and erythrocytes 
(MEP).
During hematopoiesis, the proliferation potential and life-span of cells decreases. The functional 
mature white blood cells collectively function as the immune system that provides protection and 
defense against pathogens and malignant-transformed cells.
2.2  Leukemia
The balance between HSC self-renewal and differentiation towards the various hematopoietic 
cell lineages is considered to be critical to maintain hematopoietic homeostasis.8-10 Fate decisions 
of HSCs on life and death, self-renewal and differentiation are important processes that play a 
crucial role in the regulation of HSC numbers and their lifespan. Defects in these processes can 
contribute to hematopoietic insufficiencies and the development of hematological malignancies, 
such as leukemia.
Leukemia is a type of blood cancer that starts in the bone marrow and is characterized by an 
abnormal accumulation of malignant hematopoietic cells (leukemic cells). These leukemic cells 
are arrested in their hematopoietic development and proliferate faster than normal hematopoietic 
cells. As a result, leukemic cells colonize the available space in bone marrow and hamper
General introduction
CHAPTER 
1
normal hematopoiesis resulting in reduced numbers of healthy progenitor cells. If untreated, 
leukemic cells overwhelm the bone marrow, enter the blood stream, and eventually invade 
other compartments of the human body, such as lymph nodes, spleen, liver, and the central 
nervous system. The most common types of leukemia are acute myeloid leukemia (AML), 
acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and chronic lymphocytic 
leukemia (CLL).11 Acute leukemias are characterized by a rapid progression and accumulation 
of immature malignant-transformed hematopoietic cells (myeloblasts or lymphoblasts). Chronic 
leukemias usually progress slowly as compared with acute leukemias and the malignant clone 
originates from a more mature hematopoietic cell population. Treatment modalities often include 
chemotherapy, radiation, and/or allogeneic stem cell transplantation.
3.Allogeneic stem cell transplantation
3.1 General procedure
Allogeneic stem cell transplantation (SCT) is an intensive but often final treatment modality for 
patients with leukemia or other life-threatening hematological malignancies.12;13 For allogeneic 
SCT, bone marrow has been the traditional source of donor-derived hematopoietic stem cells 
(donor HSCs).13;14 However, donor HSCs are now usually mobilized into the peripheral blood 
using hematopoietic growth factors like G-CSF, followed by leukapheresis.15 The use of these 
mobilized donor peripheral blood stem cells (donor PSCs) is associated with better engraftment 
and hematological recovery after SCT without increased risk of graft-versus-host disease 
(GVHD).16;17 Umbilical cord blood harvested at the time of delivery is also a source for donor
HSCs.18-20
Before transplantation, patients receive a severe myeloablative conditioning regimen with high 
dose chemo-radiotherapy, often combined with total body radiation (TBI), in order to eradicate all 
non-malignant patient-derived hematopoietic cells and the majority of tumor cells to ensure proper 
engraftment of the donor HSCs and to decrease the tumor burden in the patient. After conditioning, 
donor HSCs are transfused into the patient to give rise to a new hematological and immunological 
system resulting in complete donor chimerism and the induction of an immune mediated graft- 
versus-leukemia (GVL) response by donor T cells against residing tumor cells. As an alternative 
to the severe myeloablative conditioning regimen, a reduced intensity nonmyeloablative 
conditioning (RIC) regimen can be used prior to transplantation followed by a donor lymphocyte 
infusion (DLI) after SCT.21-23 Following transplantation, patients are strictly monitored and treated 
with immunosuppressive drugs to prevent GVHD .24-28 Once engraftment has been secured and 
no severe GVH reactions have occurred within the first months after SCT, immunosuppressive 
treatment can be tapered. Nevertheless, patients remain vulnerable for microbial and viral 
infections, and the development of chronic GVHD. Besides these complications, patients may 
still risk relapse of their underlying hematological malignancy. The basis for transplant related 
complications, such as GVHD, lies within the tissue compatibility between donor and recipient.
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3.2 Immunobiology
3.2.1 Alorecognition
Allorecognition is an immune process that is orchestrated by human leukocyte antigens (HLA). 
They provide the human immune system the ability to discriminate between “self” and “non­
self”, and regulate immune responsiveness to foreign invaders (e.g. bacteria, viruses, fungi) and 
malignant -transformed cells. HLA molecules are highly polymorphic proteins and are encoded 
by the HLA complex.
3.2.2 The HLA complex
The HLA complex, also known as the major histocompatibility complex (MHC) in mice, is a gene 
cluster located at chromosome 6 and is the most polymorphic region in the human genome. HLA 
molecules are encoded in two regions of the HLA complex: the class I and class II region (Figure 
2). The HLA class I region encodes the classical HLA-A, -B, -C molecules (class Ia) and the 
nonclassical HLA-E, -F, -G molecules (class Ib). They contain a highly polymorphic heavy chain 
(45 kDa), consisting of three a subunits, which is noncovalently associated to the nonpolymorphic 
ß2-microglobulin (ß2m) chain (12 kDa).29 The ß2m chain is encoded by a gene located on 
chromosome 15 outside the HLA complex. HLA class I molecules present endogenously-derived 
antigenic peptides to cytolytic CD8+ T cells. The classical HLA-A, -B, and -C antigens are expressed 
on the cell surface of all nucleated cells and are therefore considered important for transplantation 
immunobiology, whereas the nonclassical HLA-E, -F, and -G antigens show a more limited tissue 
distribution and their significance for transplantation immunobiology is still unclear. The genes 
of the HLA class II region encode HLA-DR, -DQ, and -DP molecules consisting of two highly 
polymorphic chains (a and ß) that each contain 2 subunits. Both HLA class II chains are encoded 
within the HLA complex. The HLA class II molecules are mainly expressed by antigen-presenting 
cells (APCs), such as monocytes, dendritic cells and B cells. These cells take up foreign antigens 
from the extracellular fluid. After processing, exogenous-derived antigenic peptides are loaded on 
HLA class II molecules and presented to helper CD4+ T cells.
15
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Figure 2. HLA class I and class II molecules. HLA molecules are important for allorecognition and discrimination 
between “self” and “non-self” . HLA class I molecules each consist of a highly polymorphic heavy chain (45 kDa), 
which is noncovalently associated with ß2m. They present endogenous-derived antigenic peptides to CD8+ T 
cells. HLA class II molecules each consist of two highly polymorphic heavy chains and present exogenous-derived 
antigenic peptides to CD4+ T cells.
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3.2.3 Development of GVHD
In allogeneic SCT, the immune system derived from the donor can recognize healthy host cells 
as “non-self”, resulting in GVH reactions that contribute to GVHD. The development of GVHD 
can be described in three sequential phases: (1 ) induction of “danger” signals; (2) activation, 
expansion, and differentiation of donor T cells; and (3) migration of donor T cells and recruitment 
of other effector cells followed by the destruction of host tissues (Figure 3).
Figure 3. Development o f graft-versus-host disease (GVHD). GVHD development can be described in three 
sequential phases: (1) induction of “danger” signals due to host tissue damage by the conditioning regimen prior to 
allogeneic SCT and the activation of host APCs; (2) activation, expansion, and differentiation of alloreactive donor T 
cells; and (3) migration of alloreactive donor T cells and recruitment of other effector cells followed by the destruction 
of host tissues (GVHD) and graft-versus-leukemia (GVL) reactivity.
In phase 1 , due to the toxic conditioning regimen prior to allogeneic SCT, damaged host tissues 
respond by producing “danger” signals, including proinflammatory cytokines (e.g. TNF-a, IL-
1, IL-6) and chemokines, leading to increased expression of allogeneic HLA molecules, co­
stimulatory molecules, and adhesion molecules, and activation of host APCs.3031 Phase 2 starts 
with the activation of donor T cells by host APCs expressing allogeneic HLA molecules and 
co-stimulatory molecules.3233 Donor CD4+ T cells recognize allogeneic HLA class II molecules 
presented by host APCs and are activated through co-stimulatory B7/CD28 interactions. 
Activation of these cells leads to the production of proliferative cytokines (e.g. IL-2) resulting 
in clonal expansion and differentiation into Th1 or Th2 cells (defined by the cytokines that they 
produce). These cells have been associated with differences in GVHD severity.34;35 Donor CD8+ 
T cells directly recognize allogeneic HLA class I molecules and become activated through 
co-stimulatory CD40/CD40L interactions. For proper activation and expansion, donor CD8+ T 
cells require allorecognition of host APCs and cytokine stimulation by activated donor CD4+ T 
cells.33 Allorecognition of host APCs by donor T cells is critical for GVHD initiation and occurs 
despite the early disappearance of host APCs post-SCT.3233 Donor-derived APCs are then able 
to further augment CD8+ T cell-mediated GVHD, presumably by acquiring and presenting host 
antigens (cross-priming).36 Phase 3 is characterized by the migration of the activated donor T 
cells towards GVHD target tissues (gut, skin, liver, and lung), followed by the recruitment of other
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donor effector cells (e.g. monocytes, B cells, NK cells), resulting in subsequent tissue injury.37 
During this phase GVL reactivity also takes place. Target tissue destruction and GVL reactivity 
are mediated through cell surface and soluble effector molecules (i.e. FasL, TNF-a, TRAIL, 
perforin, granzymes, IFN-y). Subsequently, tissue damage leads to increased production of 
proinflammatory cytokines inducing GVHD continuation and further aggravation of the disease 
counterbalancing successful outcome of GVL reactivity.
3.3  HLA-m atching to limit GVHD
As the incidence of acute GVHD is directly associated with the degree of mismatch between 
HLA molecules, accurate matching of HLA alleles between donor and recipient is essential. 
Development of high-resolution screening techniques have allowed transplantation centers 
to enhance the level of HLA-matching for HLA-A, -B, -C, -DR, and DQ, which contributes to 
improved engraftment and better overall survival after allogeneic SCT.38-40 In some cases, an 
isolated HLA-C mismatch between donor and recipient may be allowed, depending on the 
transplantation setting and the type and stage of the malignancy.41-43 The relevance of additional 
HLA-DP matching on clinical outcome is still under debate, but is currently not used as a matching 
criterion for donor selection.44-47 Although the golden standard is to aim for full HLA compatibility 
between donor and recipient, development of functional cellular tests have demonstrated that 
certain HLA mismatches may be functionally less immunogenic and do not necessarily result 
in poor clinical outcome (referred to as “permissible mismatches”).42;48 Given the increasing 
number of identified HLA alleles, this extends the pool of potential donors for patients that lack 
a fully HLA-identical sibling donor.
3.4  Balancing between GVHD and GVL
Despite HLA compatibility between donor and recipient, substantial numbers of patients still 
develop GVHD, due to genetic differences that lie outside the HLA complex, known as minor 
histocompatibility antigens (mHAgs).49-51 Minor HAgs are immunogenic peptides encoded by 
polymorphic genes and are presented by HLA class I and II molecules on the cell surface where 
they can be recognized by donor T cells.52-55 Removal of donor T cells from the graft may prevent 
mHAg-induced GVHD. However, radical T cell depletion increases the risk of graft failure and 
delayed immunological recovery.56;57 The use of partially or repleted T cell grafts in combination 
with RIC regimens has resulted in durable engraftment in sibling and voluntary unrelated donor 
(VUD) transplantations while significantly reducing the risk for GVHD. The reduced antitumor 
activity related to such protocols necessitates the use of pre-emptive DLI infusions, consisting of 
donor T cells, to promote GVL reactivity.2358-60 The efficacy and curative effect of DLI has been 
demonstrated in a variety of hematopoietic malignancies.61 Nevertheless, relapse may still occur 
depending on the sensitivity of the malignancy to the effects of DLI. Furthermore, escalating 
doses of DLI to boost GVL reactivity increase the risk for GVHD. Therefore, strategies for adoptive 
immunotherapy augmenting GVL reactivity and reducing GVHD are urgently needed. There is
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increasing evidence that donor T cells that mediate GVHD are not the only effectors of GVL 
and that GVHD and GVL may be separable. NK cells are one of the potential candidates for 
immunotherapeutic use and are currently exploited for NK cell-based immunotherapy, which is 
the focus of this thesis.
4. Natural Killer cells
4.1 General
NK cells are members of the innate immune system. They are important in the initial phase of 
defense against infections and play an important role in tumor surveillance. Their name was 
based on their ability to kill target cells without prior sensitization.62;63 As they are morphologically 
recognized as relatively large lymphocytes containing azurophilic granules they have also been 
known as large granular lymphocytes (LGL).64 NK cells comprise approximately 5-15% of the 
peripheral blood lymphocyte (PBL) population and are also found in lymph nodes, spleen, bone 
marrow, lung, liver, intestine, omentum and placenta.65 NK cells are believed to originate from 
the same common lymphoid progenitor lineage as T and B cells in bone marrow.66 However, they 
do not rearrange T cell receptor genes or immunoglobulin (Ig) like, respectively, T and B cells do. 
Resting NK cells can be recognized based on their expression of CD56 (neural cell adhesion 
molecule; NCAM). Since CD56 is also expressed by other immune cells, NK cells are identified 
by the expression of CD56 combined with the lack of CD3, which are both present on NK-T cells. 
NK cells can be further characterized based on their expression of CD56 in combination with 
CD16, a low affinity Fc receptor (Figure 4 ).67 In peripheral blood, approximately 90% of NK cells 
shows low expression of CD56 and high expression of CD16 on the cell surface. These cells 
are collectively referred to as the CD56dimCD16+ or CD56dim NK cell subset. The other 10% of 
NK cells shows a high level of CD56 expression and almost no expression of CD16 on the cell 
surface. Together, these cells are known as the CD56brightCD16+/- or CD56bright NK cell subset. 
The CD56dim NK cell subset is characterized by a highly cytolytic behavior towards target cells, 
whereas CD56bright NK cells abundantly produce cytokines, such as IFN-y and TNF-a, upon 
activation. The production of cytokines by NK cells influences the Th1/Th2 bias of the adaptive 
immune response by activating Th1 cells. Thereby, NK cells form a bridge between innate and 
adaptive immunity.68
NK cells lyse susceptible target cells (e.g. virus-infected cells, malignant-transformed cells) 
by one of two mechanisms: “natural killing” (no prior sensitization) or antibody dependent 
cellular cytotoxicity (ADCC). Natural killing is initiated by activating signals from a variety of 
stimulatory receptors that can be inhibited by a variety of inhibitory receptors. In ADCC, the 
activating receptor FcRyIII (CD16) binds to the Fc piece of antibodies bound to target cells. In 
both mechanisms, target cells are lysed by the release of cytolytic proteins (i.e. granzymes and 
perforines) or by the induction of apoptosis.69
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Figure 4. Natural kille r cell subsets. NK cells can be divided in two major subsets based on their expression of 
CD56 and CD16. CD56bn9ht NK cells have a high CD56 and low CD16 expression profile, and are specialized in 
cytokine secretion (e.g. TNF-a, IFN-y). In addition, they highly express inhibitory receptor NKG2A. CD56dm NK cells 
have a low CD56 and high CD16 expression profile, and are highly cytolytic. Their function is predominantly inhibited 
through KIR.
4.2 NK cell receptors
The NK cell receptor repertoire forms the basis for NK cell immune surveillance and NK 
cell activity. NK cell immune surveillance is regulated through the recognition of HLA class I 
molecules by inhibitory receptors. Subsequent activation of NK cells is triggered through the 
recognition of activating ligands by stimulatory receptors.
4.2.1 Inhibitory receptors
NK cells survey potential target cells for the absence or loss of expression of classical HLA class 
I molecules or non-classical HLA class I specific signals through inhibitory killer immunoglobulin­
like receptors (KIRs) and lectin-like receptors.7071 The cytoplasmic domains of all inhibitory 
NK cell receptors contain an immunoreceptor tyrosine-based inhibitory motif (ITIM ).72-74 These 
domains recruit intracellular tyrosine phosphatases SHP-1 or SHP-2 that mediate the inhibition 
of cytotoxicity and cytokine release.72;73;75;76
The lectin-like receptor complex CD94/NKG2A forms an inhibitory receptor that recognizes non­
classical HLA-E molecules.77 As the expression of HLA-E is promoted by the binding of signal 
sequence-derived peptides from HLA class I molecules, it is thought that HLA-E expression 
serves as a barometer of classical HLA class I expression.78 The purpose of the inhibitory CD94/ 
NKG2A receptor complex may, therefore, be to monitor the overall HLA class I expression. KIRs, 
on the other hand, allow for a more subtle immune surveillance as these receptors scan the 
presence of specific classical HLA class I molecules.
KIRs are encoded by a family of polymorphic and highly homologous genes, and recognize 
polymorphic epitopes present on HLA-A, -B, or -C molecules; HLA-A3 and -A11 are recognized 
by KIR3DL2, HLA-Bw4 is recognized by KIR3DL1 and receptors KIR2DL1, KIR2DL2, and 
KIR2DL3 are able to distinguish HLA-C into HLA group C1 and HLA group C2 molecules.79 The
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various KIRs are classified by the number of immunoglobulin-like (Ig) extracellular domains as 
2-domain (2D) or 3-domain (3D). They are further subdivided on the basis of the length of their 
cytoplasmic tail in L (long) or S (short).80 Different KIRs sharing the same number of Ig domains 
and length of the cytoplasmic tail are distinguished by number at the end of their name, e.g. 
KIR2DL2 or KIR2DL3. KIRs are clonally distributed among NK cells within each individual, which 
creates a complex combinatorial repertoire of NK cell specificities for HLA class I molecules.80
4.2.2 Stimulatory receptors
Some members of the CD94/NKG2 receptor and KIR family have stimulatory properties. NKG2C 
is a stimulatory member of the CD94/NKG2 family and competes with CD94/NKG2A for the 
recognition of HLA-E.7781 KIR2DS and KIR3DS are stimulatory members of the KIR family.82-84 
Instead of ITIM, these stimulatory receptors contain a positively charged amino acid residue in 
their transmembrane domain that associates with the negatively charged DAP-12 molecule. 
DAP-12 contains an immunoreceptor tyrosine-based activating motif (ITAM).85 There is evidence 
that the stimulatory KIRs bind self-HLA class I molecules with lower affinity as compared with the 
inhibitory receptors.8687 Thus autoimmunity can be prevented by a balance towards negative NK 
cell regulation. Similar to the inhibitory receptors, the HLA class I-specific stimulatory receptors 
are expressed in a variegated and predominantly stochastic fashion by NK cells.88 
Besides stimulatory members of the CD94/NKG2 receptor and KIR family, NK cells also express 
a variety of other stimulatory receptors. The biological roles of many of these receptors are not 
well understood, primarily because the ligands for these receptors have not been fully identified. 
The main triggering receptors for NK cell activity are the natural cytotoxicity receptors (NCR) and 
NKG2D .89-92 Their stimulation causes direct killing of target cells and their stimulatory signals can 
even override the inhibition of NK cells.
NCR consist of three members; NKp30, NKp44, and NKp46. NCR belong to the immunoglobulin 
superfamily and molecular cloning of NCR confirmed that they are structurally distinct.9394 The 
ligands for NCR remain controversial. Some groups have proposed viral antigens as being the 
ligands for NCR based on their role in the lysis of virus-infected cells.91;92;95 NCR have also 
been shown to mediate lysis of tumor cells and that NK cells with a NCRdu" phenotype are 
unable to kill tumor cells, suggesting that their ligands may be upregulated or induced upon 
malignant transformation of cells.96-98 NKp30 and NKp46 are both uniquely expressed on resting 
and activated NK cells, whereas NKp44 is only present on IL-2 activated NK cells.99 
Unlike NKG2A, NKG2D is not associated with CD94, but is a homodimer that needs association 
to the adaptor molecule DAP10 for stable cell surface expression.100 NKG2D recognizes HLA 
class I-like molecules, such as MIC A and MIC B. It has been shown that the expression of NKG2D 
ligands, MIC A/B, ULPB1, ULPB2, and ULPB3 are upregulated by cells in times of stress, virus 
infection, and malignant transformation.90^ ^102 NKG2D is constitutively expressed on all human 
NK cells and can be upregulated through stimulation by IL-15, IL-12 and IFN-a.103;104 Stimulation 
of NKG2D complements NCR activation in mediating NK cell lysis of tumor cells.105 Similarly, 
cooperation between NKG2D and stimulatory KIRs has been shown for both cytolytic activity and
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IFN-y secretion.106 Therefore, it is possible that NKG2D may serve both as a primary stimulatory 
receptor, whose engagement triggers cytotoxicity, and also as a co-stimulatory receptor, which 
cooperates with other activating receptors (e.g. activating KIR or NCR) for cytokine secretion. 
A similar phenomenon is seen on cytomegalovirus-specific T cells, where NKG2D acts as a co­
stimulatory receptor for TCR-dependent signals.107-109
Other stimulatory receptors that are involved in NK cell activation are co-stimulatory receptors 
NKp80 and 2B4 (CD244).110 NKp80 and 2B4 both function synergistically with NCR .111;112 
In addition, CD16, CD69 and DNAM-1 have been shown to trigger NK cell-mediated lysis in 
redirected cytotoxicity assays.113-115
4.3  NK cell allorecognition
4.3.1 The "missing self" hypothesis
In 1976, Snell et al.116 observed a correlation between the susceptibility of target cells to NK 
cell lysis and the absence, or low, expression of HLA class I molecules on the target cells. 
Absent or low expression of HLA class I molecules is common in virus-infected and malignant- 
transformed cells, which are the usual targets for NK cell lysis. Therefore, they proposed that NK 
cell receptors may not only interact with HLA class I molecules, but that these receptors are also 
able to detect a decrease in HLA class I expression.
It was not until 10 years later that Ljunggren and Kärre demonstrated the regulation of NK cell 
activity. They showed that murine lymphoma cells with low, or absent, MHC class I expression 
were less malignant than wild-type cells after low dose inoculation in syngeneic mice, and that 
the rejection of these cells was regulated through innate immunity, preferably through NK cell- 
mediated lysis.117 Resistance to NK cell-mediated lysis of tumors with low MHC class I expression 
could be restored by reintroduction of MHC class I molecules.118;119 Based on these data, they 
proposed the “missing self” hypothesis, which is nowadays still appreciated as the basic model 
for NK cell activation (Figure 5).120
4.3.2 Licensed to kill
As the KIR repertoire of NK cells is encoded by a set of highly polymorphic genes and segregates 
independently from HLA class I genes during NK cell development, it is essential that the KIR 
repertoire of NK cells properly corresponds with the HLA environment to provide self-tolerance 
and prevent autoimmunity. There have been several hypotheses on the acquisition of self­
tolerance by NK cells. Raulet et al.88 proposed that an individual NK cell can simultaneously 
express multiple inhibitory KIRs in a stochastic fashion. The only rule appears to be that every 
NK cell has at least one inhibitory KIR specific for self-HLA class I in order to avoid autoreactivity. 
This is referred to as the “at least one receptor” model.88 Others have suggested a “receptor 
calibration” model in which the acquisition of the KIR repertoire may be related to changes in the 
HLA class I environment and is dependent on the HLA class I haplotype.121-123 However, these 
studies involved in vitro cultures that could alter the intrinsic features of NK cells that may be 
different from the in vivo situation. Recently, the acquisition of self-tolerance was demonstrated
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in an in vivo murine study. Kim et al.124 showed that NK cells from MHC-deficient mice were 
functionally immature as they were defective in cytokine secretion upon ex vivo stimulation as 
compared with wild type NK cells, indicating that MHC-specific receptors are involved in the 
acquisition of functional competence. They also found a correlation between the expression 
of an inhibitory receptor for self-MHC class I and the capacity of an individual naive NK cell 
to be activated to produce cytokines and lyse susceptible target cells. Based on their findings 
they proposed the “licensing” model, in which NK cells acquire functional competence through 
“licensing” by self-HLA class I molecules, resulting in two types of self-tolerant NK cells: licensed 
or unlicensed. This model was confirmed by others, both in mice and human, demonstrating 
that NK cells without expression of known self-receptors were found to be hyporesponsive.125;126 
Thus, in order for NK cells to get their “license to kill”, they need to fulfill the requirement of HLA 
class I-specific receptor engagement by self-HLA.
Figure 5. “ M issing se lf”  hypothesis. NK cell activity depends on a balance between inhibitory (i.e. KIR, CD94/ 
NKG2A) and stimulatory (e.g. NCR, NKG2D) signals. In steady state, NK cells are inhibited from activation by the 
recognition of self-HLA class I molecules, which overrules potential stimulatory signals (self recognition). In case of 
virus infection or malignant transformation, cells may downregulate self-HLA class I molecules, while upregulating 
activating ligands that trigger NK cells to respond resulting in lysis of the infected/transformed cells (missing self). 
After allogeneic SCT, donor NK cells may be triggered by host leukemic cells due to reduced HLA-matched class 
I molecules (HLA-matched SCT), or the presence of non-self HLA class I molecules (HLA-mismatched SCT), 
combined with strong stimulation by upregulated activating ligands.
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5. NK cells and their therapeutic role In SCT
5.1 Evidence for GVL
Deficient HLA class I expression has been described for leukemic cells making them susceptible 
targets for NK cell-mediated lysis. However, this phenomenon was not ubiquitously observed in 
the autologous setting for patients with different forms of leukemia. In CML, NK cell numbers and 
NK cell function have been shown to decrease progressively during the spontaneous course of 
the disease, but could be recovered upon IFN-a treatment.127;128 Moreover, activated autologous 
NK cells were shown to suppress the growth of primitive CML progenitors in long-term in vitro 
cultures.129 In AML, however, autologous NK cells were demonstrated to be impaired in their 
cytolytic function, which correlated with a low NCR cell surface density (NCRduN).98 Moreover, 
these NK cells were impaired in regulating DC physiology (killing the surplus of immature DCs), 
which could lead to specific T cell tolerization by expanded immature DCs expressing leukemia- 
derived antigens.97 Allogeneic SCT may overcome the impairment of NK cell-mediated lysis.
In different SCT settings, NK cells have shown to play an important role in the anti-tumor 
response within the first months after transplantation.130-133 In haploidentical SCT, Ruggeri et al. 
134 showed that donor alloreactive NK cells isolated from peripheral blood of the recipient were 
able to lyse tumor cells derived from the recipient, implying that within one month after SCT, NK 
cells may be able to provide some degree of immune reactivity by targeting residual tumor cells 
still present in the recipient. Moreover, fast recovery of NK cells and predicted GVL reactivity 
towards host tumor cells has been associated with decreased relapse rates and better overall 
survival of the patient.135-137 Altogether these data suggest that NK cells play an important role in 
the control and clearance of leukemic cells after allogeneic SCT.
5.2 Evidence for the prevention of GVHD
The haploidentical transplantations performed by Ruggeri et al.132 additionally suggested that 
NK cells may prevent the development of GVHD. For patients, the prevalence of GVHD was 
significantly lower using grafts with potential NK cell alloreactivity in the GVL direction as compared 
with grafts without potential NK cell alloreactivity. In a murine model, they demonstrated that 
mice transplanted with non-T cell depleted grafts could be rescued from GVHD upon infusion of 
alloreactive NK cells. Mice infused with non-alloreactive NK cells died as they were not protected 
from GVHD. They also demonstrated that alloreactive NK cells are able to lyse recipient APCs, 
thereby preventing interaction with donor T cells which otherwise would initiate GVHD. Recently, 
a novel mechanism for NK cell-mediated GVHD reduction was demonstrated, whereby 
alloreactive donor NK cells were able to inhibit and lyse alloreactive donor T cells during the 
initiation of GVHD .138 Overall, these studies demonstrate that alloreactive NK cells may, directly 
or indirectly, reduce or prevent the occurrence of GVHD while retaining GVL reactivity.
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5.3  Exploitation of NK cell alloreactivity
The ability to induce GVL reactivity while reducing or preventing GVHD makes alloreactive NK 
cells important candidates for immunotherapeutic strategies in leukemia treatment. Since 2005, 
several studies have explored the safety of NK cell-based immunotherapy within various settings. 
Koehl et al.139 demonstrated the feasibility of good manufacturing practice (GMP)-compliance NK 
cell isolation and expansions for clinical applications. In this study, IL-2 activated NK cells were 
used for repeated transfusions in three pediatric patients with multiple relapsed ALL or AML. 
Unfortunately, all three patients died of relapse or disease-related complications. The feasibility 
of NK-DLI was tested by Passweg et al.140 in patients after haploidentical SCT, demonstrating 
that NK cell infusions after SCT were well tolerated without the induction of GVHD. The feasibility 
of NK cell infusions was further assessed by Miller et al.141 in a non-transplantation setting and 
demonstrated successful adoptive transfer and in vivo expansion of haploidentical NK cells 
in patients with poor-prognosis AML. However, only 5 out of 19 patients showed complete 
hematological remission. Shi et al.142 later showed that infusion of haploidentical KIR-ligand 
mismatched NK cells proved safe and feasible for advanced multiple myeloma patients in the 
setting of autologous SCT. In this study, 50% of the patients achieved (near) complete remission. 
Overall, these studies indicate that NK cell-based immunotherapies may be safe, well tolerated, 
and do not induce GVHD. Nevertheless, results also demonstrate that the success of NK-cell 
based immunotherapies may depend on the type of malignant disease, stage, and the overall 
health of the patient.
6. scope and outline of this thesis
The development of NK cell-based immunotherapies for cancer treatment is still in its infancy. 
So far, the exploitation of NK cell alloreactivity for immunotherapeutic purposes has only 
been pursued in the HLA-haploidentical setting. However, for the treatment of hematological 
malignancies, HLA-matching between donor and recipient is the preferred setting for allogeneic 
SCT and immunotherapeutic DLI (chapter 1). Therefore, the main focus of this present thesis 
was to explore the facilitation of alloreactive donor NK cells in HLA-matched allogeneic SCT. 
For this purpose, we studied the effects of two different graft types, the feasibility of skewing 
NK cell alloreactivity towards specific malignant cells, and the potential side-effects of 
immunosuppressive regimens.
In chapter 2, we studied the alloreactive potential of mature donor-derived NK cells when given as 
part of the graft in HLA-matched allogeneic SCT. The results of this study elegantly demonstrate 
that the use of CD3+/CD19+ depleted grafts facilitates strong NK cell cytolytic responses directly 
after SCT, and the rapid emergence of a NK cell receptor phenotype that is more prone to 
activation as compared with the use of conventional CD34+ selected grafts, which are devoid of 
donor NK cells. In chapter 3, we examined the plasticity of the KIR repertoire and the cytolytic 
response of mature human peripheral blood NK cells in the presence of specific KIR receptor-
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ligand (i.e. HLA-C) mismatches. Here, we show that HLA class I can skew the mature NK cell 
phenotype and enrich the alloreactive NK cell population towards leukemic target cells. This may 
be important for future clinical applications of NK cell-based immunotherapies using mature NK 
cells in transplantation settings. As immunosuppressive drugs (ISDs) are frequently used for 
GVHD prophylaxis after allogeneic SCT or DLI, we further explored the effect of commonly used 
ISDs (i.e. cyclosporin A (CsA), mycophenolic acid (MPA), and rapamycin (Rapa)) on human 
peripheral blood NK cells in vitro (chapter 4). Our results showed that CsA, MPA and Rapa each 
have distinct effects on NK cell phenotype and function, which may have important implications 
for NK cell function in vivo after transplantation.
As NK cell alloreactivity may also be exploited in non-transplant settings (i.e. adoptive cancer 
immunotherapy), we further contributed to the development of a clinical grade NK cell product 
and established an extremely efficient cytokine-based culture system for ex vivo expansion of 
NK cells from hematopoietic stem and progenitor cells from umbilical cord blood (UCB) (chapter 
5). The ex vivo-generated NK cells efficiently lysed myeloid leukemia and melanoma tumor 
cell lines, and mediated cytolysis of primary leukemia cells at low NK:target ratios. This culture 
system exemplifies a major breakthrough in producing pure NK cell products from limited 
numbers of CD34+ cells for NK cell-based immunotherapy.
As thorough knowledge of NK cell development is essential for the development of NK cell- 
based immunotherapies, we finally studied NK cell development in various human tissues using 
10-color flow cytometry (FCM) (chapter 6 ). Using newly developed 10-color FCM panels, we 
were able to identify seven NK cell developmental stages in bone marrow and found phenotypical 
evidence that NK cell development is divided over multiple compartments of the human body 
(i.e. bone marrow, lymph nodes, spleen, peripheral blood) combined with differential in situ 
maturation of the NK cell receptor repertoire.
Finally, chapter 7 summarizes this thesis and the applicability of NK cell-based immunotherapies 
in combination with allogeneic SCT or as a standalone immunotherapy in the treatment of 
leukemia is put in perspective.
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Abstract
Natural killer (NK) cells play an important role in the anti-tumor response early after stem cell 
transplantation (SCT). As part of a prospective randomized phase III study, directly comparing 
the use of CD3+/CD19+ depleted peripheral blood stem cell (PBSC) harvests with CD34+ selected 
PBSC harvests in allogeneic HLA-matched SCT, we here show that, the use of CD3+/CD19+ 
cell depleted PBSC grafts leads to early NK cell repopulation and reconstitution of the CD56dim 
and CD56bright NK cell subsets, with concomitant high cytolytic capacity. In the CD34 group this 
process took significantly longer. Also, in the CD3/19 group after reconstitution, 
a higher percentage of killer immunoglobulin-like receptor (KIR) positive NK cells was found. 
Although similar percentages of CD94 positive NK cells were found in both groups, in the CD34 
group, almost all expressed the inhibitory CD94/NKG2A complex, whereas in the CD3/19 group, 
the inhibitory CD94/NKG2A and the activating CD94/NKG2C complex were equally distributed. 
This preferential development of NKG2C expressing NK cells in the CD3/19 group was paralleled 
by a loss of NKG2A-mediated inhibition of NK cell degranulation. These results show that the 
use of CD3+/CD19+ depleted grafts facilitates strong NK cell cytolytic responses directly after 
SCT, and the rapid emergence of a NK cell receptor phenotype that is more prone to activation.
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Introduction
Natural killer (NK) cells are potent immune effector cells involved in the clearance of virus-infected 
and tumor cells. They are able to lyse infected or abnormal cells without prior sensitization or 
preactivation by antigen-presenting cells. NK cells survey potential target cells through a range 
of inhibitory and stimulatory receptors that detect the loss (or reduction) of expression of human 
leukocyte antigen (HLA) class I molecules or other nonclassical HLA class I specific signals.12 The 
balance between the inhibitory and stimulatory signals triggers and modulates the NK cell effector 
function and the response of NK cells towards other cells.
The cytolytic function of NK cells is regulated by killer immunoglobulin-like receptors (KIR) including 
both inhibitory receptors (KIR-DL) and stimulatory receptors (KIR-DS). Whereas the ligands for 
the activating receptors are not yet unequivocally established, the ligands of KIR-DL receptors are 
specific for HLA class I molecules. KIR receptors are clonally distributed among NK cells within 
each individual.3 Next to the KIR, another important receptor in modulating NK cell responses is the 
CD94/NKG2 heterodimeric complex. This receptor is part of the C-type lectin family and its ligand is 
the HLA-E class I molecule.4 The CD94/NKG2 heterodimer can either have an inhibitory (NKG2A) 
or a stimulatory (NKG2C) function. Other NK cell receptors include the natural cytotoxicity receptors 
(NCR; NKp30, NKp44 and NKp46) and NKG2D (a C-type lectin homodimer). These receptors are 
capable of activating NK cells, whereby inducing NK cell-mediated cytolytic responses.5 
As NK cells are efficient effectors in eradicating tumor cells, they play an important role in the 
anti-tumor response after allogeneic stem cell transplantation (SCT).6-9 In HLA-haploidentical 
SCT, Ruggeri et a/.10 showed that donor alloreactive NK cells isolated from peripheral blood of the 
recipient were able to lyse tumor cells derived from the recipient, implying that within one month 
after SCT, NK cells may be able to provide some degree of immune reactivity by targeting residual 
tumor cells still present in the recipient. Indeed, fast recovery of NK cells and predicted alloreactivity 
towards host tumor cells have been associated with decreased relapse rates and better overall 
survival of the patient.11-13 Recently, however, Nguyen et a/.14 showed that early-reconstituting NK 
cells have an immature phenotype and that NK cell alloreactivity is impaired at an early stage after 
haploidentical SCT. The results of this study emphasize that proper reconstitution of the NK cell 
receptor repertoire is probably more important for the induction of alloreactive NK cell responses 
than just fast NK cell recovery. One way to overcome delayed immune reconstitution of NK cells 
following SCT is to change the selection procedure of the graft. Recent data have shown that graft 
selection for haploidentical SCT by depletion of CD3+ and CD19+ cells, instead of positive CD34+ 
selection, leads to faster engraftment and better overall immune reconstitution.15 
In our centre, a phase III clinical study started in January 2006, directly comparing the use of 
CD3+/CD19+ depleted peripheral blood stem cell (PBSC) harvests with commonly applied CD34+ 
selected PBSC harvests in allogeneic HLA-matched SCT. We investigated the immunological 
recovery and function of the NK cells after allogeneic SCT for a follow-up period of one year and 
compared the results between patients either having received a CD3+/CD19+ cell depleted graft or 
a CD34+ cell selected graft.
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Materials and methods
Study population
In a single-centre randomized phase III clinical study at the Radboud University Nijmegen Medical 
Centre (RUNMC), patients with AML in first complete remission, ALL in first complete remission 
or high risk MDS (RAEB, RAEB-t) in complete remission, eligible for allogeneic peripheral blood 
stem cell transplantation (PSCT) received G-CSF-mobilized peripheral blood stem cells of an 
HLA-identical sibling donor (SIB) or an HLA-A, -B, -C, -DR, -DQ-matched voluntary unrelated 
donor (VUD). In this study, patients were randomized to receive a peripheral blood stem cell 
graft processed either by positive CD34+ immunomagnetic selection or T (CD3+) and B cell 
(CD19+) depletion by negative immunomagnetic selection using a CliniMACS cell selector 
device (Miltenyi Biotec, Bergisch Gladbach, Germany). All transplants contained at least 3x106 
CD34+ cells and 0.5 x106 T cells/kg body weight. The amount of T cells was achieved by adding 
back cells from the harvest. Between January 2006 and November 2007, 23 patients were 
included in this study. This study was approved by the medical ethics committee of the RUNMC 
and written informed consent was provided by patients and donors according to the Declaration 
of Helsinki. Table 1 outlines the demographics of the patients selected for this study. This study 
is registered at http://clinicaltrials.gov as “T-Cell and B-Cell Depletion in Allogeneic Peripheral 
Blood Stem Cell Transplantation” (registration number: NCT00306332).
Table 1. Patient characteristics.
Patient groups
CD34+ selection CD3+/19+ depletion
N 14 9
Median age of recipient, years 
(range) 46 (22-61) 47 (25-60)
Median age of donor, 
years (range) 46 (25-65) 42 (22-72)
Donor/recipient relation
SIB
VUD
6
8
5
4
Diagnosis
AML
ALL
MPD (low risk)
MDS
NHL
8
3
0
2
1
4
2
1
2
0
Abbreviations: SIB, sibling donor; VUD, voluntary unrelated donor; AML, acute myelogenous leukemia; ALL, acute 
lymphoblastic leukemia; MPD, myeloproliferative disorder; MDS, myelodysplastic syndrome; NHL, non-Hodgkin 
lymphoma.
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Patient treatm ent procedures
All patients transplanted with a graft from a sibling donor were conditioned with idarubicine (total 
dose 42 mg/m2) i.v.16, cyclophosphamide (120 mg/kg body weight) i.v., and fractionated total 
body irradiation (TBI) given in two equal fractions on days -2 and -1 to a total dose of 9 Gy. In
2 patients TBI was replaced by busulphan (3.2 mg/kg body weight) intravenously. In patients 
transplanted with a graft from a voluntary unrelated donor (VUD) the conditioning regimen 
consisted of cyclophosphamide (120 mg/kg body weight), anti-thymocyte globulin (ATG) (2 mg/ 
kg body weight) every 24 hours at four consecutive days (day -7 to -3) i.v and fractionated TBI 
given in two equal fractions on days -2 and -1 to a total dose of 9 Gy. The stem cells were infused 
24 hours after completion of TBI or 72 hours after the last dose of busulphan. All patients were 
treated with cyclosporine A (CsA) 3 mg/kg/d i.v. from day -1 to +14, followed by 2 mg/kg/d i.v. 
infusion until oral administration of CsA (6 mg/kg/d) was possible. CsA was gradually tapered off 
and discontinued 12 weeks post-grafting. Patients who did not develop acute GVHD > grade 2 
and/or chronic GVHD, according to the criteria described by Glucksberg and Shulman, received 
pre-emptive donor lymphocyte infusion (DLI) at a dose of 0.1 x 108 CD3+ cells/kg body weight. All 
patients received oral selective gut decontamination (Ciprofloxacin), as well as co-trimoxazole 
for Pneumocystis carinii prophylaxis and oral acyclovir for prophylaxis of herpes infections.
Collection and preparation of samples
41
Blood samples (50 ml) were taken from patients before and at 0.5, 1, 2, 3, 6 , 9, and 12 
months after SCT. When possible, blood samples were collected from each donor before SCT 
Peripheral blood mononuclear cells (PBMC) were isolated by density gradient centrifugation 
using Lymphoprep (Nycomed Pharma, Roskilde, Denmark). A fraction of the isolated PBMC was 
used to analyze the phenotype of the NK cells in detail. The remaining cells were cryopreserved 
in liquid nitrogen until further use. To evaluate immunological recovery, immunophenotyping was 
performed on fresh blood samples from patients.
Phenotypic analysis
The phenotype of NK cells was analyzed by four-color flow cytometry measured on a Coulter 
Epics XL (Beckman Coulter, Miami, FL, USA). For cell surface staining, the following conjugated 
mAbs were used: CD45-PE, CD16-FITC (Dako, Glostrup, Denmark), CD3-ECD, CD56-PCy5, 
CD158a,h-PE, CD158b/b2j-PE, NKG2A-PE, NKp30-PE, NKp44-PE, NK46-PE (Beckman 
Coulter, Miami, FL, USA), NKB1-PE (BD Biosciences, Erembodegem, Belgium), CD94-PE 
(Immunotech, Marseille, France), NKG2C-PE and NKG2D-PE (R&D Systems, Minneapolis,
CA, USA). Isotype controls were used for marker settings. Analysis was performed using 
CXP analysis software (Beckman Coulter). All flow cytometric analyses were performed with a 
combination of CD3, CD16 and CD56 mAbs combined to a fourth specificity to gate specifically
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on CD3-CD56dimCD16brighl and CD3-CD56brighlCD16low/neg NK cell populations and to distinguish 
them from NK-T and T cells. A dual platform technique was used to evaluate the immunological 
recovery of NK cells. With this technique, the absolute numbers of NK cells were calculated 
based on the flow cytometrically assessed percentage of CD45+CD56+CD16+/-CD3- cells and the 
white blood cell count from a hematology cell analyzer (ADVIA120 Hematology System, Bayer 
Diagnostics, Leverkusen, Germany).
Functional analysis
For functional studies, cryopreserved PBMC were thawed and cultured overnight in the 
presence or absence of rhIL-2 (100 U/ml; Chiron, Amsterdam, the Netherlands) and rhIL-15 (10 
ng/ml; BioSource International, Camarillo, CA, USA) in culture medium consisting of RPMI 1640 
supplemented with pyruvate (0.02 mM), penicillin (100 U/ml), streptomycin (100 |jg/ml), and 
10% human pooled serum (HPS), in a 37 oC, 95% humidity, 5% CO2 incubator.
51Chromium-release assay
Pre-stimulated or unstimulated PBMC were used to examine the NK cell cytolytic activity using 
the major histocompatibility complex (MHC) class I-deficient human erythroleukemia K562 cell 
line (ATCC#; CCL-243) as target cells at PBMC:target ratios ranging from 80:1 to 0.625:1 in 
a standard 4-h 51Cr-release assay. All experiments were performed in triplicates and for each 
patient all samples were run together in one assay in order to avoid inter-assay variation. The 
percentage specific lysis was calculated as follows: % specific lysis = ((experimental release - 
spontaneous release)/(maximum release - spontaneous release))x100%. In order to express 
NK cell cytolytic activity independent of an arbitrary selection of E:T ratio and to allow reliable 
comparisons between samples of patients tested at different moments in time, the specific lysis 
was converted into Lytic Units (LU). LU are defined as the number of effector cells contained in 
106 effector cells required to lyse 20% of the target cells.17
Redirection assays
Redirection assays were performed using the P815 cell line (ATCC#; TIB-64) as target cells. P815 
cells were incubated in culture medium with pre-stimulated PBMC at an E:T ratio of 1:2 in the 
presence of mAbs (10 |jg/ml) specific for NKG2C, NKG2A and NKp46 (R&D Systems, Minneapolis, 
CA, USA) or with IgG1, IgG2a and IgG2b isotype controls (R&D Systems, Minneapolis, CA, USA) 
at 37 oC, 95% humidity and 5% CO2. E:T ratio's were based on the amount of live NK cells present 
in the PBMC fractions after overnight culture. To measure NK cell degranulation, cells were 
washed after two hours of incubation, stained on ice with fluorochrome-conjugated anti-CD107a 
(BD Biosciences, Erembodegem, Belgium), anti-CD56 and anti-CD3 mAbs and analyzed by flow 
cytometry. To calculate the specific degranulation, non-specific degranulation induced by isotype 
controls was deducted from the degranulation given by specific triggering. IFN-y produced by NK 
cells was analyzed by intracellular staining after 5 hours of incubation with P815 target cells at
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37 oC with 5 ng/|jl of Brefeldin A (Sigma-Aldrich) for the last 4 hours. First, a surface staining was 
performed using anti-CD56 and anti-CD3 mAbs. For intracellular staining, Fix and Fix/Perm buffer 
(eBioscience, San Diego, CA, USA) were used according to the manufacturer's instructions in 
combination with IFN-Y-PeCy7 mAb (eBioscience, San Diego, CA, USA).
Statistical analysis
Nonparametric tests were used to compare continuous variables between two groups. To test 
differences between both patient groups or within one group between donors and recipients after 
SCT, a Mann-Whitney U test was performed. A Wilcoxon signed rank test was used to compare 
differences within each group between recipients before and after SCT. P-values <.05 were 
considered statistically significant.
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Results
Patients
Patients eligible for inclusion in the study were randomized on a 1:1 basis for treatment with 
either a positive CD34+ selected graft (CD34 group) or a T and B cell-depleted graft (CD3+/ 
CD19+ depletion; CD3/19 group). Between January 2006 and November 2007, 14 patients were 
included in the CD34 group and 9 patients were included in the CD3/19 group. Patient and 
donor characteristics are depicted in Table 1. The composition of the grafts selected by CD34+ 
selection and CD3+/CD19+ depletion are summarized in Table 2.
Table 2. Graft composition.
Patient groups
CD34+ selection CD3+/19+ depletion
Nuclear cells (x108/kg) 7 ± 3 634± 156
CD3+ cell (x106/kg) 0.43 ±0.1 0.58 ±0.1
Log T cell depletion 2.9 2.8
NK cells (CD56+CD3‘) (x106/kg) 0.03 ± 0.02 26.6 ± 5.2
CD19+ cell (x106/kg) 0.08 ± 0.06 0.40 ± 0.20
Log B cell depletion 3.0 2.4
CD34+ cell (x106/kg) 4.6 ± 1.6 8.8 ± 3.9
CFU-GM (x106/kg) 53 ±47 113 ± 31
BFU-E (x106/kg) 30 ± 19 207 ± 67
Abbreviations: CFU-GM, colony-forming units-granulocytes and macrophages; BFU-E, burst-forming units- 
erythrocytes.
After SCT, patients of both groups showed similar engraftment kinetics and there were no 
remarkable differences in the immunosuppressive regimens between the two groups (Table 3). 
There were no major differences in the occurrence of graft versus host disease (GVHD), fungal 
infections and relapse rate. The incidence of bacterial infections was slightly higher in the CD34 
group, possibly due to the fact that the CD34+ selected grafts contained less monocytes and 
granulocytes. In case of viral infections, we saw a tendency towards a higher infection rate in 
the CD3/19 group. This is due to a higher number of CMV reactivations that occurred within the 
CD3/19 group (4 patients vs. 1 patient in the CD34 group).
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Table 3. Clinical follow-up.
Patient groups
CD34+ selection CD3+/19+ depletion
N
Median follow-up; months 
(range)
14
12(1-12)
9
6 (2-12)
Engraftmenta 
>0.5x106/ml neutrophils 
>20x106/ml platelets
11 (10-15) 
11 (9-21)
11 (10-16) 
11 (8-21)
Immunosuppression b 
CsA
Additional steroids
82 (23-570) 
3
85 (55-570) 
1
Acute GVHD 
No
Grade I 
Grade II 
Grade III 
Grade IV
8
2
2
2
0
5
3
1
0
0
Chronic GVHD0 
No
Limited
Extensive
6
4
2
CM 
CM
Infections
Viral
Bacterial
Fungal
4
10
3
5
5
2
Relapse
No
Yes
10
4
6
3
45
a;The hematological recovery for each group is given as median days with ranges. b;The immunosuppression for 
each group is given in median days after transplantation with ranges (CsA) and the number of patients receiving 
additional steroids. c;Within 3 months after SCT, 2 patients died within the CD34 group and 1 patient died within the 
CD3/19 group.
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Repopulation of NK cells after SCT
To study NK cell repopulation and reconstitution of the NK cell receptor repertoire, peripheral 
blood samples were taken from each patient prior to SCT and at 0.5, 1, 2, 3, 6 , and 12 months 
after SCT and were analyzed for the presence of NK cells by flow cytometric analysis. At each 
time point, the absolute numbers of NK cells were analyzed within whole blood samples (Figure
IA). In the CD34 group, at day 14 after SCT only limited amounts of NK cells were present in the 
peripheral blood as compared to absolute NK cell numbers prior to SCT. The absolute numbers 
of NK cells reached pre-SCT levels one month after SCT. Thereafter, levels slowly increased and 
reached significant levels at 6 months after SCT (P<.05, compared to numbers prior to SCT). 
In the CD3/19 group, absolute numbers of NK cells in the peripheral blood reached pre-SCT 
level already at fourteen days after SCT. One month after SCT, the absolute NK cell numbers 
increased even further (P<.05). Comparison of the CD34 group with the CD3/19 group shows 
that at day 14 after SCT significantly higher numbers of NK cells were present in the CD3/19 
group (P<.05).
The repopulation of the CD56brighl and CD56dim NK cell subsets was analyzed within isolated 
PBMC fractions by gating on the lymphocytes by CD45+ and a low side scatter and subsequently 
on CD56+ and CD3- cells. In the CD34 group, the repopulation of the two NK cell subsets seemed 
to start with the development of the CD56brighl NK cells. The balance between the CD56brighl and 
CD56dim NK cell subsets was in favor of the CD56brighl NK cells until 6 months after SCT (Figure
IB). This is comparable with the results described by previous studies in which the development 
of NK cells after SCT was studied.1819 In contrast, in the CD3/19 group, both NK cell subsets 
were already present at fourteen days after SCT (data not shown). Moreover, the outgrowth 
of the CD56brighl NK cell subset was less profound as seen within the CD34 group and the 
balance between the CD56brighl and CD56dim NK cell subsets was more comparable with the 
donor situation prior to SCT
In contrast to the different reconstitution kinetics of the NK cells, the reconstitution of both T and 
B cells was comparable between the CD34 and CD3/19 group during the first three months after 
SCT (Figure S1).
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Figure 1. Recovery o f NK cells after SCT. (A) The recovery of NK cells (CD45+CD56+CD3-) after SCT within the 
CD34 group and the CD3/19 group. NK cell numbers were analyzed within whole blood samples of recipients before 
SCT (R) and at several time points after SCT using flow cytometry. Within each group, differences between recipients 
before SCT and after SCT were analyzed using the Wilcoxon signed rank test. The Mann-Whitney U test was used 
to test differences between both groups; *P<.05, ***P<.001. (B) Repopulation of NK cells and the different NK cell 
subsets, analyzed in freshly isolated PBMC fractions by flow cytometry, using CD3, CD45, CD16 and CD56 mAbs. 
Displayed are the ratios of the CD56bri9ht:CD56dim NK cell subsets before SCT and at different time points after SCT. R 
= recipients before SCT, D = donors. Within each group, differences between donors and recipients after SCT were 
analyzed using the Mann-Whitney U test; **P<.01, ***P<.001.
Reconstitution of the NK cell receptor repertoire
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As the repopulation of the CD56dim and CD56b^i9h, NK cell subsets was much faster in the 
CD3/19 group, suggesting an earlier presence of mature NK cells, we investigated whether this 
phenomenon was also reflected in the reconstitution of the NK cell receptor repertoire after SCT.
Comparison o f KIR expression between the CD34 and the CD3/19 groups 
In both groups, reconstitution of KIR2DL/S1, KIR2DL/S2/3 and KIR3DL1 expression was 
monitored in the total NK cell population (CD45+CD3-CD56+) during the follow-up at different 
time points after SCT (Figure 2).
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Figure 2. Reconstitution of KIR expression by NK cells. The reconstitution of KIR2DL/S1 (CD158a,h), KIR2DL/ 
S2/3 (CD158b1b2,j) and KIR3DL1 (NKB1) expression by CD45*CD56*CD3- NK cells was analyzed by flow cytometry 
in freshly isolated PBMC fractions, at different time points after SCT. Displayed are the percentage KIR positive cells 
in recipients before SCT (R), in donors (D) and in recipients at 1, 3, 6 and 12 months after SCT. Data are shown for 
the CD34 group and the CD3/19 group. Within each group, differences between donors and recipients after SCT 
were analyzed using the Mann-Whitney U test; *P<.05, **P<.01, ***P<.0001.
The reconstitution of KIR3DL1 + NK cells already reached donor level within one month after SCT. 
Notably, during the remaining follow-up the percentage of KIR3DL1 + NK cells was decreased 
and did not regain donor levels during the rest of the follow-up. Compared to KIR2DL/S, the 
reconstitution of KIR3DL1 seemed to show an opposite reconstitution pattern over time. This 
phenomenon has previously been described after HLA-mismatched/haploidentical SCT.20 
In the CD3/19 group, KIR reconstitution was faster compared to the CD34 group (Figure 2). 
While in the CD34 group full reconstitution took a year, as has also been described by others21, 
the NK cells in the CD3/19 group reached normal expression frequencies directly after SCT. 
Here, the amount of KIR2DL/S1 + NK cells was only significantly decreased up to one month 
after SCT compared to donor level and within one year after SCT, expression levels were fully 
restored. In addition, the amount of KIR2DL/S2/3+ and KIR3DL1+ NK cells were already at donor 
level at 14 days after SCT (data not shown). Remarkably, during the remaining time of the follow- 
up the number of KIR2DL/S2/3+ NK cells was enhanced from a median level of 19 percent at 2 
months after SCT to 30 percent at one year after SCT. Similar to the CD34 group, reconstitution 
of the KIR3DL1+ NK cells followed the same pattern over time and did not significantly decrease 
compared to donor level. Thus, as the reconstitution of the number of KIR2DL/S+ NK cells 
was rather slow in the CD34 group and was significantly lower within the first months after
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SCT, frequencies of KIR2DL/S expression in the CD3/19 group were not significantly different 
from donor level and reconstituted faster to full donor level. In summary, the NK cells quickly 
recovered in the CD3/CD19 group and maintained similar percentages of KIR bearing NK cells 
as compared to the donor before SCT.
Alternative reconstitution of CD94/NKG2A/C expression
During NK cell development, KIR expression is preceded by expression of CD94/NKG2A .22 
In the first months after SCT, NK cell subsets were shown to be characterized by a high 
frequency of CD94/NKG2A expression and low expression of KIR.19-21 This suggests that at 
early stages after SCT, the function of NK cells is primarily regulated through the interaction of 
CD94/NKG2 heterodimeric complexes with HLA-E molecules. In both groups, the frequency of 
CD94 expressing NK cells was upregulated during the first 3 months after SCT, after which the 
percentage of CD94 expressing NK cells slowly decreased towards donor level (Figure 3).
Figure 3. Reconstitution of CD94 expression by NK cells. CD94 expression by the CD45*CD56*CD3- NK cell 
population in freshly isolated PBMC fractions of donors (D) and of recipients before (R) and at 1, 3, 6 and 12 months 
after SCT, was analyzed using flow cytometry. Data are shown for the CD34 group and the CD3/19 group. Within 
each group, differences between donors and recipients after SCT were analyzed using the Mann-Whitney U test; 
**P<.01, ***P<.0001.
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In the CD34 group, the amount of CD94+ NK cells was higher during the first months after SCT 
However, frequencies of CD94 expressing NK cells between the two groups were similar from 3 
months to one year after SCT. Remarkably, the NKG2A expression levels in the CD3/19 group 
were significantly decreased from a median percentage of 76 percent at one month to 36 percent 
at one year after SCT (P<.05) while at the same time the frequency of NKG2C expressing NK 
cells was significantly increased from a median of 8 to 53 percent, respectively (P<.01) (Figure 
4A). This phenomenon appeared to be specific for the CD3/19 group, as this was not seen within 
the CD34 group (Figure 4B).
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Figure 4. Reconstitution o f NKG2A and NKG2C expression by NK cells after SCT. Expression of the inhibitory 
NKG2A and the activating NKG2C receptors by CD45*CD56*CD3- NK cells was analyzed by flow cytometry in freshly 
isolated PBMC fractions from recipients of both CD3/19 and CD34 groups. (A) Percentages of NKG2A and NKG2C 
expressing NK cells in recipients before SCT (R), in donors (D) and in recipients at 1, 3, 6 and 12 months after SCT 
in both groups. Differences between groups were analyzed using the Mann-Whitney U test; *P<.05, **P<.01. (B) A 
representative example of NKG2A and NKG2C expression on NK cells in individual recipients of either group over 
time. Histogram analysis shows the percentage of receptor expressing NK cells at different time points after SCT.
We observed no differences in the reconstitution of the other activating NK cell receptors (Figure 
5). Although the frequencies of NKp30 expression seemed to drop slightly in the CD3/19 group 
as compared to the CD34 group, percentages of NKG2D and NCR expression were similar in 
both groups following SCT. In addition, frequencies of NKG2D, NKp30 and NKp44 expressing 
NK cells did not significantly change compared to donor levels. In both groups, the amount of 
NKp46 expression was significantly higher directly after SCT and remained above donor levels 
throughout the rest of the follow-up.
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Figure 5. Reconstitution o f activating NK cell receptors NKG2D, NKp30, NKp44 and NKp46. Percentages 
of NKG2D, NKp30, NKp44 and NKp46 expressing CD45+CD56+CD3- NK cells were analyzed in freshly isolated 
PBMC fractions for both the CD34 group and the CD3/19 group at 1, 3, 6 and 12 months after SCT. Within each 
group, differences between donors and recipients after SCT were analyzed using the Mann-Whitney U test; **P<.01, 
***P<.0001.
Cytolytic potential of repopulated NK cells
Cytolytic activity against HLA class I-negative target cells
We observed that, whereas in the CD34 group only few NK cells were present at day 14 after 
SCT and full repopulation in the CD34 group took place from one to two months after SCT, in 
the CD3/19 group the repopulation of NK cells had already taken place just after SCT. Also, 
we observed that the ratio of CD56bright versus CD56dim NK cells in the CD3/19 group after SCT 
was distinct from that found in the CD34 group. Thus, we set out to investigate whether the 
repopulation profiles and phenotypic differences were paralleled by a distinct functional activity 
of the cell populations. To assess the cytolytic potential of the repopulated NK cells after SCT, we 
performed cytolytic assays using the K562 cell line as a target. Prior to the assay, NK cells were 
incubated overnight in the absence or presence of IL-2 and IL-15 (Figure 6).
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Figure 6. NK cell cyto ly tic  activ ity  against K562 target cells. Thawed PBMC fractions were cultured overnight 
in the absence (A) or presence (B) of 100 U/ml IL-2 and 10 ng/ml IL-15, and subsequently incubated with 51Cr- 
labeled K562 target cells in a standard 4-h 51Cr release assay. Displayed are the Lytic Units (LU) within each PBMC 
fraction of the CD34 group and the CD3/19 group before SCT (R) and at 0.5, 1, 2, 3, 6 and 12 months after SCT. 
LU comparisons between recipients before SCT and after SCT were analyzed using the Wilcoxon signed rank test; 
*P<.05, **P<.01. Differences between groups were analyzed using the Mann-Whitney U test; *P<.05.
Unstimulated NK cells derived from the CD34 and CD3/19 group prior to SCT showed equal 
cytolytic activity (Figure 6A). But, after SCT, the NK cells in the CD3/19 group not only appeared 
to show a faster reconstitution of the different NK cell subsets and the NK cell receptor repertoire, 
at fourteen days after SCT they also showed stronger cytolytic capacity. Moreover, at this time 
point the cytolytic activity was even higher than before SCT (P<.05) and this was maintained 
throughout the rest of the follow-up. Parallel to the duration of NK cell repopulation, in the CD34 
group enhanced cytolytic activity levels were only reached at one to two months after SCT 
Although enhanced, the trend in cytolytic activity was similar for the pre-stimulated NK cells 
(Figure 6 B). This implies that the use of CD3+/19+ depleted grafts for SCT may lead to an earlier 
and longer time frame of NK cell cytolytic activity after SCT
Diminished NK ceil inhibition through NKG2A triggering in the CD3/19 group 
Previous studies showed that high expression levels of CD94/NKG2A after SCT may lead to 
impaired cytolytic NK cell function.14 As the NKG2A:NKG2C ratio in the CD3/19 group was in 
favor of the stimulatory NKG2C receptor, we set out to investigate whether this distinct phenotype 
was associated with enhanced functional activity. To this end, we set up a redirection assay in 
which NK cells were triggered by P815 cells labeled with NKG2C and NKp46 specific antibodies 
in the absence or presence of NKG2A specific antibodies. Typically, triggering of NK cells with 
NKp46 and NKG2C antibodies leads to NK cell degranulation, whereas NKG2A triggering leads 
to inhibition of NK cell degranulation. At one month after SCT, the CD3/19 and CD34 groups 
showed similar NKG2A-mediated inhibition of NK cell degranulation (Figure 7), which is in line 
with the similar percentage of NKG2A expressing NK cells in both groups (Figure 5).
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Figure 7. Redirected degranulation of NK cells by specific triggering of the activating NKG2C and NKp46 
receptors in the presence or absence o f NKG2A specific antibodies. PBMC fractions of the CD34 group (n=6) 
and the CD3/19 group (n=5) were stimulated overnight with IL-2 (100 U/ml) and IL-15 (10 ng/ml) and subsequently 
incubated for 2 h at a NK:target cell ratio of 1:2 in a redirection assay using P815 target cells and NKG2A, NKG2C, 
NKp46 or isotype control mAbs. Specific degranulation was determined within the CD56*CD3- NK cell population as 
the percentage of CD107*CD56*CD3- NK cells with specific mAbs minus the percentage of CD107*CD56*CD3- NK 
cells in the presence of isotype control mAbs. Negative values are displayed as equal to 0. Specific degranulation 
was determined for recipients at 1, 3 and 6 months after SCT. Significance of inhibition through NKG2A was analyzed 
using the Wilcoxon signed rank test; NS = not significant, *P<.05
Notably, from one month post-SCT onwards, only in the CD3/19 group the inhibitory effect of 
NKG2A triggering was diminished, corresponding with an increased frequency of CD94/NKG2C+ 
NK cells and a decreased percentage of CD94/NKG2A+ NK cells. In the CD34 group the inhibitory 
effect of NKG2A triggering was maintained. In addition, the percentage of degranulating NK 
cells as induced by NKG2C and NKp46 triggering tended to be higher in the CD3/19 group as 
compared to the CD34 group (3 months: median of 16 vs. 3%; at 6 months: median of 9 vs. 3%). 
The level of degranulation, induced by NKG2C and NKp46 triggering was also reflected in the 
IFN-y production (data not shown), as the NK cells within the CD3/19 group produced higher 
levels of IFN-y.
In conclusion, we demonstrate that the use of CD3/19 depleted grafts for allogeneic HLA- 
matched SCT leads to a preferential development of NKG2C expressing NK cells, paralleled by 
a loss of NKG2A-mediated inhibition of NK cell degranulation at later stages after SCT
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Discussion
Immediately after stem cell transplantation, alloreactive NK cells have been shown to be 
beneficial not only for boosting the anti-tumor response, but also for the prevention of GVHD 
as well as infections. In these cases, full functional activity of NK cells already in the early 
phase after SCT is essential, and therefore the presence of NK cells in the graft appears to be 
beneficial for transplant outcome.15;23 In the current study, we show that patients that received 
a CD3+/CD19+ cell depleted graft, which contains NK cells in substantial numbers, exhibited a 
faster recovery of a functional NK cell receptor repertoire as compared to patients that received 
a conventional CD34+ graft while both groups were treated under the same immunosuppressive 
regimen as part of their GVHD prophylaxis. Furthermore, transplantation with a CD3+/CD19+ cell 
depleted graft resulted in the development of a functionally different NK cell population that was 
more prone to activation via the NKG2C/CD94 receptor complex and less sensitive to inhibition 
via the NKG2A/CD94 receptor complex.
Several studies have shown that the beneficial effect of NK cell activity after SCT is dependent 
on the fast reconstitution of a cytolytic NK cell repertoire that is regulated by KIR24 and that 
a slower reconstitution towards a KIR dependent repertoire is associated with poor clinical 
outcome.14;20;21;25 In the group receiving a CD3+/CD19+ cell depleted graft, we observed functional 
NK cells already at 14 days after SCT, with KIR expressing NK cell numbers similar to those 
found in the donor before SCT. After 14 days, the cytolytic activity and number of KIR expressing 
cells increased even further and remained high during follow up. In contrast, in patients that 
received a CD34+ cell selected graft KIR reconstitution took much longer, whereby during the 
first six months after SCT the repertoire was skewed towards NKG2A expressing cells rather 
than KIR expressing cells, a phenomenon also described by others.21
So it would appear that the conditions created after SCT using a CD3+/CD19+ cell depleted graft 
support the development of a KIR based repertoire. The clinical relevance of such a finding is 
exemplified by the fact that in the clinical studies that reported a role for NK cells in the anti­
tumor response after SCT, the nature of the interaction between KIR and HLA class I appeared 
decisive for the outcome.8;9;25-27 The most straightforward example hereof is the haploidentical 
SCT setting, whereby donor NK cells expressing KIR specific for self HLA class I ligands sense 
the absence of this ligand in the recipient. This results in cytolytic responses against the recipient 
tumor cells and reduced risk of relapse (“missing self”).8;28-30 A similar phenomenon can also be 
observed in HLA-matched SCT for AML, when the donor expresses a KIR for which the ligand 
is missing in the patient (“missing ligand”).27 Although it is appealing to incorporate the receptor- 
ligand model into the criteria for donor selection in HLA-matched SCT, recent findings in the 
haploidentical setting demonstrated that this model is more complex as not only inhibitory KIR, 
but also certain activating KIR play a crucial role in the process of tumor cell recognition and 
eradication.31
The high NK cell numbers observed in the CD3/19 group may be the result of NK cells present 
in the graft. Indeed it has been shown that alloreactive NK cells can expand and persist for at
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least 28 days.32 Alternatively and not mutually exclusive, the high numbers may be a result of de 
novo generation from CD34+ progenitor cells since the dose of CD34+ cells was much higher in 
the CD3/19 group as compared to the CD34 group.
Caligiuri and Freud33 have proposed a model for NK cell development based on different 
maturation stages of NK cells in secondary lymphoid organs. According to this model, NK cells 
go through four maturation stages before they become mature peripheral NK cells (stage V). 
In the last stage (IV) before reaching maturity, the NK cells have high expression of CD56 and 
express NKG2A. In stage V, the NK cells have a lower level of CD56 expression and are KIR 
and/or NKG2A positive.34 This fits the observations made after SCT using a CD34+ cell selected 
graft. We and others1821 observed that most of the NK cells found in peripheral blood in the first 
six months after SCT resemble those in stage IV (CD56bright and NKG2A+), and that gradually 
over time more NK cells reach stage V. Clinical data suggest that a sustained high number of NK 
cells resembling stage IV (CD56bright and NKG2A+) is associated with poor clinical outcome.1420 
Interestingly, the formation of the NK cell receptor repertoire in case of CD3+/CD19+ cell depleted 
grafts is clearly different. Not only is there a faster shift to a KIR based repertoire, but the reduction 
in NKG2A expressing cells appears to coincide with the occurrence of a population expressing 
the activating NKG2C receptor. At one year after SCT as much as 50% of the NK cells express 
NKG2C. Normally, in peripheral blood only few mature NK cells express NKG2C. Also, only low 
numbers of stage IV NK cells express NKG2C .33 The occurrence of the NKG2C expressing NK 
cell population may have important consequences for the anti-tumor response after SCT. The 
stimulatory receptor NKG2C, like NKG2A binds to HLA-E, although the affinity of NKG2C for 
HLA-E appears to be lower.35 The NK cells in the CD3/19 group were more prone to activation 
by NKG2C and NKp46 triggering in terms of cytolytic activity and IFN-y production. Furthermore, 
the inhibitory effect of NKG2A triggering on the whole population was lost at later stages after 
SCT, coinciding with the occurrence of NKG2C expressing NK cells. In contrast, NK cells in the 
CD34 group maintained a high frequency of NKG2A expressing cells and NKG2A triggering 
completely inhibited cytolytic NK cell activity. A similar observation was made for NK cells after 
CD34+ haploidentical SCT.14 Also in this patient group practically all NK cells expressed NKG2A 
during the first four months after SCT and expression of HLA-E on the tumor cells completely 
blocked the cytolytic activity of NKG2A+ NK cells. This may suggest that a shift in balance from 
a CD94/NKG2A+ to a more CD94/NKG2C+ phenotype in the CD3/19 group, and a subsequent 
overruling of NKG2A-mediated inhibition, may lead to a stronger anti-tumor response and a 
better clinical outcome.
Although the two patient groups are yet too small to compare clinical outcomes, we did observe 
that human cytomegalovirus (CMV) reactivation was more common in the CD3/19 group (4 out of 
9 patients) than in the CD34 group (1 out of 14 patients). In previous studies it was demonstrated 
that CMV has an impact on the expression of NK cell receptors on NK cells and CD8+ T cells 
irreversibly resulting in increased CD94/NKG2C expression levels and subsequently the loss of 
CD94/NKG2A expression.36-38 However, when we excluded the CMV positive patients from our 
analyses, the change from an overall NKG2A+ to a more NKG2C+ phenotype was also seen in
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patients that did not suffer from CMV reactivation (data not shown). The alternative reconstitution 
of the NK cell receptor repertoire, characterized by the change in balance of CD94/NKG2A+ NK 
cells to more CD94/NKG2C+ NK cells, and its impact on clinical outcomes after SCT is therefore 
a subject for further study.
In summary, in this study we show that the use of selectively depleted grafts (CD3+/CD19+ 
cell depletion) as compared to CD34+ cell selected grafts in HLA-matched SCT leads to faster 
reconstitution of the KIR repertoire resulting in a longer time frame after SCT for NK cell cytolytic 
activity. Moreover, at a later stage after SCT, there was a large population of NKG2C expressing 
cells and NK cells appeared to be more prone to activation. Extended studies are underway to 
reveal whether these findings have an effect on clinical outcome.
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supplemental material
Figure S1. Reconstitution of T, B, and NK cells for the CD34 and CD3/19 group. Shown is the reconstitution for 
T, B, and NK cells (x106/L) within the CD34 (upper panel) and CD3/19 group (lower panel) after SCT. Concentrations 
of cells are depicted as median concentrations at day 14, 30, 60, 90, 180 and 365 after SCT.
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Abstract
In allogeneic stem cell transplantation (SCT), NK cells are able to perform graft-versus-leukemia 
(GVL) responses without the induction of graft-versus-host disease (GVHD), a feature that can 
be exploited for cellular immunotherapy. NK cell alloreactivity is induced when inhibitory killer 
immunoglobulin-like receptors (KIR) fail to recognize HLA molecules on potential target cells. In 
this study, we examined the plasticity of the KIR repertoire and the cytolytic response of mature 
human peripheral blood NK cells in the presence of specific KIR receptor-ligand (i.e. HLA-C) 
mismatches. We show that the introduction of specific KIR-ligand mismatches (KIR vs. HLA-C) 
in vitro favors the outgrowth of KIR+ NK cells lacking their cognate ligand leading to an increased 
frequency of alloreactive KIR+ NK cells within the whole NK cell population. Furthermore, after 
culture, these KIR+ NK cells are more cytolytic on a per cell basis towards KIR-ligand mismatched 
K562 target cells and primary leukemic target cells. This study demonstrates that HLA class I 
can skew the mature NK cell phenotype and enrich the alloreactive NK cell population towards 
leukemic target cells, which may be important for future clinical applications of NK cell-based 
immunotherapies in transplantation settings.
Skewing NK cell alloreactivity
Introduction
Circumventing graft-versus-host disease (GVHD) while boosting graft-versus-leukemia (GVL) 
responses after hematopoietic stem cell transplantation (SCT) is one of the major challenges 
within the field of transplantation today.1-4 In this respect, natural killer (NK) cells are of interest for 
use in immunotherapeutic strategies as they form the first line of defense in mediating immunity 
against microbial pathogens and are efficient effectors in eradicating tumor cells without inducing 
severe GVHD.5-8
NK cells survey potential target cells for the absence or loss of expression of HLA class I 
molecules or other non-classical HLA class I specific signals through killer cell immunoglobulin­
like receptors (KIR) and the inhibitory CD94/NKG2A receptor complex.910 Overall, HLA class I 
expression is surveyed by the lectin-like receptor CD94/NKG2A through its recognition of the 
ubiquitously expressed HLA-E molecule.11 KIR allow for a more subtle surveillance as these 
receptors recognize specific epitopes present on HLA-A, -B, or -C molecules. HLA-A3 and -A11 
are recognized by KIR3DL2, HLA-Bw4 is recognized by KIR3DL1 and receptors KIR2DL1 and 
KIR2DL2/3 are able to distinguish HLA-C into HLA-C1 and HLA-C2 molecules.12 
In allogeneic SCT, anti-leukemic NK cell alloreactivity can be facilitated by allowing mismatches 
for specific KIR-ligands (HLA), i.e. HLA-B and/or HLA-C, between donor and recipient (KIR 
ligand-ligand model). The introduction of certain HLA mismatches has been shown to induce NK 
cell-mediated GVL responses, without inducing severe GVHD, and to contribute to decreased 
relapse, better engraftment and improved overall survival.13-15 However, others state that the 
induction of NK cell alloreactivity is not dependent on HLA mismatching, but is rather induced by 
the presence of an inhibitory KIR in the donor's genotype with the absence of the corresponding 
KIR-ligand in the recipient's HLA repertoire (receptor-ligand model).16-18 In SCT, the KIR repertoire 
of NK cells was shown to be important for the induction of alloreactive NK cell responses.19-22 
However, studies have focused on the KIR repertoire and its reconstitution of NK cells emerging 
from CD34+ cells after SCT and less is known about the plasticity of the KIR repertoire of mature 
human NK cells when used for immunotherapeutic strategies.
In this study, we set up an in vitro culture system based on the receptor-ligand model and 
investigated the plasticity of the phenotype and cytolytic response of mature human peripheral 
NK cells within a KIR receptor-ligand (KIR vs. HLA-C) mismatched environment. Results 
demonstrate that the presence of a specific KIR-ligand (HLA-C) present on feeder cells skews 
the response of healthy donor NK cells by favoring the outgrowth of NK cells expressing the 
KIR that lacks its cognate KIR-ligand, resulting in an oligoclonal increase of specific alloreactive 
NK cells bearing improved cytolytic ability. These results may be important for future clinical 
applications of NK cell-based immunotherapy within the field of transplantation.
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Materials and methods
Cell isolation and genotyping
Buffy coats from healthy human donors were purchased from Sanquin Blood Bank, Nijmegen, 
The Netherlands, upon written informed consent with regard to scientific use according to Dutch 
law. Peripheral blood mononuclear cells (PBMC) were isolated by density gradient centrifugation 
(Lymphoprep; Nycomed Pharma, Roskilde, Denmark). NK cells were negatively selected 
(Miltenyi Biotec, Bergisch Gladbach, Germany) resulting in a purity of more than 95%. Parallel 
to the experiments, HLA-C and KIR genotyping were performed on small samples from all buffy 
coats (Table 1). Data analysis was focused on NK cell donors having KIR2DL1, 2 and 3 in their 
KIR repertoire.
Table 1. KIR genotype and HLA-C type of NK cell donors.
aCoding for KIR genotype and HLA-C type; 1 = present, 0 = not present, ND = not able to determine. bThe following 
donors were selected for detailed analysis based on the presence of KIR2DL1/2/3; 2, 3, 4, 5, 6, 7, 9, 11, 13, 14.
Cell lines
Single-cell-derived clonal K562 cell lines expressing HLA-Cw*0301 (K562-C1) and HLA- 
Cw*0403 (K562-C2) were used as feeder cells during culture and as target cells in functional 
assays. Briefly, HLA class-I deficient K562 cells were transfected with full length HLA-Cw0301 
cDNA inserted into the EcoRI and HindIII sites of expression vector pcDNA3.1(-) (Invitrogen, 
Paisley, UK) and HLA-Cw*0403 cDNA ligated into the pEF6/V5-His expression vector (pEF6/ 
V5-His TOPO TA Expression Kit; Invitrogen, Paisley, UK). The cell lines K562-Cw*0301 and 
K562-Cw*0403 showed stable and strong HLA class I expression (>95%) analyzed by flow cy­
tometry using the HLA class I antibody W6/32 (Sigma, Steinheim, Germany). The expression
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of HLA-Cw*0301 and HLA-Cw*0403 was confirmed by mRNA profiling (sequencing of HLA-Cw 
cDNA). As a control, HLA class I-negative K562 cells transfected with empty vector pcDNA3.1 
were used (K562-Cneg).
In vitro culture system
Freshly isolated NK cells were cultured with irradiated K562-C1, K562-C2, and K562-Cneg feeder 
cells in a 1:1 ratio in the presence of rhIL-2 (10 U/ml; Chiron, Amsterdam, the Netherlands) and 
rhIL-15 (1 ng/ml; BioSource International, Camarillo, CA, USA) in culture medium consisting of 
RPMI 1640 medium supplemented with pyruvate (0.02 mM), glutamax (2mM), penicillin (100 U/ 
ml), streptomycin (100 |jg/ml), and 10% human pooled serum (HPS), in a 37 oC, 95% humidity, 
5% CO2 incubator.
CFSE based division analysis
Cell division was studied by CFSE dilution patterns. Freshly isolated NK cells were labeled with
0.1 |jM CFSE (Molecular Probe, Eugene, OR, USA), aliquoted in CFSE labeling buffer (PBS 
containing 0.02% HPS), for 10 minutes at RT in the dark. The reaction was stopped by addition 
of equal volumes of cold HPS. Subsequently, cells were washed three times with CFSE labeling 
buffer and resuspended in culture medium. CFSE-labeled NK cells were cultured as described 
above and were analyzed using flow cytometry.
Flow cytometry
Non-CFSE labeled NK cells were phenotypically analyzed on the FC500 (Beckman Coulter, 
Miami, FL, USA) using the following conjugated mAbs: NKAT2-FITC (KIR2DL/S2/3), CD158a-PE 
(KIR2DL/S1), NKB1-PE (KIR3DL1), CD3-PC5, CD56-PC7 (Beckman Coulter). CFSE-labeled 
NK cells were analyzed on the Gallios™ using the following conjugated mAbs: CD16-FITC 
(Dako), CD3-ECD, CD56-APC-A750, CD158b-PC7 (KIR2DL/S2/3), CD158e1-APC (KIR3DL1), 
CD158a-APC-A700 (KIR2DL/S1), CD45-PO (all provided by Beckman Coulter). For 10-color 
flow cytometry, fluorochrome combinations were balanced to avoid antibody interactions, 
sterical hindrance and to detect also dimly expressing populations. Before 10-color analyses 
were performed, all conjugates were titrated and individually tested for sensitivity, resolution and 
compensation of spectral overlap. Isotype controls were used to define marker settings.
Functional analysis
The functionality of NK cells was studied by degranulation patterns (CD107a expression) 
upon target encounter. To this end, NK cells were harvested from culture and viable NK cells 
were plated in 96-well V-bottom plates in culture medium supplemented with fluorochrome-
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conjugated anti-CD107a (1:200; BD Biosciences, Erembodegem, Belgium). Subsequently, non­
irradiated K562-C1, K562-C2, K562-Cneg, or Kasumi-1 (HLA-C1 homozygous) target cells were 
added at an E:T ratio of 1:2 and incubated at 37 oC, 95% humidity, 5% CO2. After 4 hours, the 
degranulation of NK cells was phenotypically analyzed by flow cytometry.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 5.0. Results of different conditions 
were compared using paired student t-tests or repeated measures ANOVA analysis with the 
Tukey multiple comparison test for post-testing. P-values <.05 were considered statistically 
significant.
results
To study the phenotypical changes and cytolytic response of mature peripheral NK cells within 
a KIR-ligand mismatched environment, we set up an in vitro culture system in which KIR-ligand 
mismatches were introduced through HLA-C transfected K562 cells. To this end, freshly isolated 
NK cells were cultured in the presence of IL-2 and IL-15 together with irradiated K562 feeder 
cells transfected with HLA-C1 (K562-C1), HLA-C2 (K562-C2), or an empty vector (K562-Cneg) 
in a 1:1 ratio. Subsequently, NK cells were phenotypically and functionally analyzed.
NK cell phenotype is skewed in vitro by m ism atched KIR-ligands
At day 7 of culture, NK cells were phenotypically analyzed for KIR2DL/S1/2/3 and KIR3DL1. As 
all donors showed a KIR3DL1 expression between 0 to 2% (data not shown), we omitted this from 
further analysis and focused on the expression of KIR2DL/S1+KIR2DL/S2/3- (single KIR2DL/ 
S1+) and KIR2DL1-KIR2DL/S2/3+ (single KIR2DL/S2/3+). Skewing of the NK cell phenotype was 
seen for both KIR subsets in the presence of a specific KIR-ligand mismatched environment 
(e.g. KIR vs. HLA-C) (Figure 1). Single KIR2DL/S1+ NK cells were significantly more present 
within cultures containing “mismatched” HLA-C1+ feeder cells compared to cultures containing 
“matched” HLA-C2+ or HLA-C negative feeder cells (Figure 1A). Visa versa, percentages of 
single KIR2DL/S2/3+ NK cells showed elevated levels in the presence of “mismatched” HLA-C2+ 
feeder cells compared to cultures containing “matched” HLA-C1+ or, although not in all cases, 
HLA-C negative feeder cells (Figure 1B). Thus, in vitro data suggest that a specific KIR-ligand 
mismatched environment leads to a favored NK cell phenotype in which NK cells preferably 
express the KIR receptor for which the cognate ligand is lacking.
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Figure 1. Distribution of KIR2DL/S1 and KIR2DL/S2/3 on K IR3DL1- NK cells at day 7 of culture in a non­
specific (HLA-Cneg), HLA-C1 and HLA-C2 environment. Freshly isolated NK cells were cultured in the presence 
of irradiated HLA-Cneg, HLA-C1+, and HLA-C2+ K562 feeder cells. The phenotype of NK cells was analyzed at 
day 7 of culture. (A) Shown are the percentages of single KIR2DL/S1+ cells within the total NK cell population after 
non-specific (HLA-Cneg), HLA-C1 and HLA-C2 stimulation at day 7 of culture. Differences between the different 
stimulation settings were analyzed using repeated measures ANOVA analysis; *P<.05, ***P<.001. (B) Shown are the 
percentages of single KIR2DL/S2/3+ cells within the total NK cell population after non-specific (HLA-Cneg), HLA-C1 
and HLA-C2 stimulation at day 7 of culture. Differences between the different stimulation settings were analyzed 
using repeated measures ANOVA analysis; *P<.05.
Mism atched KIR-ligand induces oligoclonal division of specific KIR positive NK  
cells
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To investigate whether the skewed NK cell phenotype through a KIR-ligand mismatched 
environment was due to clonal expansion of specific KIR+ subsets, we performed CFSE 
based division analyses. To this end, CFSE-labeled NK cells were cultured within a KIR-ligand 
mismatched environment. At day 7, the cell division of the cultured CFSE-labeled NK cells was 
analyzed (Figure 2). In the presence of both HLA-C1+ and HLA-C2+ feeder cells, KIR negative 
NK cells were able to divide within culture. However, in the presence of HLA-C1+ feeder cells,
2 out of 3 donors showed that single KIR2DL/S1 + NK cells had a higher division percentage 
than single KIR2DL/S2/3+ NK cells (Figure 2; open bullets). The opposite effect was seen in 
the presence of HLA-C2+ feeder cells as single KIR2DL/S2/3+ NK cells were triggered to divide 
more than single KIR2DL/S1 + NK cells (Figure 2; closed bullets). Thus, within a KIR-ligand 
mismatched environment, KIR+ NK cells that lack their cognate ligand are more prone to expand 
in culture compared to the KIR+ NK cells that are able to recognize their proper ligand in vitro.
This suggests that KIR-ligand mismatching guides the proliferation of allospecific KIR+ NK cells.
Overall, these results suggest that the introduction of NK cells to a specific KIR-ligand mismatched 
environment triggers the outgrowth of KIR+ NK cells lacking their cognate KIR-ligand and therefore 
skews the NK cell phenotype towards a specific KIR repertoire. As these reactive NK cells can be 
cytolytic towards the same KIR-ligand mismatched cells, we further hypothesized that a specific 
KIR-ligand mismatched environment may lead to an increase of specific cytolytic KIR+ NK cells 
within the whole NK cell population.
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Figure 2. Division of single KIR2DL/S1+, single KIR2DL/S2/3+ and KIRneg NK cell subsets at day 7 of culture in 
an HLA-C1 and HLA-C2 environment. CFSE-labeled NK cells were cultured in the presence of irradiated HLA-C1 + 
and HLA-C2+ K562 feeder cells and analyzed at day 7 of culture. Shown are the results for 3 donors of which NK 
cells were cultured in an HLA-C1 (o) and an HLA-C2 ( • )  environment. Depicted are the percentages of divided cells 
within the KIR negative, single KIR2DL/S1 + and single KIR2DL/S2/3+ NK cell subsets at day 7 of culture. Differences 
in division between the different NK cell subsets were analyzed using repeated measures ANOVA analysis; **P<.01.
Skewing of KIR+ NK cells is associated with increased functional alloreactivity
To investigate whether a KIR-ligand mismatched environment leads to an increase of specific 
cytolytic KIR+ NK cells within the whole alloreactive (CD107+) NK cell population, HLA-C1 and 
HLA-C2 stimulated NK cells were analyzed for their degranulation potential against K562-C1 
and K562-C2 target cells at day 7 of culture (Figure 3). Results showed that stimulation with 
“mismatched” HLA-C1 + feeder cells led to an increase of cytolytic KIR2DL/S1 + NK cells against 
K562-C1 target cells as compared to the percentage of KIR2DL/S1 + NK cells stimulated by 
“matched” HLA-C2+ feeder cells (Figure 3A,B). Vice versa, stimulation of NK cells with 
“mismatched” HLA-C2+ feeder cells increased the percentage of KIR2DL/S2/3+ NK cells within 
the alloreactive CD107+ NK cell pool against K562-C2 target cells compared to the percentage 
of KIR2DL/S2/3+ NK cells stimulated by “matched” HLA-C1 + feeder cells (Figure 3A,C). These 
results show a clear trend, albeit not significant, that stimulation of NK cells with a specific KIR- 
ligand mismatch may lead to an increase of specific cytolytic KIR+ NK cells within the whole 
alloreactive NK cell pool against target cells expressing the same KIR-ligand mismatch. As the 
percentage of the specific cytolytic KIR+ NK cells increased, we further investigated whether this 
would lead to an enhanced cytolytic alloresponse on a per cell basis.
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Figure 3. Distribution of single KIR2DL/S1+ and single KIR2DL/S2/3+ NK cells within the alloreactive (CD107+) 
NK cell population upon target encounter. Freshly isolated NK cells of 4 donors were cultured in an HLA-C1 and 
HLA-C2 environment and analyzed for degranulation (CD107+) at day 7 of culture against K562-C1 and K562-C2 
target cells. (A) Shown are the results for one representative donor. The upper panels depict the percentages of 
alloreactive (CD107+) single KIR2DL/S1 + NK cells within the whole CD107+ NK cell pool upon K562-C1 target 
encounter at day 7 of culture in an HLA-C1 and HLA-C2 environment. The lower panels depict the percentages 
of alloreactive (CD107+) single KIR2DL/S2/3+ NK cells within the whole CD107+ NK cell pool upon K562-C2 target 
encounter at day 7 of culture in an HLA-C1 and HLA-C2 environment. (B) Shown are the percentages of single 
KIR2DL/S1+ NK cells within the alloreactive (CD107+) NK cell population upon K562-C1 target encounter at day 7 of 
culture in an HLA-C1 and HLA-C2 environment. Differences between the different stimulation settings were analyzed 
using paired t-tests. (C) Shown are the percentages of single KIR2DL/S2/3+ NK cells within the alloreactive (CD107+) 
NK cell population upon K562-C2 target encounter at day 7 of culture in an HLA-C1 and HLA-C2 environment 
Differences between the different stimulation settings were analyzed using paired t-tests
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Increased specific cytolytic alloresponse upon KIR-ligand mismatching
As we were interested to know whether specific cytolytic KIR+ NK cells show enhanced 
alloreactivity when pre-stimulated by target cells lacking the inhibitory KIR-ligand, we tested the 
degranulation potential of KIR2DL/S1+ NK cells against KIR-ligand mismatched (K562-C1) target 
cells after 7 days of pre-stimulation with “mismatched” HLA-C1+ feeder cells (K562-C1) and 
compared this with pre-stimulation with HLA-negative feeder cells (K562-Cneg) or unstimulated 
NK cells (D0) (Figure 4A). Stimulating the cells non-specifically for 7 days (K562-Cneg) led to an 
enhanced cytolytic alloresponse (% degranulating cells) of KIR2DL/S1 + NK cells as compared 
to freshly isolated NK cells (D0) against K562-C1 target cells. Thus, stimulation of NK cells by 
co-culture with K562 cells leads to increased alloreactivity. More importantly, stimulation of NK 
cells in the presence of the specific KIR-ligand mismatch for KIR2DL/S1 + (C1) showed an even 
stronger cytolytic response of KIR2DL/S1+ NK cells towards K562-C1 target cells as compared 
to non-specifically stimulated NK cells (Cneg).
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Figure 4. Degranulation of single KIR2DL/S1+ NK cells on a per cell basis upon target encounter. Freshly 
isolated NK cells of 3 donors were cultured in a non-specific (HLA-Cneg) and HLA-C1 environment. NK cells were 
analyzed for degranulation before culture (D0) and at day 7 of culture upon the encounter of (A) K562-C1 target 
cells and (B) the HLA-C1 homozygous primary tumor cell line Kasumi. Differences in degranulation within the single 
KIR2DL/S1 + NK cell subset before and after culture were analyzed repeated measures ANOVA analysis; *P<.05, 
**P<.01.
As priming of NK cells towards their target is of interest for future NK cell therapies against 
hematological malignancies or for treatment of solid tumors, we further investigated if the 
specific KIR-ligand mismatched stimulation would trigger the cytolytic KIR+ NK cell subset 
towards increased killing of a primary tumor cell line. To this end, we tested freshly isolated NK 
cells before culture (D0) and non-specific stimulated (Cneg) and specific KIR-ligand mismatched 
stimulated NK cells (C1) at day 7 of culture against a primary HLA-C1 homozygous tumor cell 
line (Kasumi) (Figure 4B). Comparable to the alloreactivity towards K562-C1 target cells, results 
show that overall stimulation of NK cells within culture (Cneg) leads to enhanced alloreactivity 
of KIR2DL/S1 + NK cells towards the primary HLA-C1 homozygous Kasumi tumor cell line. In 
addition, the alloreactivity of the KIR2DL/S1 + NK cells is further improved when NK cells are 
specifically stimulated with “mismatched” HLA-C1 + feeder cells. Thus, by specifically introducing 
a KIR-ligand mismatch within the culture system, specific KIR+ NK cells can be primed to give 
a better cytolytic alloresponse towards non-previously encountered primary tumor cell lines 
bearing the same KIR-ligand mismatch.
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Discussion
Regulation of cytolytic responses of alloreactive NK cells through interactions between inhibitory 
KIR and HLA class I ligands has well been described.12 In this study, we show that the phenotype 
of mature human NK cells from healthy donors can be skewed through KIR-ligand (KIR vs. 
HLA-C) mismatches resulting in an enrichment of specific alloreactive NK cells bearing higher 
cytolytic responses towards specified targets. A simplified model summarizing our findings is 
shown in Figure 5. This is the first study that uses a designed in vitro culture system, in which 
specific KIR-ligand mismatched feeder cell lines skew mature human NK cell phenotype and its 
cytolytic response.
Figure 5. Skewing of the human KIR repertoire of mature peripheral NK cells leads to enrichm ent of specific 
cytolytic KIR* NK cells against HLA-C1* or HLA-C2* target cells. Proposed model showing a simplified summary 
on how the human NK cell KIR repertoire and the NK cell cytolytic response can be skewed in vitro in the presence of 
an HLA-C1 or HLA-C2 environment. Here, a human peripheral NK cell population is shown containing KIR negative, 
KIR2DL/S1* (red), KIR2DL/S2/3* (blue), and KIR2DL/S17KIR2DL/S2/3* (red and blue) NK cells. In the presence of 
“mismatched” irradiated HLA-C1* feeder cells (upper scheme), KIR2DL/S1* NK cells expand in culture leading to 
an increase in cytolytic KIR2DL/S1* NK cells within the whole alloreactive NK cell population upon HLA-C1* target 
encounter. In addition, these cytolytic KIR2DL/S1* cells are more alloreactive on a per cell basis as compared 
to freshly isolated or non-specific stimulated KIR2DL/S1* NK cells. Vice versa, in the presence of “mismatched” 
irradiated HLA-C2* feeder cells (lower scheme), KIR2DL/S2/3* NK cells expand in culture leading to an increase in 
cytolytic KIR2DL/S2/3* NK cells within the whole alloreactive NK cell population upon HLA-C2* target encounter. In 
addition, although not analyzed in this study, these cytolytic KIR2DL/S2/3* cells may be more alloreactive on a per 
cell basis as compared to freshly isolated or non-specific stimulated KIR2DL/S2/3* NK cells.
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Previous research by Rose et al.23 showed that the KIR repertoire of human NK cells can be 
skewed according to the KIR ligand-ligand model13, but not by the receptor-ligand model.16 They 
showed that when feeder cells were mismatched with NK cells for a specific KIR-ligand (ligand­
ligand mismatch), the frequency of the cognate KIR in the NK cell population would increase 
compared to autologous or allogeneic HLA-matched cultures. Our results, however, when using 
HLA-C1 homozygous donor NK cells, support the receptor-ligand model.16 In this setting, the NK
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cell population from these donors showed an increase in the frequency of KIR2DL/S1 + cells when 
cultured in the presence of HLA-C1 feeder cells and of KIR2DL/S2/3+ cells in the presence of 
HLA-C2 feeder cells. Thus, we show that as well in an HLA-matched as in an HLA-mismatched 
situation, KIR positive NK cells lacking their cognate ligand in culture are able to increase in 
frequency. The difference in these findings is most likely explained by the substantially different 
culture methods used in these two studies. The former study tested polyclonal NK cells starting 
from CD3+-depleted PBL which were broadly activated by PHA and cultured in the presence of 
high amounts of IL-2 together with HLA-mismatched PBMC and later PHA-blasts for a duration 
twice as long as our culture protocol.23 Our culture setup may be more subtle as we used highly 
purified and freshly isolated NK cells and cultured them directly, without pre-activation, in the 
presence of low amounts of IL-2 and IL-15 with HLA-homozygous or HLA-negative K562 tumor 
cell lines for only 7 days. Although the initial amount and increase of cell numbers are not that 
high as in the former study, without severe pre-activation and cytokine stimulation, this setup, 
that focuses purely on the interaction between KIR and HLA-C, may allow for the detection of a 
more genuine reaction of mature human NK cells in vitro.
Remarkably, in our CFSE based division analyses, the effect through HLA-C2 mismatching 
tended to be stronger than HLA-C1 mismatching. However, this might be explained by the 
results of the HLA-C typing of the donors. Of the 3 donors used for these experiments (Table 1; 
donors 11, 13 and 14), 2 out of 3 were HLA-C1 homozygous, whereas only one was HLA-C1/ 
C2 heterozygous. According to the NK cell “licensing/education” model24"26, KIR2DL/S1+ NK cells 
of HLA-C1 homozygous donors may be hyporesponsive as these cells lacked their cognate 
ligand in vivo. This subsequently results in a damped response within a mismatched HLA-C1 
environment. From these same donors, the KIR2DL/S2/3+ NK cells are properly armed as their 
ligand, HLA-C1, has been present in vivo and thus these cells are perfectly able to respond within 
a mismatched HLA-C2 environment. The KIR2DL/S1+ and KIR2DL/S2/3+ NK cell subsets from 
the HLA-C1/C2 donor are both properly armed and thus able to respond within, respectively, a 
mismatched HLA-C1 or HLA-C2 environment (Figure 2B). Thus, these results suggest that the 
self HLA-C background of NK cells is an important determinant for the strength of their response 
in the presence of a KIR-ligand mismatch ex vivo. Concerning adoptive transfer of mature NK 
cells for immunotherapeutic purposes, the results of this study suggest that the presence of 
inhibitory KIR on donor NK cells in absence of its cognate ligand in the recipient as well as the 
HLA-background of the donor NK cells are two key factors that determine the alloreactive NK 
cell response within the recipient.
During NK cell maturation, the KIR repertoire is pre-dominantly formed by the KIR genotype of 
the cells and is only mildly influenced by the HLA class I type.27;28 The minor role of HLA class I 
in shaping the KIR repertoire is also reflected in the setting of allogeneic SCT, as reconstitution 
of the KIR repertoire mainly reflects that of the donor and not the recipients'.19;29 This in vitro 
study, however, shows that the KIR repertoire of human mature NK cells can be reshaped 
in the presence of a specific KIR-versus-HLA mismatch. Moreover, in vitro reshaping of the 
KIR repertoire of mature NK cells, within a specific KIR-versus-HLA mismatched environment,
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increases the cytolytic response of the alloreactive KIR+ NK cells against target cells lacking 
the cognate ligand. Thus, as the KIR genotype is important in the formation of the basic KIR 
repertoire during NK cell maturation, the HLA class I environment is pre-dominant in reshaping 
the KIR repertoire and determining the strength of the cytolytic NK cell response after NK cell 
maturation.Overall, these findings hold promise for future transplantation strategies using mature 
NK cells as effectors and future research is warranted to optimize and exploit the skewing of NK 
cell responses towards specific targets for the immunotherapeutic treatment of hematological 
malignancies.
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Abstract
Cyclosporin A (CsA), rapamycin (Rapa) and mycophenolic acid (MPA) are frequently used for 
GVHD prophylaxis and treatment after allogeneic stem cell transplantation (SCT). As NK cells 
have received great interest for immunotherapeutic applications in SCT, we analyzed the effects 
of these drugs on human cytokine-stimulated NK cells in vitro. Growth-kinetics of CsA-treated 
cultures were marginally affected, whereas MPA and Rapa severely prevented the outgrowth 
of CD56bright NK cells. Single-cell analysis of NK cell receptors using 10-color flow cytometry 
revealed that CsA-treated NK cells gained a similar expression profile as cytokine-stimulated 
control NK cells, mostly representing NKG2A+KIR-NCR+ cells. In contrast, MPA and Rapa 
inhibited the acquisition of NKG2A and NCR expression and NK cells maintained an overall 
NKG2A-KIR+NCR+/- phenotype. This was reflected in the cytolytic activity, as MPA- and Rapa- 
treated NK cells, in contrast to CsA-treated NK cells, lost their cytotoxicity against K562 target 
cells. Upon target encounter, IFN-y production was not only impaired by MPA and Rapa, but also 
by CsA. Overall, these results demonstrate that CsA, MPA and Rapa each have distinct effects 
on NK cell phenotype and function, which may have important implications for NK cell function 
in vivo after transplantation.
ISD and NK cell function
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DJGraft-versus-host disease (GVHD) is a major complication after allogeneic stem cell transplantation 
(SCT) resulting in high mortality rates. Various immunosuppressive drugs (ISD) are applied to 
efficiently prevent GVHD. These drugs mainly focus on targeting and suppressing unwanted 
adaptive immune responses. However, the effect on NK cell responses after SCT remains largely 
unknown.
NK cells have shown to possess immunotherapeutic activity in SCT. NK cells form the first line 
of defense in mediating immunity against microbial pathogens, directly through cytolysis of 
virus-infected cells and indirectly by the production of inflammatory cytokines such as IFN-y.12 
Furthermore, NK cells of donor origin are efficient effectors in eradicating tumor cells without 
inducing severe GVHD.3-5 In HLA-haploidentical SCT, Ruggeri et al.6 showed that donor 
alloreactive NK cells isolated from peripheral blood of recipients were able to lyse tumor cells 
derived from the recipient. This implicates that NK cells may provide immune reactivity after SCT 
by targeting residual tumor cells. For HLA-matched SCT, we have previously shown that the use 
of NK cell-enriched stem cell grafts leads to early NK cell repopulation with concomitant high 
cytolytic capacity within the first months after SCT7
The cytolytic and cytokine-producing activities of NK cells are regulated through a range of inhibitory 
and stimulatory receptors. Killer immunoglobulin-like receptors (KIR), including inhibitory (KIR- 
DL) and stimulatory receptors (KIR-DS), specifically recognize HLA-A,-B and -C molecules.8 The 
CD94/NKG2 heterodimeric complex, with its inhibitory (NKG2A) and stimulatory (NKG2C) form, is 
part of the C-type lectin family and recognizes HLA-E class I molecules.9 Other stimulatory NK cell 
receptors include the natural cytotoxicity receptors (NCR; NKp30, NKp44 and NKp46), NKG2D (a 
C-type lectin homodimer) and 2B4 (CD244).10 The balance between the inhibitory and stimulatory 
signals triggers and modulates NK cell effector function.1112 Although NK cells are exposed to ISD 
administered to the patient post-SCT, they have to exert optimal anti-tumor reactivity and produce 
cytokines. Among the various ISD, cyclosporin A (CsA), rapamycin (Rapa) and mycophenolic 
acid (MPA; the active metabolite of MMF) have been applied successfully for the prevention of 
GVHD.13-17 However, these drugs may influence NK cell reactivity, which could have implications 
for their use in clinical immunotherapeutic settings. Due to distinct experimental designs, previous 
studies on the effect of CsA on human and murine NK cells have shown contradictory results 
with respect to the functional activity of NK cells after treatment.18-23 In contrast to CsA, the effect 
of Rapa and MPA has been studied less extensively. A previous study on rat NK cells directly 
comparing CsA with Rapa, showed that Rapa, in contrast to CsA, significantly inhibited the growth 
and cytotoxicity of rat NK cells.22 Also, in a mouse SCT model, it has been shown that MMF does 
not inhibit graft-versus-leukemia responses or the activity of lymphokine-activated killer (LAK) 
cells, suggesting that MPA may not affect functional NK cell responses after SCT.24 Here, we 
tested the effects of CsA, Rapa and MPA on peripheral human NK cells and show that these 
drugs each have a distinct impact on NK cell phenotype and function, which may have important 
implications for NK cell function in vivo after transplantation.
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Materials and methods
Cell isolation
Buffy coats from healthy human donors were purchased from Sanquin Blood Bank, Nijmegen, 
The Netherlands, upon written informed consent with regard to scientific use. PBMC were 
isolated by density gradient centrifugation (Lymphoprep; Nycomed Pharma, Roskilde, Denmark). 
NK cells were negatively selected (Miltenyi Biotec, Bergisch Gladbach, Germany) resulting in a 
purity of more than 95%.
Culture conditions and ISD
Freshly isolated NK cells were cultured in the presence of rhIL-2 (100 U/ml; Chiron, Amsterdam, 
the Netherlands) and rhIL-15 (10 ng/ml; BioSource International, Camarillo, CA, USA) in 
culture medium (RPMI 1640 medium supplemented with pyruvate (0.02 mM), glutamax (2mM), 
penicillin (100 U/ml), streptomycin (100 |jg/ml), and 10% human pooled serum (HPS)), in a 37 
oC, 95% humidity, 5% CO2 incubator. CsA (Novartis Pharma B.V., Arnhem, The Netherlands), 
MPA (Sigma-Aldrich, Zwijndrecht, The Netherlands), or Rapa (LC Laboratories, Woburn, MA, 
USA) was added at final concentrations ranging from 0.01 to 10 jg/m l (CsA and MPA) or 0.1 
to 100 ng/ml (Rapa) based on therapeutic serum levels handled at our medical centre and 
previously published data.25-28
Flow cytometry
Cells were phenotypically analyzed using the FC500 and the Gallios™ Flow Cytometer (Beckman 
Coulter, Miami, FL, USA). The following conjugated mAbs were used for four-color stainings 
(analyzed on the FC500): CD16-FITC (Dako, Glostrup, Denmark), CD69-PE, CD3-ECD, CD56- 
PC7 (Beckman Coulter). To exclude dead cells from analysis, 7-amino-actinomycin-D (7-AAD; 
Sigma-Aldrich) was added to cells prior to acquisition. For 10-color analyses on the Gallios™, 
the following conjugated mAbs were combined: CD16-FITC (Dako), CD159c-PE (NKG2C; R&D 
Systems, Minneapolis, CA, USA), CD3-ECD, CD56-APC-A750, CD158b-PC7 (KIR2DL/S2/3), 
CD158e1-APC (KIR3DL1), CD158a-APC-A700 (KIR2DL/S1), CD159a-PB (NKG2A), CD45- 
PO, CD336-PE (NKp44), CD337-PC5.5 (NKp30), CD335-PC7 (NKp46), CD314-APC (NKG2D), 
CD244-APC-A700 (2B4) (all provided by Beckman Coulter). The combinations were balanced in 
fluorochrome combinations to avoid antibody interactions, sterical hindrance and to detect also 
dimly expressing populations. Before 10-color analyses were performed, all conjugates were 
titrated and individually tested for sensitivity, resolution and compensation of spectral overlap. 
Isotype controls were used to define marker settings.
Proliferation assays
CFSE based proliferation analysis
Freshly isolated NK cells were labeled with 0.1 |jM CFSE (Molecular Probe, Eugene, OR, USA),
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aliquoted in CFSE labeling buffer (PBS containing 0.02% HPS), for 10 minutes at RT in the dark. X  
The reaction was stopped by addition of equal volumes of cold HPS. Subsequently, the cells were pp 
washed three times with CFSE labeling buffer and resuspended in culture medium. The CFSE- 
labeled NK cells were cultured as described above and were analyzed using flow cytometry.
Quantitative flow cytometric analysis
Freshly isolated NK cells were incubated with CD16-FITC (Dako) and CD56-PC5 (Beckman 
Coulter) for 20 minutes at RT in the dark. CD56brightCD16+/- and CD56dimCD16+ cells were separated 
using high purity FACS (Altra flow cytometer, Beckman Coulter). After 5 days of culture, cells 
were stained for CD56 and CD16 and counted by flow cytometry using Flow-Count fluorospheres 
(Beckman Coulter). 7-AAD (Sigma-Aldrich) was used to exclude dead cells from analyses.
Cytotoxicity assay
HLA class-I deficient K562 target cells were labeled with 3.7 MBq (100 jC i) chromium-51 (51Cr;
Perkin Elmer, Boston, MA, USA) for 2 hours in a 37 oC, 95% humidity, 5% CO2 incubator. Labeled 
target cells were washed four times with culture medium and plated in triplicate in 96-well V-bottom 
plates (103 cells/well). NK cells were harvested from culture and viable NK cells were added in a 
1:1 ratio and incubated for 4 hours at 37 oC, 95% humidity, 5% CO2. Supernatant was harvested 
and analyzed using a gamma counter. The percentage specific lysis was calculated as follows:
% specific lysis=((experimental release-spontaneous release)/(maximum release-spontaneous 
release))x100%. To assess the IFN-y production of NK cells during target encounter, parallel 
incubations with unlabeled K562 target cells were performed.
ELISA
IFN-y production of NK cells during incubation with K562 cells was measured by ELISA (Sanquin 
(CLB), Amsterdam, The Netherlands). Supernatants were collected after 4 hours of incubation 
and stored at -80 oC until further use. IFN-y ELISA was performed according to the manufacturer's 
instructions.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 4.0. For comparisons between cytokine- 
stimulated control NK cells and NK cells cultured in the presence of ISD, we used ANOVA analysis 
with Dunnett's multiple comparison test for post-testing. Paired t-tests were used to analyze the 
statistical difference between freshly isolated NK cells and cytokine-stimulated control NK cells.
The Wilcoxon signed rank test was used for non-normally distributed data. P-values <.05 were 
considered statistically significant.
>
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Results
D ose-dependent inhibition of NK cell proliferation
To study the effect of CsA, Rapa, and MPA on the proliferation capacity of isolated NK cells, 
CFSE-labeled NK cells were cultured in the presence of 100 U/ml IL-2 and 10 ng/ml IL-15 with 
increasing concentrations of the drugs. After a 5-day culture, CFSE dilution patterns showed a 
median proliferation rate of 44% (range 22-78%) of cytokine-stimulated control NK cells (Figure 
1A), in five different division cycles (Figure 1B). Rapa and MPA significantly inhibited NK cell 
proliferation in a dose-dependent way. In contrast, CsA only showed a trend towards reduced 
proliferation.
Figure 1. Proliferation of NK cells at day 5 of culture after CsA, Rapa and MPA treatm ent. (A) The proliferation 
of NK cells isolated from 4 different donors with increasing amounts of CsA, Rapa and MPA. Results are shown in 
median with range. Differences between the cytokine-stimulated control and drug-treated NK cells were analyzed 
using ANOVA; *P<.05, **P<.01, ***P<.001. (B) CFSE division patterns of cytokine-stimulated control and CsA-, 
Rapa- and MPA-treated NK cells from one representative donor. Numbers in the upper right are the percentage of 
divided cells.
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Freshly isolated NK cells can generally be separated into two distinguishable subsets. The 13 
CD56brightCD16+/- subset comprises 5-10% of all peripheral blood NK cells, while the rest has a |E  
CD56dimCD16+ phenotype.29 In steady state, the CD56brightCD16+/- subset is described to be more ^  
immunoregulatory through cytokine production (e.g. IFN-y, TNF-a), whereas the CD56dimCD16+ 
subset is more cytotoxic. After activation, both subsets are able to produce cytokines and 
possess cytolytic activity. We analyzed the proliferation capacity of both subsets under influence 
of the different ISD. The enriched CD56brightCD16+/- and CD56dimCD16+ subsets, having equal 
expression patterns of the IL-2 and IL-15 receptor (Figure S1, Table S1), were incubated 
separately in the presence or absence of CsA, Rapa and MPA (Figure 2).
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Figure 2. CD56brightCD16+/- and CD56dimCD16+ NK cell subsets at day 5 of culture after CsA, Rapa and MPA 
treatm ent. (A) Fold expansion of sorted CD56bnshtCD16*/- NK cells (upper panel) and sorted CD56d'mCD16* NK cells 
(lower panel) isolated from 4 different donors with increasing amounts of CsA, Rapa and MPA. Results are shown 
in median with range. (B) CD56/CD16 phenotype of CD56bnghtCD16*/- and CD56d'mCD16* NK cells before and after 
culture of one representative donor. The upper panels show the CD56/CD16 phenotype of both NK cell subsets 
before and after culture without ISD. The lower panels show the phenotype of the NK cell subsets after CsA, Rapa 
and MPA treatment. (C) The percentage of C D56"CD16* cells within the sorted CD56bnght subset before (start) and 
after culture in the absence (CTRL) or presence of CsA, Rapa and MPA. Results are shown in median with range. (D) 
The percentage of C D56"CD16* cells within the sorted CD56dim subset before (start) and after culture in the absence 
(CTRL) or presence of CsA, Rapa and MPA. Results are shown in median with range. The difference cytokine- 
stimulated control NK cells before (Start) and after culture (CTRL) was analyzed using paired t tests; *P<.05, **P<.01, 
***P<.001. Differences between the cytokine-stimulated control (CTRL) and drug-treated NK cells were analyzed 
using ANOVA; *P<.05, **P<.01, ***P<.001.
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The cytokine-stimulated control CD56brigh,CD16+/- cells showed a significant increase in cell 
number after 5 days of culture as compared to the initial amount of cells (P=.014), whereas the 
amount of CD56dimCD16+/- cells decreased (P=.065) suggesting that the proliferation seen in the 
whole NK cell population (Figure 1) is only due to the proliferation of the CD56brighlCD16+/- NK 
cell subset (Figure 2A). Treatment of either NK cell subset with ISD showed that Rapa and MPA 
impaired the growth of the CD56brighlCD16+/- cells, whereas CsA only inhibited the growth of these 
cells at higher concentrations. In contrast to the CD56brighlCD16+/- subset, Rapa and MPA did not 
affect the amount of CD56dimCD16+ cells. However, CsA showed a significant decrease at 1000 
ng/ml. Thus, Rapa and MPA only influence the amount of NK cells within the CD56brighlCD16+/' 
subset, whereas CsA is capable of affecting NK cell numbers of both subsets.
Rapa and MPA, but not CsA, affect the C D 56bright/C D 5 6 dim balance
Interestingly, while maintaining their CD56brighl phenotype, the sorted CD56brighlCD16+/- subset 
increased the expression of CD16 during culture (P<.05), whereas the CD56dimCD16+/- cells 
elevated their CD56 expression (P<.05) and lowered their CD16 expression (Figure 2B (upper 
panels), C, D). In the CD56brighlCD16+/- subset, Rapa (10 ng/ml, P<.05; 50 ng/ml, P<.01) and MPA 
(500 ng/ml, P<.001) dose-dependently inhibited the upregulation of CD16 expression, whereas 
CsA-treated CD56brighlCD16+/- cells revealed a similar phenotype as compared to cytokine- 
stimulated control cells at day 5 of culture (Figure 2B (left panels), C, D). As cytokine-stimulated 
control CD56dimCD16+/- cells elevated their CD56 expression, especially Rapa inhibited the 
upregulation of CD56 with increasing concentrations (10 ng/ml and 50 ng/ml, P<.01; Figure 2B 
(right panels), C, D). This inhibition was also seen after treatment with CsA and MPA, although 
to a lesser extent.
The differential immunosuppressive effect on the proliferation and phenotype of the separately 
cultured NK cell subsets was also reflected on the phenotype in cultures of the whole NK cell 
population. During culture, the balance between the CD56brighl and CD56dim subsets shifted 
towards a more CD56brighl phenotype during culture (Figure 3A,B). As CsA showed to have a 
marginal effect on the growth of CD56brighlCD16+/- cells and did not strongly affect the changing 
phenotype of the NK cell subsets (Figure 2), the whole NK cell population showed the same shift 
towards a CD56brighl phenotype as compared to cytokine-stimulated control cells (Figure 3A,B). 
In contrast, mainly due to their strong inhibitory effect on the proliferation of the CD56brighl subset, 
the majority of the NK cell population after Rapa and MPA treatment maintained a CD56dim 
phenotype. Thus, under immunosuppressive treatment, Rapa and MPA, but not CsA, inhibit the 
outgrowth of CD56brighl NK cells and thereby affect the CD56brighl/CD56dim distribution of the whole 
NK cell population.
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Figure 3. CD56brightCD16+/- and CD56dimCD16+ distribution within the NK cell population before and after culture 
with CsA, Rapa and MPA. (A) Shown are two representative donors before (start) and after culture in the absence 
(CTRL) or presence of CsA (1000 ng/ml), Rapa (50 ng/ml) and MPA (500 ng/ml). Gated are the CD56brightCD16+/- and 
CD56dimCD16+ NK cells. (B) The percentage of CD56bri9htCD16+/- (left panel) and CD56dimCD16+ (right panel) NK cells 
within the NK cell population. Shown are the results for 7 different donors before and after culture. The difference 
between cytokine-stimulated control NK cells before (S) and after culture (CTRL) was analyzed using paired t tests; 
***P<.001. Differences between the cytokine-stimulated control (CTRL) and drug-treated NK cells were analyzed 
using ANOVA; **P<.01.
Differential phenotypical changes of cultured NK cells under immunosuppressive 
treatment
Using 10-color flow cytometry, we analyzed the effect of the different ISD on the phenotype of 
cultured NK cells. After a 5-day culture, cytokine-stimulated control NK cells showed a significant 
increase in the percentage of activating receptors (NKG2D, NCR) as compared to freshly 
isolated NK cells (Table 1). In addition, the percentage of KIR+ cells was reduced, paralleled 
by a significant increase in the percentage of NKG2A+ cells. Thus, in a cytokine-driven NK cell 
culture, the NK cell population appears to reach a more activated state and shifts the inhibitory 
control by the KIR repertoire towards control by the NKG2A receptor complex. 
Cytokine-stimulated NK cells treated with CsA only showed minor changes in the percentages 
of NK cell receptor-positive cells as compared to cytokine-stimulated control NK cells (Table 
1). With respect to KIR expression, the percentage of KIR2DL/S2/3+ NK cells was significantly 
lower (P<.05) and there was significant less increase of the percentage of NKG2A+ NK cells 
(P<.05). With regard to NCR expression, the percentage of NKp30+ NK cells was significantly 
higher as compared to cytokine-stimulated control NK cells (P<.05). In contrast to the minor 
changes observed for CsA treatment, MPA treatment had a major impact on the NK cell receptor 
repertoire, i.e. the percentage of KIR+ NK cells remained significantly higher (P<.01 for KIR2DL/ 
S1 and KIR2DL/S2/3) and the percentage of NKG2A+ NK cells was significantly lower (P<.01) 
as compared to cytokine-stimulated control NK cells. Furthermore, the KIR/NKG2A distribution
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within the NK cells much resembled the situation of freshly isolated NK cells. Nevertheless, 
MPA allowed for the activation of NK cells since the percentage of NK cells positive for NCR 
and NKG2D increased during NK cell culture. For all NK cell receptors analyzed, Rapa showed 
to have intermediate effects on the NK cell receptor repertoire as compared to CsA and MPA. 
In summary, MPA, and Rapa to a lesser extent, inhibited reformation of the NK cell receptor 
repertoire during culture, whereas CsA only had mild effects on the NK cell receptor repertoire.
Table 1. NK cell phenotype after culture.
Isolation
%
CTRL
% 1P
CsA
% 2P
Rapa
% 2P
MPA
% 2P
KIR2DL/S1 21 (13-28) 17(8-24) ns 16(5-21) ns 20 (9-31) <.01 25 (16-36) <.01
KIR2DL/S2/3 40(16-62) 31 (14-43) ns 24 (7-44) <.05 30(15-50) ns 48(19-61) <.01
KIR3DL1 15(0.0-28) 5(0.1-16) <.01 3(0.3-15) ns 3(0.3-16) ns 4(0.4-21) ns
NKG2A 44(16-58) 84 (68-94) <.001 72 (45-89) <.05 69(44-81) <.01 50 (34-74) <.01
NKG2C 14 (4-50) 13(7-34) ns 14(7-31) ns 13(6-27) ns 20 (6-38) ns
NKG2D 59(46-81) 95 (44-98) <.05 94 (56-99) ns 84(19-97) <.05 77 (14-92) <.01
2B4 (CD244) 99 (96-100) 96 (88-98) <.05 97 (86-98) ns 86 (78-95) <.01 88 (78-96) <.01
NKp30 51 (29-57) 83 (28-94) ns 93 (69-99) <.05 74 (17-95) ns 55(11-88) <.05
NKp44 1.1 (0.3-2) 64 (37-96) <.001 65 (29-95) ns 33 (10-87) <.01 19(5-59) <.01
NKp46 69 (36-78) 90 (56-94) <.05 81 (50-88) ns 85 (56-93) ns 85 (48-92) ns
NK cells were isolated and cultured for 5 days in the absence (CTRL) or presence of immunosuppressive drugs 
(CsA; 1000 ng/ml, Rapa; 50 ng/ml, MPA; 500 ng/ml). Isolated NK cells and (un)treated NK cells were analyzed 
by flow cytometric analysis using anti-KIR, -NKG2A, -NKG2C, -NKG2D, -CD244 and -NCR mAbs. Medians (with 
ranges) are shown (n=7). 1The difference between cytokine-stimulated control NK cells before (Isolation) and after 
culture (CTRL) was analyzed using the Wilcoxon signed rank test. 2Differences between the cytokine-stimulated 
control (CTRL) and drug-treated NK cells were analyzed using ANOVA. ns indicates no significant difference.
Differential distribution of K IR /N KG 2A  and N CR  upon immunosuppressive 
treatm ent
By using KIR and NKG2A/C monoclonal antibodies (mAbs) in one 10-color panel and NKG2D, 
2B4, NCR mAbs in a second 10-color panel, we could analyze the expression of multiple 
combinations of different NK cell receptors on a single-cell level.
As there were no significant changes in NKG2C expression (Table 1), we focused our analysis 
on NK cell subsets positive for KIR and/or NKG2A. This analysis showed that freshly isolated 
NK cells largely consist of subsets that either express NKG2A without KIR (median:26%) or 
KIR without NKG2A (median:42%) (Figure 4Ai). Only a small proportion of cells expressed 
both receptors (median:10%) and the remaining cells had no expression of NKG2A and KIR. 
Culturing NK cells with IL-2 and IL-15 significantly changed the distribution of these subsets as 
almost all NK cells expressed NKG2A either in combination with KIR expression (median:25%)
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or without KIR expression (median:58%). The percentages of NKG2A negative NK cell subsets X  
were significantly decreased after culture. As compared to cytokine-stimulated control cells, pp 
CsA-treated cells showed a similar distribution pattern of NKG2A+ and/or KIR+ NK cells after ^
_p^
culture and most of the cells were NKG2A+KIR- (median:58%) (Figure 4Aii). However, there were 
significant less NKG2A+KIR+ NK cells and significant more NKG2A-KIR- NK cells present within 
the whole NK cell population. In contrast to CsA treatment, MPA-treated, and to a lesser extent 
Rapa-treated, NK cells had a similar distribution of NKG2A and KIR as freshly isolated NK cells 
and in this respect significantly differed from cytokine-stimulated control cells.
87
Figure 4. KIR/NKG2A and NCR distribution within the NK cell population. Shown are the results for 7 different 
donors in median with range. (A) The distribution of KIR and NKG2A expression within the NK cell population from (i) 
freshly isolated NK cells (start) versus cytokine-stimulated control NK cells (CTRL) cultured for 5 days and (ii) the KIR 
and NKG2A expression after 5 days of culture in the absence (CTRL) versus presence of CsA (1000 ng/ml), Rapa 
(50 ng/ml) and MPA (500 ng/ml). (B) The expression of the different NCR (NKp30, NKp44, NKp46) within the NK cell 
population: — = NCR negative; +-- = single NCR+ (cells expressing only one of the NCR); ++- = double NCR+ (cells 
expressing two different NCR); +++ = triple NCR+ (cells expressing all three NCR). Shown are the distribution of NCR 
expression within the NK cell population from (i) freshly isolated NK cells (start) and cytokine-stimulated control NK 
cells (CTRL) cultured for 5 days and (ii) the NCR expression after 5 days of culture in the absence (CTRL) versus 
presence of CsA (1000 ng/ml), Rapa (50 ng/ml) and MPA (500 ng/ml). The difference between cytokine-stimulated 
control NK cells before and after culture (CTRL) was analyzed using the Wilcoxon signed rank test; *P<.05, **P<.01. 
Differences between the cytokine-stimulated control (CTRL) and drug-treated NK cells were analyzed using ANOVA; 
*P<.05, **P<.01.
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Further analysis of the stimulatory NCR receptors (NKp30, NKp44, NKp46) and their distribution 
within the NK cell population, showed that freshly isolated NK cells either contained single (one 
NCR; median:37%) or double (combination of two different NCR; median:35%) NCR+ NK cells 
or did not express any NCR (median:21%) (Figure 4Bi).
After culture, the NK cell population showed a more activated phenotype as they primarily 
consisted of triple NCR+ NK cells (expression of all three NCR; median:56%), only 2% remained 
NCR-. CsA treatment had no effect on the acquisition of NCR by NK cells and showed the same 
distribution pattern as cytokine-stimulated control NK cells (Figure 4Bii). As MPA-treated NK cells 
were hampered in their upregulation of NKp30 and NKp44 (Table 1), most NK cells were single 
(median:28%) or double (median:39%) NCR+ and only a median of 27% expressed all three 
NCR (Figure 4Bii). As compared to MPA-treated NK cells, Rapa inhibited NCR upregulation to 
a lesser extent and revealed a median expression distribution of 20% single, 31% double, and 
28% triple NCR+ NK cells. Thus, while KIR/NKG2A data suggest that the NK cells maintain their 
original status, NCR data indicate that the cells are able to upregulate NCR expression, albeit it 
significantly lower than the cytokine-stimulated control NK cells.
In summary, MPA and Rapa inhibited the NK cell receptor repertoire from shifting towards an 
overall NKG2A+KIR-NCR+ phenotype and maintained an overall NKG2A-KIR+NCR+/- phenotype, 
whereas CsA-treated NK cells were hardly different from cytokine-stimulated control NK cells. 
Detailed analysis on KIR/NKG2A and NCR modulation within sorted and separately cultured 
CD56brightCD16+/- and CD56dimCD16+ subsets, revealed that both subsets are subjected to 
change in phenotype after culture (Figure S2, S3). Thus, the net results for the whole NK cell 
population are based on the KIR/NKG2A and NCR modulation of both NK cell subsets together 
with the proliferation of the CD56brighl subset.
Cytolytic activity and IFN -y production after immunosuppressive treatm ent
As the balance between the inhibitory and stimulatory receptors of the NK cell receptor repertoire 
was differentially affected by CsA, Rapa and MPA, we assessed the overall cytotoxicity against 
MHC class I-negative K562 target cells in a 1:1 ratio. In parallel, we analyzed the IFN-y production 
after the encounter with K562 target cells. To analyze the overall activation of NK cells before 
target encounter, we analyzed the expression of CD69, an early lymphocyte activation marker 
that plays a role in various NK cell functions.30
Upon NK cell isolation from healthy donor PBMC fractions, only few NK cells express CD69 
(data not shown). After culture, Rapa showed a dose-dependent inhibition of CD69 expression 
with a significant lower percentage of CD69+ cells at 100 ng/ml. Although not significant, CsA- 
and MPA-treated NK cells showed a trend towards a dose-dependent inhibition in the median 
percentage of CD69 expression (Figure 5A).
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Figure 5. Activation, cytolytic activity and IFN-y  production after culture with CsA, Rapa and MPA. After 
culture in the absence or presence of CsA, Rapa and MPA, the expression of CD69, the cytolytic NK cell activity 
and the IFN-y production was analyzed. (A) Expression of the early activation marker CD69 at day 5 of culture after 
CsA, Rapa and MPA treatment. Shown are the results for 5 different donors in median with range. (B) The cytolytic 
activity (specific lysis) was measured in a 4 hr 51Cr-release assay containing NK cells in a 1:1 ratio with K562 target 
cells. Shown are the results for 6 different donors in median with range. (C) Supernatant of parallel 4 hr co-cultures, 
containing NK cells from the same donors (n=6) and K562 target cells in a 1:1 ratio, was analyzed in ELISA assays 
for the production of IFN-y. Differences between the cytokine-stimulated control (0 ng/ml) and drug-treated NK cells 
were analyzed using ANOVA; *P<.05, **P<.01.
After a 5-day culture, NK cells showed to be significantly impaired in their cytolytic activity after 
Rapa and MPA treatment, but not after CsA treatment (Figure 5B). However, as CsA did not 
affect the cytolytic activity of the NK cells, IFN-y production was severely impaired (Figure 5C). 
Thus, upon target encounter, Rapa- and MPA-treated NK cells, but not CsA-treated NK cells, are 
impaired in their cytolytic activity. IFN-y production was affected by all three ISD.
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Discussion
Within the first months after SCT, NK cells contribute to graft-versus-leukemia (GVL) responses 
without the induction of GVHD and form a first line of defense against infectious agents. This 
makes NK cells attractive candidates for immunotherapeutic purposes in SCT. The presence 
of NK cells in the graft proved to be beneficial for clinical outcome.3132 In these cases, NK cells 
need to be fully functional in the early phase after SCT, despite high level of immunosuppressive 
treatment. Therefore it is important to study the influence of ISD on NK cell activity in order to 
select the drug with less influence on NK cell function. In this study, we show that CsA, Rapa 
and MPA have diverse effects on NK cell phenotype and function, which may have important 
implications for their use in GVHD prophylaxis.We show that CsA had minor effects on NK 
cell proliferation, whereas Rapa and MPA severely inhibited the outgrowth of CD56brighlCD16+/' 
NK cells. As we showed that CsA-treated NK cells had a similar CD56bright/CD56dim distribution 
as cytokine-stimulated control NK cells, Wang et al.21 revealed that CsA could even increase 
the percentage of CD56bright NK cells as compared to cytokine-stimulated control cells. This 
difference might be explained by our distinct gating strategy, as we, in contrast to Wang et al.21, 
also included the CD56brighlCD16+ cells within our CD56bright subset, in consensus with gating 
strategies described by Cooper et al.29 When excluding the CD16+ cells from the CD56brighl 
subset, we also noticed a tendency towards a higher percentage of CD56brightCD16- NK cells 
after CsA (Figure 3A). Treatment of NK cells with CsA had a minimal effect on the changes within 
the NK cell receptor distribution during culture, resembling the NK cell receptor repertoire of 
cytokine-stimulated control NK cells. However, MPA- and Rapa-treated NK cells were inhibited in 
their shift towards a NKG2A+KIR-NCR+ phenotype and largely maintained a NKG2A-KIR+NCR+/" 
phenotype, also observed in freshly isolated NK cells. However, in contrast to freshly isolated 
or cytokine activated NK cells the MPA or Rapa treated cells were significantly inhibited in their 
cytolytic capacity. Thus, MPA and Rapa are able to inhibit shifts in the NK cell receptor repertoire 
and also inhibit cytolytic capacity, whereas CsA does not interfere with changes in the NK cell 
receptor repertoire within an in vitro culture system and leaves the cytolytic capacity intact. 
Recently, we also demonstrated that CsA does not affect NK cell receptor repertoire shifts and 
function in vivo, as we showed, in a randomized phase III study, that transplantation with CD3+/ 
CD19+ cell depleted grafts, in contrast to CD34+ enriched grafts, resulted in the development of a 
different NK cell population which was more prone to activation due to equal distribution of NKG2A 
and NKG2C.7 Both patient groups were treated with the same immunosuppressive regimen, 
using CsA as a first-line agent, as part of their GVHD prophylaxis. Thus, MPA and Rapa, but not 
CsA, are likely to inhibit the outgrowth of functional NK cells and therefore could have a negative 
effect on NK cell mediated GVL responses in vivo after SCT. Clearly, MPA and Rapa showed 
a dose-dependent inhibition in NK cell cytotoxicity against K562 target cells, whereas CsA did 
not affect cytotoxicity. In addition, each of the ISD severely inhibited the IFN-y production upon 
target encounter. As NK cells are a major source of IFN-y, wich plays a major role in facilitating 
GVL effects and preventing GVHD33, this could have clinical implications for patients after SCT
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A recent study, however, showed that CsA-treated NK cells sustain their IFN-y production after X  
IL-12 and IL-18 stimulation.21 This suggests that CsA selectively inhibits IFN-y production upon pp 
target encounter, but sustains the IFN-y production capacity after IL-12 and IL-18 stimulation.
Fauriat et al.34 recently described that upon target encounter the CD56dim subset, and not the 
CD56bright subset, is responsible for IFN-y production, whereas the CD56bright subset is the major 
source of IFN-y during IL-12 and IL-18 stimulation. Thus, our data suggest that CsA, Rapa, and 
MPA treatment clearly inhibit the CD56dim cells from producing IFN-y, leaving the CD56bright cells 
as the only remaining NK cells left for IFN-y production. As MPA, and Rapa to a lesser extent, 
prevent the outgrowth of CD56bright cells, this could have important implications for the overall 
IFN-y production and therefore the IFN-y-mediated GVL effects after SCT. In contrast, as CsA 
does not inhibit the outgrowth of CD56bright NK cells, the overall IFN-y production after SCT might 
be less affected and IFN-y-mediated GVL effects driven by cytokines should remain intact. As 
the immunotherapeutic applications for NK cells have received huge interests in the field of 
SCT, it is important to gain insight in the effects of the limiting conditions in the different settings 
of transplantation in which NK cells need to be able to function. Immunosuppression is one of 
the conditions that may influence NK cell functionality. In this study, we have demonstrated that 
CsA, in contrast to Rapa and MPA has the least effect on NK cell phenotype and function in 
vitro. Thus, this study clearly suggests that the choice of immunosuppressive treatment might 
affect the outcome of NK cell therapy in vivo after transplantation. Additional studies on NK cell 
phenotype and function of patients after SCT using different immunosuppressive strategies are
91warranted to survey the in vivo effect of the different immunosuppressive regimens in more 
detail.
Acknowledgements
Technical support on the Gallios™ and specified conjugated mAbs were kindly provided 
by Beckman Coulter. The authors thank Rob Woestenenk (Dept. of Laboratory Medicine 
- Laboratory of Hematology) for cell sorting. We also thank Talia Latuhihin for her technical 
support in the early stages of this work.
ISD and NK cell function
References
1. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. 
Blood. 1990;76(12):2421-2438.
2. Trinchieri G. Biology of natural killer cells. Adv Immunol. 1989;47:187-376.
3. Cook MA, Milligan DW, Fegan CD et al. The impact of donor KIR and patient HLA-C 
genotypes on outcome following HLA-identical sibling hematopoietic stem cell 
transplantation for myeloid leukemia. Blood. 2004;103(4):1521-1526.
4. Giebel S, Nowak I, Wojnar J et al. Impact of activating killer immunoglobulin-like 
receptor genotype on outcome of unrelated donor-hematopoietic cell transplantation. 
Transplant Proc. 2006;38(1):287-291.
5. Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell 
alloreactivity in mismatched hematopoietic transplanta Science. 2002;295(5562): 
2097-2100.
6. Ruggeri L, Capanni M, Casucci M et al. Role of natural killer cell alloreactivity in HLA- 
mismatched hematopoietic stem cell transplantation. Blood. 1999;94(1):333-339.
7. Eissens DN, Schaap NP, Preijers FW et al. CD3(+)/CD19(+)-depleted grafts in HLA- 
matched allogeneic peripheral blood stem cell transplantation lead to early NK
cell cytolytic responses and reduced inhibitory activity of NKG2A. Leukemia. 
2010;24(3):583-591.
8. Parham P. MHC class I molecules and KIRs in human history, health and survival.
Nat Rev Immunol. 2005;5(3):201-214.
9. Braud VM, Allan DS, O'Callaghan CA et al. HLA-E binds to natural killer cell 
receptors CD94/NKG2A, B and C. Nature. 1998;391(6669):795-799.
10. Moretta A, Bottino C, Vitale M et al. Activating receptors and coreceptors involved in 
human natural killer cell-mediated cytolysis. Annu Rev Immunol. 2001;19:197-223.
11. Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood 
Rev. 2006;20(3):123-137.
12. Papamichail M, Perez SA, Gritzapis AD, Baxevanis CN. Natural killer lymphocytes: 
biology, development, and function. Cancer Immunol Immunother. 2004;53(3): 
176-186.
13. Cutler C, Li S, Ho VT et al. Extended follow-up of methotrexate-free 
immunosuppression using sirolimus and tacrolimus in related and unrelated donor 
peripheral blood stem cell transplantation. Blood. 2007;109(7):3108-3114.
14. Haentzschel I, Freiberg-Richter J, Platzbecker U et al. Targeting myco phenolate 
mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell 
transplantation. Bone Marrow Transplant. 2008;42(2):113-120.
15. Schleuning M, Judith D, Jedlickova Z et al. Calcineurin inhibitor-free GVHD 
prophylaxis with sirolimus, mycophenolate mofetil and ATG in allo-SCT for leukemia 
patients with high relapse risk: an observational cohort study. Bone Marrow
ISD and NK cell function
Transplant. 2008;43(9):717-723.
>
16. Vogelsang GB, Arai S. Mycophenolate mofetil for the prevention and treatment of pp 
graft-versus-host disease following stem cell transplantation: preliminary findings.
N,
Bone Marrow Transplant. 2001;27(12):1255-1262.
17. Neumann F, Graef T, Tapprich C et al. Cyclosporine A and mycophenolate mofetil 
vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis 
after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant. 
2005;35(11):1089- 1093.
18. Introna M, Allavena P, Spreafico F, Mantovani A. Inhibition of human natural killer 
activity by cyclosporin A. Transplantation. 1981;31(2):113-116.
19. Kosugi A, Shearer GM. Effect of cyclosporin A on lymphopoiesis. III. Augmentation of 
the generation of natural killer cells in bone marrow transplanted mice treated with 
cyclosporin A. J Immunol.1991;146(5):1416-1421.
20. Petersson E, Qi Z, Ekberg H et al. Activation of alloreactive natural killer cells is 
resistant to cyclosporine. Transplantation. 1997;63(8):1138-1144.
21. Wang H, Grzywacz B, Sukovich D et al. The unexpected effect of cyclosporin A 
on CD56+CD16- and CD56+CD16+ natural killer cell subpopulations. Blood. 
2007;110(5):1530-1539.
22. Wai LE, Fujiki M, Takeda S, Martinez OM, Krams SM. Rapamycin, but not 
cyclosporine or FK506, alters natural killer cell function. Transplantation.
2008;85(1):145-149.
23. Lin SJ, Kuo ML. Effect of cyclosporin A on interleukin-15-activated umbilical cord 
blood natural killer cell function. Cytotherapy. 2008;10(4):397-405.
24. Shapira MY, Hirshfeld E, Weiss L et al. Mycophenolate mofetil does not 
suppress the graft-versus-leukemia effect or the activity of lymphokine-activated killer 
(LAK) cells in a murine model. Cancer Immunol Immunother. 2005;54(4):383-388.
25. Bornhauser M, Schuler U, Porksen G et al. Mycophenolate mofetil and cyclosporine 
as graft-versus-host disease prophylaxis after allogeneic blood stem cell 
transplantation. Transplantation. 1999;67(4):499-504.
26. Cutler C, Kim HT, Hochberg E et al. Sirolimus and tacrolimus without methotrexate 
as graft-versus-host disease prophylaxis after matched related donor peripheral 
blood stem cell transplantation. Biology of Blood and Marrow Transplantation. 
2004;10(5):328-336.
27. Jenke A, Renner U, Richte M et al. Pharmacokinetics of intravenous mycophenolate 
mofetil after allogeneic blood stem cell transplantation. Clin Transplant. 2001;15(3):
176-184.
28. Kagawa Y, Sawada J, Yamada S et al. Relationship between development of 
nephrotoxicity and blood concentration of cyclosporine A in bone-marrow 
transplanted recipients who received the continuous intra venous infusion. Biol 
Pharm Bull. 2003;26(8):1115-1119.
93
ISD and NK cell function
29. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer cell 
subsets. Trends Immunol. 2001;22(11):633-640.
30. Borrego F, Robertson MJ, Ritz J, Pena J, Solana R. CD69 is a stimulatory receptor 
for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor. 
Immunology. 1999;97(1):159-165.
31. Bethge WA, Haegele M, Faul C et al. Haploidentical allogeneic hematopoietic 
cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 
depletion: fast engraftment and low toxicity. Exp Hematol. 2006;34(12):1746-1752.
32. Kim DH, Sohn SK, Lee NY et al. Transplantation with higher dose of natural killer 
cells associated with better outcomes in terms of non-relapse mortality and infectious 
events after allogeneic peripheral blood stem cell transplantation from HLA-matched 
sibling donors. Eur J Haematol. 2005;75(4):299-308.
33. Yang YG, Wang H, Asavaroengchai W, Dey BR. Role of Interferon-gamma in GVHD 
and GVL. Cell Mol Immunol. 2005;2(5):323-329.
34. Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of human NK cell 
cytokine and chemokine production by target cell recognition. Blood. 2010;115(11): 
2167-2176.
ISD and NK cell function
Supplemental material
>
Em
j j
4
Figure S1. Expression of IL2Ra (CD25) and IL2Rß (CD122) on sorted CD56brightCD16+/- and CD56dimCD16+ NK 
cell subsets. Sorted CD56brightCD16+/- and CD56dimCD16+ subsets were cultured separately in the presence of 100 
U/ml IL-2 and 10 ng/ml IL-15. The expression and distribution of IL2Ra (CD25, x-axis) and IL2Rß (CD122, y-axis) 
were analyzed at the start of culture and at day 5 of culture. Shown are the results for one representative donor (n=4).
Table S1. Expression of IL2Ra (CD25) and IL2Rß (CD122) on sorted CD56brightCD16+/- and CD56dimCD16+ 
NK cells.
IL2Rß (CD122) (%) IL2Ra (CD25) (%)
CD56bri9ht CD56dim CD56bright CD56dim
Start 98.2 ± 1.2 99.0 ± 0 .9 1.4 ± 0 .8 0.1 ±0 .0 9
Day 5 83.1 ± 2 .2 79.5 ± 8 .3 2.1 ± 1 .0 1.3 ± 0 .8
CD56brightCD16+/- and CD56dimCD16+ subsets were sorted out of freshly isolated NK-cells and cultured in the presence 
of 100 U/ml IL-2 and 10 ng/ml IL-15. Shown are the mean percentages +/- error of CD25 and CD122 expression of 
4 different donors at the start and at day 5 of culture.
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Figure S2. KIR/NKG2A and NCR distribution within the CD56brightCD16+/- NK cell subset. Shown are the results 
of sorted CD56bri9htCD16+/- cells of 3 different donors in median with range. (A) The distribution of KIR/NKG2A  
expression at (i) the start of culture (Start) versus cytokine-stimulated CD56b^9htCD16+/- cells cultured for 5 days 
(CTRL) and (ii) the KIR/NKG2A expression after 5 days of culture in the absence (CTRL) versus presence of CsA 
(1000 ng/ml), Rapa (50 ng/ml) and MPA (500 ng/ml). (B) The expression of the different NCR (NKp30, NKp44, 
NKp46) by CD56bnghtCD16+/- cells before and after culture: — = NCR negative; +-- = single NCR+ (cells expressing 
only one of the NCR); ++- = double NCR+ (cells expressing two different NCR); +++ = triple NCR+ (cells expressing all 
three NCR). Shown are the distribution of NCR expression at (i) the start of culture (Start) versus cytokine-stimulated 
CD56b^9htCD16+/- cells cultured for 5 days (CTRL) and (ii) the NCR expression after 5 days of culture in the absence 
(CTRL) versus presence of CsA (1000 ng/ml), Rapa (50 ng/ml) and MPA (500 ng/ml). The difference between 
cytokine-stimulated control CD56b^9htCD16+/- cells before and after culture (CTRL) was analyzed using the Wilcoxon 
signed rank test; *P<.05, **P<.01, ***P<.001. Differences between the cytokine-stimulated control (CTRL) and drug- 
treated CD56bnghtCD16+/- cells were analyzed using ANOVA; *P<.05, **P<.01, ***P<.001.
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Figure S3. KIR/NKG2A and NCR distribution within the CD56dimCD16+ NK cell subset. Shown are the results of 
sorted CD56dimCD16+ cells of 4 different donors in median with range. (A) The distribution of KIR/NKG2A expression 
at (i) the start of culture (Start) versus cytokine-stimulated CD56dimCD16+ cells cultured for 5 days (CTRL) and (ii) the 
KIR/NKG2A expression after 5 days of culture in the absence (CTRL) versus presence of CsA (1000 ng/ml), Rapa 
(50 ng/ml) and MPA (500 ng/ml). (B) The expression of the different NCR (NKp30, NKp44, NKp46) by CD56dimCD16+ 
cells before and after culture: —  = NCR negative; +-- = single NCR+ (cells expressing only one of the NCR); ++- = 
double NCR+ (cells expressing two different NCR); +++ = triple NCR+ (cells expressing all three NCR). Shown are 
the distribution of NCR expression at (i) the start of culture (Start) versus cytokine-stimulated CD56dimCD16+ cells 
cultured for 5 days (CTRL) and (ii) the NCR expression after 5 days of culture in the absence (CTRL) versus presence 
of CsA (1000 ng/ml), Rapa (50 ng/ml) and MPA (500 ng/ml). The difference between cytokine-stimulated control 
CD56dimCD16+ cells before and after culture (CTRL) was analyzed using the Wilcoxon signed rank test; *P<.05, 
**P<.01, ***P<.001. Differences between the cytokine-stimulated control (CTRL) and drug-treated CD56dimCD16+ 
cells were analyzed using ANOVA; *P<.05, **P<.01, ***P<.001.
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Abstract
Immunotherapy based on natural killer (NK) cell infusions is a potential adjuvant treatment for 
many cancers. Such therapeutic application in humans requires large numbers of functional 
NK cells that have been selected and expanded using clinical grade protocols. We established 
an extremely efficient cytokine-based culture system for ex vivo expansion of NK cells from 
hematopoietic stem and progenitor cells from umbilical cord blood (UCB). Systematic refinement 
of this two step system using a novel clinical grade medium resulted in a therapeutically 
applicable cell culture protocol. CD56+CD3- NK cell products could be routinely generated from 
freshly selected CD34+ UCB cells with a mean expansion of >15,000 fold and a nearly 100% 
purity. Moreover, our protocol has the capacity to produce more than 3-log NK cell expansion 
from frozen CD34+ UCB cells. These ex v/vo-generated cell products contain NK cell subsets 
differentially expressing NKG2A and killer immunoglobulin-like receptors. Furthermore, UCB- 
derived CD56+ NK cells generated by our protocol uniformly express high levels of activating 
NKG2D and natural cytotoxicity receptors. Functional analysis showed that these ex v/vo­
generated NK cells efficiently target myeloid leukemia and melanoma tumor cell lines, and 
mediate cytolysis of primary leukemia cells at low NK:target ratios. Our culture system exemplifies 
a major breakthrough in producing pure NK cell products from limited numbers of CD34+ cells 
for cancer immunotherapy.
Expansion UCB-derived NK cells
Introduction
Natural killer (NK) cells are CD56+CD3- large granular lymphocytes that exert innate immunity 
against viral infections and cancer.1 NK cells recognize and subsequently react to virus-infected 
and transformed cells without prior immunization, basically through the balance of signals from 
inhibitory and activating receptors.2 Therefore, NK cells have been previously described as 
promising effectors for adoptive immunotherapy against cancer.3 The anti-tumor potential of 
NK cells has been best demonstrated during therapy of leukemia patients with allogeneic stem 
cell transplantation (SCT). Ruggeri et al.4 demonstrated that NK cell alloreactivity can control 
relapse of acute myeloid leukemia (AML) without causing graft-versus-host disease (GVHD) in 
the setting of HLA-mismatched haploidentical allogeneic SCT. In addition, haploidentical NK cell 
infusions together with IL-2 in a non-transplantation setting have been associated with complete 
hematologic remission in poor-prognosis patients with AML.5 These encouraging results point 
out that allogeneic NK cell-based immunotherapy may be a promising therapeutic strategy for 
AML in both the non-transplant and post-transplant setting.5;6
To date, most clinical studies exploiting allogeneic NK cells for adoptive immunotherapy have 
been performed with NK cells selected from leukapheresis products by immunomagnetic beads 
selection protocols.7-12 In order to circumvent limitations in cell numbers, purity and state of 
activation of such blood-derived NK cells, ex vivo expansion of NK cells with higher purity will 
facilitate the infusion of a greater number of activated NK cells in patients with a relatively large 
tumor burden or permits multiple NK cell infusions.8;13;14 Therefore, development of innovative 
strategies enabling the generation of clinically relevant NK cell products with high cell numbers, 
high purity and functionality promises a major breakthrough in NK cell-based immunotherapy.
In this study, we developed a cytokine-based method for large scale expansion of functional 
CD56+ NK cells from hematopoietic stem and progenitor cells. Similar studies have been 
performed previously focusing on either CD34+ hematopoietic progenitor cells (HPC) from bone 
marrow (BM) or umbilical cord blood (UCB).15-17 However, most of these culture systems are 
unsuitable for clinical application because of the use of animal sera, animal-derived proteins and 
supportive feeder cell lines. Furthermore, most of these methods yielded only limited NK cell 
numbers for successful adoptive immunotherapy in cancer patients. In order to surmount these 
shortcomings, we established a two-step culture scheme in which we used a novel clinical grade 
medium to generate more than 3 to 4-log fold-expanded functional CD56+ NK cells from freshly 
selected or cryopreserved CD34+ UCB cells, respectively. The CD56+ NK cell products generated 
by this method have a very high purity, contain various NKG2A and killer immunoglobulin-like 
receptor (KIR) expressing mature subsets and efficiently lyse AML and solid tumor cells. These 
findings exemplify that this culture system could hold great promise for the ex vivo generation of 
clinical grade NK cell products for cellular immunotherapy against cancer.
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Materials and Methods
Cell lines
Cell lines (K562, KG1a, Lama, Kasumi, BLM and FM3) were cultured in Iscove's modified 
Dulbecco's medium (IMDM; Invitrogen, Carlsbad CA, USA) containing 50 U/ml penicillin, 50 
|jg/ml streptomycin and 10-20% fetal calf serum (FCS; Integro, Zaandam, The Netherlands) 
Characteristics of the cell lines used in functional assays are shown in Table 1. Clonal K562 
cell lines expressing HLA-Cw*0301 and/or HLA-Cw*0403 were used as target cells to analyze 
specificity of the UCB-derived NK cells. Briefly, K562 cells were transfected with full length 
HLA-Cw0301 cDNA inserted into the EcoRI and HindIII sites of expression vector pcDNA3.1(-) 
(Invitrogen, Paisley, UK) and HLA-Cw*0403 cDNA ligated into the pEF6/V5-His expression vector 
using the TOPO TA Expression kit (Invitrogen). The cell lines K562-Cw*0301, K562-Cw*0403 
and K562-Cw*0301/0403 showed stable and strong HLA class I expression (>95%) analyzed by 
flow cytometry (FCM) using the HLA class I antibody W6/32 (Sigma, Steinheim, Germany). The 
(co-)expression of HLA-Cw*0301 and HLA-Cw*0403 was confirmed by sequencing of HLA-Cw 
cDNA.
Selection of C D 34-positive stem and progenitor cells
UCB units have been obtained at birth after normal full-term delivery with written informed consent 
with regard of scientific use from the cord blood bank of the Radboud University Nijmegen 
Medical Center (RUNMC). UCB samples were stored at room temperature and processed within 
24 h after collection. Mononuclear cells (MNC) were isolated by Ficoll-Hypaque (1.077 g/ml; GE 
Healthcare, Uppsala, Sweden) density gradient centrifugation. Alternatively, UCB samples were 
thawed at 37°C and resuspended in CliniMACS buffer (Miltenyi Biotech, Bergisch Gladbach, 
Germany) containing 5% HSA, 3.5 mM MgCl2 and 100 U/ml Pulmozyme (Genentech). After 
30 min of incubation, thawed UCB cells were washed and used for CD34+ cell selection. CD34+ 
cells were selected from UCB cells using anti-CD34 immunomagnetic bead separation (Miltenyi 
Biotech, Bergisch Gladbach, Germany) according to manufacturer's instructions. The cell 
number and purity of the enriched CD34+ fraction was analyzed by FCM. Purity of the obtained 
cell populations was 85±13%.
Ex vivo expansion of CD34-positive progenitor cells
CD34+ UCB cells (between 1x104 and 3*105 per ml) were plated into 24-well tissue culture 
plates (Corning Incorporated, Corning, NY) using Methods I, II or III (Figure 1) in the following 
basal media: StemSpan® H3000 (Stemcell Technologies, Grenoble, France), Stemline I™ 
and Stemline II™ Hematopoietic Stem Cell Expansion Medium (Sigma-Aldrich, Zwijndrecht, 
The Netherlands) and Glycostem Basal Growth Medium (GBGM®) (Clear Cell Technologies,
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Beernem, Belgium). H3000 and Stemline media were supplemented with 20 mg/ml ascorbic 
acid, 50 jmol/l ethanolamine, 50 jmol/l sodium selenite, 25 jm ol ß-mercaptoethanol (all Sigma 
Aldrich), 100 U/ml penicillin, 100 |jg/ml streptomycin and 2 mmol/L L-glutamine (all Invitrogen). 
All media used in Method I and II were supplemented with 10% human serum (HS; Sanquin 
Blood Bank, Nijmegen, The Netherlands) and a low-dose cytokine cocktail consisting of 10 pg/ 
ml GM-CSF, 250 pg/ml G-CSF, 50 pg/ml LIF, 200 pg/ml MIP-1a (all Stemcell Technologies) and 
50 pg/ml IL-6 (CellGenix, Freiburg, Germany), which was based on studies using the fetal liver- 
derived stromal cell line AFT024.32 In Method III, LIF and MIP-1a were left out of the low-dose 
cytokine mixture. In addition, a high-dose cytokine cocktail was added consisting of 27 ng/ml 
SCF (CellGenix), 25 ng/ml Flt3L (CellGenix), 25 ng/ml TPO (Stemcell Technologies) and 25 ng/ 
ml IL-7 (Stemcell Technologies). During the first 14 days of culture, low molecular weight heparin 
(LMWH) (Clivarin®; Abbott, Wiesbaden, Germany) was added to the expansion medium in a 
final concentration of 25 jg/ml. In Method II and III, TPO was replaced by 20 ng/ml IL-15 at day 
9-14. Cell cultures were refreshed with new medium every 2-3 days. Cultures were maintained 
in a 37 °C, 95% humidity, 5% CO2 incubator.
Method I: Day 0 -14 Day 14 -35
-1x10 CD34* cells/ml 
seeded in H3000, Stemline I 
and II
Method II:
~3x104 CD34* cells/ml 
seeded in H3000, Stemline I 
and GBGM
Method III:
~1-3x105 CD34* cells/ml 
from cryopreserved UCB 
seeded in and GBGM
SCF, IL-7, Flt3L, SCF, IL-7, IL-15,
TPO IL-2
G-CSF, GM-CSF, G-CSF, GM-CSF,
IL-6, MIPIcc, LIF IL-6, MIPIcc, LIF
Day 0 -9 Day 9 -14 Day 14 -35
SCF, IL-7, Flt3L, SCF, IL-7, FIÍ3L, SCF, IL-7, IL-15,
TPO IL-15 IL-2
G-CSF, GM-CSF, G-CSF, GM-CSF, G-CSF, GM-CSF,
IL-6, MIPIcc, LIF IL-6, MIP1a, LIF IL-6, MIPIcc, LIF
Day 0 -9 Day 9 -14 Day 14 -35
SCF, IL-7, Flt3L, SCF, IL-7, Flt3L, SCF, IL-7, IL-15,
TPO IL-15 IL-2
G-CSF, GM-CSF, G-CSF, GM-CSF, G-CSF, GM-CSF,
IL-6 IL-6 IL-6
NK cell products described 
in Figure 1, S1A+B and 
supplemental video
NK cell products described 
in Figure 2, 3, 4, 5, 
S1C-F, S2, S3, S4, S5
NK cell products described 
in Table 1 and 
Figure S1F+G
Figure 1. Schematic diagram of the different culture methods used for the ex vivo  generation of CD56+ NK 
cells from cytokine-expanded CD34+ UCB cells. In Method I-III different combinations of cytokines were tested as 
described in detail in Materials and Methods starting with different numbers of initially seeded CD34* cells. In Method 
I and II, NK cells were generated from freshly selected UCB donors and the culture duration was 5 weeks. In Method 
III, CD34* cells were used from cryopreserved UCB donors and the culture period was 6 weeks. Finally, the diagram 
depicts which NK products were used and displayed as results in figures and supplemental material.
Differentiation of ex  vivo-expanded C D 34-positive cells into NK cells
Expanded CD34+ UCB cells were differentiated and further expanded using NK cell differentiation 
medium. This medium consisted of the same basal medium as used for the CD34 expansion 
step supplemented with 10% HS, the low-dose cytokine cocktail (as previously mentioned) and 
a new high-dose cytokine cocktail consisting of 20 ng/ml IL-7, 22 ng/ml SCF, 1000 U/ml IL-2 
(Proleukin®; Chiron, München, Germany) and 20 ng/ml IL-15 (CellGenix). Flt3L (20 ng/ml) was
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only added to the differentiation medium in Method I (Figure 1). Medium was refreshed twice 
a week from day 14 onwards. Total and CD56+ cell expansion at each week of culture was 
calculated by the number of cultured cells divided by the number of seeded cells. The number of 
seeded cells was reduced by dilution with fresh differentiation medium. The theoretical total cell 
numbers were calculated by multiplying the expansion rate per week with the number cultured 
cells.
Flow cytometry
Cell numbers and expression of cell-surface markers were determined by FCM. Briefly, cells 
were incubated with the appropriate concentration antibodies for 30 min at 4 °C. After washing, 
cells were resuspended in Coulter® Isoton® II Diluent (Beckman Coulter) and analyzed using 
the Coulter FC500 flow cytometer (Beckman Coulter). Cell numbers and NK cell purity have 
been determined by gating on CD45+ cells in combination with forward scatter (FS) and side 
scatter (SS). For phenotypic analysis of the NK cell products, living cells were gated only on FS/ 
SS and further analyzed with the specific antigen of interest. The following conjugated antibodies 
were used: anti-CD16-FITC (NKP15), anti-CD94-FITC (HP-3D9), anti-NKG2D-PE (1D11) (BD 
Biosciences Pharmingen, Breda, The Netherlands), anti-CD161-PE (191B8), anti-NKG2A-PE 
(Z199), anti-CD122-PE (CF1) (Immunotech, Marseille, France), anti-NKG2C-PE (134591), anti- 
NKp80-PE (239127) (R&D System, Abingdon, UK), anti-CD45-ECD (J33), anti-CD117-PE-Cy5 
(104D2D1), anti-CD34-PE-Cy7 (581), anti-CD56-PE-Cy7 (N901), anti-NKp30-PE (Z25), anti- 
NKp44-PE (Z231), anti-NKp46-PE (BAB281), anti-CD158a,h-PE (EB6.B), anti-CD158b/b2,j-PE 
(GL183), anti-CD158e1/e2-PE (Z27), anti-CD158i-PE (FES172), anti-CD3-ECD (UCHT1), anti- 
CD244-PE (C1.7), anti-CD25-PE-Cy5 (B1.49.9), anti-CD7-PECy5 (8H8.1), anti-CD2-FITC (39. 
C1.5) (all Beckman Coulter, Woerden, The Netherlands) and anti-HLA-ABC-PE (W6/32) (Dako, 
Enschede, The Netherlands).
Flow cytom etry-based cytotoxicity and degranulation studies
FCM-based cytotoxicity assays were performed as described previously33 with minor 
adaptations. Target cells were labeled with 0.5 jM  carboxyfluorescein diacetate succimidyl 
ester (CFSE; Molecular Probes Europe, Leiden, The Netherlands) in a concentration of 1*107 
cells per ml for 10 min at 37 °C. The reaction was terminated by adding an equal volume of 
FCS, followed by incubation at room temperature for 2 min and stained cells were washed 
twice with 5 ml IMDM/10% FCS. After washing, cells were resuspended in IMDM/10% FCS to 
a final concentration of 2*105/ml. CD56+ NK cells were washed with PBS and resuspended in 
IMDM/10% FCS to a final concentration of 2*105/ml. Target cells (2*104) were co-cultured with 
effector cells at different E:T ratio's in a total volume of 200 j l  IMDM/10% FCS in 96-wells flat- 
bottom plates. NK cells and target cells alone were plated out in triplicate as controls. NK cell 
co-cultures with primary AML cells were supplemented with IL-3 (50 ng/ml), SCF (25 ng/ml),
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Flt3L (20 ng/ml), GM-CSF (100 ng/ml) and G-CSF (100 ng/ml). To measure degranulation by 
NK cells, anti-CD107a (H4A3; BD Biosciences) was added in a 1:200 dilution to the co-cultures. 
After incubation for 4 or 24 h at 37 °C, 50 j l  supernatant was collected and stored at -20 °C for 
later use to measure cytokine production. Cells in the remaining volume were harvested and 
the number of viable target cells was quantified by FCM. Target cell survival was calculated as 
follows: % survival = ((absolute no. viable CFSE+ target cells co-cultured with NK cells)/(absolute 
no. viable CFSE+ target cells cultured in medium))x100%. The percentage specific lysis was 
calculated as follows: % lysis = (100-(% survival)). Degranulation of NK cells during co-culture 
was measured by cell surface expression of CD107a.34 After 2, 4 or 24 hrs of incubation at 37 
°C, the percentage of CD107a+ cells was determined by FCM.
IFN -y production assay
Production of IFN-y by target cell-stimulated NK cells was measured in the supernatant of the 
co-cultures by ELISA (Pierce Endogen, Rockford, IL, USA). Absorbance was measured at 450 
nm with a Multiscan MCC/340 ELISA reader (Titertek, Huntsville, Alabama, USA).
Life imaging NK cell-m ediated killing
NK cell-mediated killing of solid tumor cell lines was visualized by life imaging on a Zeiss Axiovert 
35 M inverted contrast microscope (Zeiss, Sliedrecht, The Netherlands) which was placed in 
a 37 °C incubator. Images were digitized in 768x512 pixels with a camera (VarioCam, PCO 
computer Optics GmbH, Kelheim, Germany), coupled with the Pixel Pipeline in a Macintosh-G4. 
Video recordings of microscopic fields were made continuously (1 image/min) using an in house 
developed software program version of the IPlab 3.5.5. image program (Scananlytics Inc. USA 
All). Images were further processed using the NIH Image 1.61 program, resulting in a Quick­
Time movie.
Statistics
Results from different experiments are described as mean ± standard deviation of the mean 
(SD). Statistical analysis was performed using ANOVA and Duncan Post-hoc comparison. 
P-values <.05 were considered statistically significant.
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Results
Ex vivo progenitor cell expansion and NK cell differentiation
The aim of this study was to develop an efficient cytokine-based ex vivo culture system for the 
expansion of CD34+ cells followed by the subsequent log-scale generation of CD56+CD3- NK 
cells. To identify a suitable medium for clinical applicable expansion and differentiation of NK 
cells, we tested different basal media using a two-step in vitro differentiation scheme (Figure 1). 
Initially, we compared the media H3000, Stemline I and Stemline II seeding 1x104 CD34+ cells 
using Method I. We detected a strong increase in CD34+ cell numbers in all three media, resulting 
in a mean expansion rate for all experiments (n=15) of 48±7 fold and 78±27 fold after 1 and 2 
weeks of culture, respectively. The total cell expansion was associated with a gradual decline of 
the frequency of CD34+ cells from 84±16% at day 0 till 47±14% at week 1 and 17±9% at week
2 (Figure S1A and S1B).
Next, we investigated whether the expanded UCB-derived CD34+ cells were able to differentiate 
into CD56+ NK cells. The differentiation step was monitored by the analysis of the cell 
surface molecules CD34, CD117, CD56, CD94 and CD161, which have been described to 
be expressed at different human NK cell developmental stages in vivo.18 We observed after
3 weeks total culture duration that the percentage of CD34+ cells further declined, while the 
CD56+CD161+CD94+ NK cell population increased to 10-18% (Figure 2A). Thereafter, the 
population of CD56+CD161+CD94+ cells rapidly increased to 60-77% after 4 weeks and 80-96% 
after 5 weeks of culture (Figure 2A).
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^  Figure 2. Ex vivo  generation of CD56+ NK cells from cytokine-expanded CD34+ UCB cells. CD34-enriched 
UCB cells were expanded for two weeks using three different media (H3000, Stemline I and Stemline II) and sub­
sequently differentiated into NK cells for three additional weeks in the same basal medium using Method I (Figure 
1). Cell cultures were weekly analyzed for cell numbers and phenotype using FCM. (A) Representative example of 
antigen expression during the two-step culture period using H3000 medium. One week after the onset of the NK cell 
differentiation step 2 (i.e. after 3 weeks total culture duration) the CD56*CD161*CD94* NK cell population increases 
and reaches high purity after 3 weeks of differentiation (i.e. week 5). (B) Mean CD56* cell frequency during the 5 
week culture period for three different media, which have been tested in parallel experiments using 3-6 UCB donors. 
(C) Mean total CD56* NK cell numbers after initial seeding of 1x104 CD34* UCB cells during 5 weeks of culture using 
Method I. Data represent a theoretical calculation based on the actual expansion rates of CD56* cells. Total yield 
of CD56* cells at each week was calculated by multiplying the expansion rate per week with the number of cultured 
cells. (D) Mean fold expansion of total cells after initial seeding of 1x104 CD34* UCB cells during 5 weeks of culture 
using Method I. Data represent a theoretical calculation based on the actual expansion rates of total cells.
Although we could not detect significant differences between the different basal media, the purity 
of the CD56+ cell product appeared slightly higher with H3000 medium (77±24%; n=3) and 
Stemline I medium (75±21%; n=6) as compared to Stemline II medium (66±17%; n=6) (Figure 
2B). Furthermore, a trend was observed towards higher CD56+ cell numbers with Stemline I 
medium (range 4x106-1.1x108 CD56+ cells; n=6) followed by H3000 (5.2x106-5.4x107 CD56+ 
cells; n=3) and Stemline II medium (range 1x106-2x107 CD56+ cells; n=6) (Figure 2C). The mean 
total cell expansion after 5 weeks of culture with Stemline I medium was ~4,400-fold and with 
H3000 medium ~3,200-fold, but only ~850-fold expansion with Stemline II (Figure 2D). These 
results indicate that the culture conditions support an effective outgrowth of CD56+ NK cells with 
a high purity of the final NK cell product after a culture period of 5 weeks using various basal 
media.
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Superior expansion of extremely pure NK cell products was achieved using a 
novel clinical grade medium
Although high expansion rates and purities could be obtained with current commercially available 
basal media, we were not satisfied with the purity of the CD56+ NK cell product following 5 weeks 
of culture using Method I (Figure 1). To further increase the efficiency of our culture method, we 
tested a newly formulated serum-free medium, designated Glycostem Basal Growth Medium 
(GBGM®), which is produced under GMP conditions and suitable for clinical applications.
In addition, we slightly adjusted the cytokine conditions during the expansion step, since we 
observed that expansion of CD34+ cells as well as total cells was most prominent during the 
first week of culture (Figure S1A and S1C). Furthermore, to increase the balance towards 
expansion of NK cell progenitors we added IL-15 instead of TPO to the expansion medium 
from day 9 of culture, and left out Flt3L in the differentiation medium (Figure 1). Using this 
modified Method II, culture in GBGM® resulted in the highest total cell expansion during the first 
week and subsequent differentiation into CD56+ NK cells (Figure 3 and Figure S1E). The total 
cell expansion rate in GBGM® increased to >15,000 fold (range 16,991-73,666; n=3) (Figure 
3A). More importantly, ex vivo generation of CD56+ NK cells in GBGM® yielded a significant 
higher purity of 99%±1% (n=3) compared to H3000 with 88±3% (n=3; P<.05) and Stemline I 
with 63±24% (n=3; P<.05), respectively (Figure 3B). These data demonstrate that the inventive
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modified culture system using the newly formulated GBGM® medium results in more than 4-log 
expansion of pure human NK cells from freshly selected CD34+ UCB cells.
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Figure 3. Superior expansion of UCB-derived CD56+ NK cells using a novel clinical grade medium. The new
GBGM® medium was compared with two previously tested media in the NK cell generation system according to 
Method II (Figure 1). Cell cultures were weekly analyzed for cell numbers and phenotype using FCM. (A) Fold 
expansion of total cells after initial seeding of 1x104 CD34+ UCB cells was determined during 5 weeks of culture. Data 
represent the calculation based on the actual expansion rates of total cells and are displayed as mean±SD of three 
different experiments. (B) CD56+ cell frequency during the differentiation stage for three different media, which have 
been tested in parallel experiments using three UCB donors. Data are depicted as mean±SD; *P <.05.
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Phenotypic profile of CD56+ NK cells derived from expanded CD34+ cells
Flow cytometric analysis revealed that the ex wVo-generated NK cells after 5 weeks of culture 
contained a homogeneous cell population displaying high expression of CD56 in the absence of 
CD3 (Figure 4A). A high frequency of this CD56+CD3- NK cell population displayed expression 
of CD94, while only a limited subset was positive for CD16. Furthermore, NK cell products 
displayed homogeneous and relatively high expression of NKG2D and the natural cytotoxicity 
receptors (NCR) NKp30, NKp44 and NKp46, whereas NKG2A was more differentially expressed 
(Figure 4B and Figure S2A). Additionally to these findings we detected high expression of 2B4 
(CD244) and NKR-P1 (CD161) as typical NK cell receptors, while NKG2C and NKp80 were 
absent or expressed at relatively low levels. In addition, we observed high expression of MHC 
class I (HLA-ABC) and cytokine receptor chains for IL-2 and IL-15 (CD122; IL-2/IL-15Rß) and 
SCF (CD117; c-kit-R), which are important for NK cell differentiation, expansion and activation. 
KIR repertoire analysis showed significant individual differences in the frequency of KIR- 
expressing NK cell subsets between various UCB donors. KIR+ NK cell subsets could already 
be detected at week 4 of culture and remained relatively stable until the end of the culture period 
at week 5 (Figure 4C and Figure S2B). While some CD56+ NK cell products contained positive 
cells for all four KIR phenotypes analyzed (Figure 4C), others specifically lacked the KIR2DL1/ 
DS1+ subset (Figure S2B). Generally, the KIR2DL2/DL3/DS2+ subset was present in a higher 
proportion in all NK cell products analyzed so far, which is in agreement with earlier observations 
that recovery of KIR2DL2/DL3/DS2+ NK cells is faster compared to the KIR2DL1/DS1 + subset 
following HSCT.19
Taken together, these results illustrate that UCB-derived NK cells generated with our optimized 
culture system contain developmentally mature NK cell populations expressing NKG2A, KIR 
and various activating receptors.
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Figure 4. Phenotypical profile of ex vVo-generated NK cells using Method II with GBGM. (A) Flow cytometric 
analysis of a representative NK cell product generated from CD34+ UCB progenitor cells. Cells at 5 weeks of culture 
were analyzed for expression of CD56, CD3, CD94 and CD16. (B) Expression of a repertoire of receptors important 
for regulating NK cell activity, including C-type lectin receptors, natural cytotoxicity receptors and cytokine receptors. 
Histograms show expression of the antigen of interest (black histogram) compared to the specific isotype control 
(grey histogram). (C) Acquisition of KIR+ NK cell subsets during ex vivo NK cell generation from expanded CD34+ 
UCB cells. KIR expression was determined at week 4 and 5 during the differentiation step by FCM.
Expansion UCB-derived NK cells
Ex  v/Vo-generated CD56+KIR+ and CD56+NKG2A+ NK cells are functionally 
regulated by M H C  class I expression
Phenotypic analysis showed that our ex vivo-generated NK cell products contained up to 10% 
CD56+KIR+ cells and a high proportion (40-60%) CD56+NKG2A+ cells. To determine cytolytic 
activity of these subsets and investigate if this activity is regulated by the expressed inhibitory 
receptors, we performed CD107a-based degranulation assays using HLA-negative K562 cells 
and KG1a cells expressing relatively high levels of HLA-A,-B,-C and -E (Table 1).
Table 1. HLA-C subtype, KIR group and cell surface expression of HLA molecules by the different target cell 
lines.
Cell line HLA-Cw typing1 KIR group HLA-A,-B,-C2 HLA-E2
K562 Cw*03, Cw*05 C1 &C2 <1 2
KG1a Cw*04, Cw*16 C1 &C2 101 5
Lama Cw*05, Cw*12 C1 &C2 73 5
Kasumi Cw*03 C1 9 <1
BLM Cw*07 C1 121 <1
FM3 Cw*05 C2 132 6
1HLA-Cw typing was performed by SSO-PCR using sequence specific primers according to ASHI guidelines. 
2Expression of HLA molecules was measured by FCM and expressed as delta MFI (= MFI specific antibody - MFI 
isotype control). HLA class A and B subtypes of the cell lines were: K562 (A*11, A*31, B*18, B*40), Lama (A*02, 
A*25, B*18, B*44), Kasumi (A*26, B*40, B*48), KG1a (A*30, B*53, B*78), BLM (A*02, B*07) and FM3 (A*02, B*44).
For these experiments, we used two ex vivo-generated NK cell products that contained 
approximately 15-30% CD56+CD107a+ cells upon co-culture with K562 (Figure 5 and Figure
S3). In contrast, KG1a cells hardly stimulated degranulation of these NK cell products, indicating 
that cytolytic activity is inhibited by HLA expression.
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Figure 5. Responsiveness of ex vVo-generated KIR+ and NKG2A+ NK cells to MHC class I-deficient target 
cells. Ex vivo-generated NK cells using Method II with GBGM were incubated alone, or 18 hours with MHC class 
I-negative K562 or MHC class I-expressing KG1a cells at an E:T ratio of 1:1. Cells were then stained for CD56, CD3, 
KIR or NKG2A, and the degranulation antigen CD107a. (A) Degranulation of total CD56+CD3- NK cells and KIR2DL2/ 
DL3+ NK cell subset expanded for 5 weeks from CD34+ UCB cells. Density plots are gated on CD56+CD3- NK cells 
and the histogram plots show the CD107a degranulation of the KIR2DL2/DL3+ NK cells. (B) Degranulation of total 
CD56+CD3- NK cells and NKG2A+ NK cell subset expanded for 6 weeks from CD34+ UCB cells. Density plots are 
gated on CD56+CD3- NK cells and the histogram plots show the CD107a degranulation of the NKG2A+ NK cells.
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Similarly, around 35% of the CD56+KIR2DL2/DL3+ subset degranulated upon triggering by K562, 
while only a small percentage (<5%) expressed CD107a following co-culture with KG1a (Figure 
5A and Figure S3). In agreement with these results, degranulation by the CD56+KIR2DL2/DL3+ 
subset could be specifically inhibited by K562 cells transfected with the HLA-C group 1 allele 
HLA-Cw3, while transfection of the HLA-C group 2 allele HLA-Cw4 allele had no effect (Figure
S4). Finally, we observed that also the dominant CD56+NKG2A+ subset was able to efficiently 
degranulate in response to K562 (28% CD107a+ cells), while degranulation towards KG1a was 
low probably due to relative high expression of HLA-E molecules (Figure 5B and Table 1). These 
data demonstrate that the KIR+ and NKG2A+ subsets within the UCB-derived NK cell products 
are fully responsive mediating strong degranulating activity, which is regulated by the expression 
of MHC class I molecules on the engaged target cells.
Ex  v/Vo-generated NK cells efficiently target leukemia and solid tum or cells
To determine the cytotoxic potential of the ex vivo-generated NK cell products, we performed
flow cytometry-based cytotoxicity assays using various myeloid leukemia cell lines (K562, Lama,
Kasumi and KG1a), primary AML cells and two melanoma cell lines (BLM and FM3). Ex vivo-
generated NK cells in GBGM® mediated efficient lysis of K562 cells (~40% and ~90% after
4 and 24 hrs, respectively) at a very low E:T ratio of 2:1 (Figure 6A). Furthermore, profound
lysis could be observed against MHC class I-expressing KG1a cells (~20% and ~40% after 4
113and 24 hrs, respectively). Interestingly, NK cells cultured in GBGM® showed higher cytotoxic 
and degranulating activity as compared to NK cells cultured in H3000 medium from the same 
UCB donor (Figure S5A-C). Furthermore, we found that GBGM-derived NK cells showed higher 
expression of the activating receptors NKG2D, NKp30, NKp44 and NKp46 (Figure S5D).
In addition to effective lysis of K562, also the leukemia cell lines Lama and Kasumi as well as the 
BLM and FM3 melanoma cells were efficiently lysed by the NK cells (Figure 6D). Interestingly, a 
monolayer of FM3 melanoma cells was completely destroyed within one hour of co-culture with 
NK cells (Movie S1). High NK cell-mediated cytolytic activity against leukemia and melanoma 
cell lines was associated with a high percentage of CD107a+ NK cells (Figure 6B and 6E) and 
significant production of IFN-y (Figure 6C and 6F).
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Figure 6. Functional activity of ex v/Vo-generated CD56+ NK cells using Method II with GBGM. (A) Specific 
cytotoxicity of a CD56+ NK cell product (98% purity) against the myeloid leukemia cell lines K562 and KG1a. Specific 
lysis was determined after 4 and 24 hours of co-culture in a FCM-based cytotoxicity assay at an E:T ratio of 2:1. 
Data are displayed as mean±SD of triplicate wells. (B) Degranulation of CD56+ NK cells was determined by FCM 
as the percentage of CD107a+ cells. Results are depicted as mean±SD of triplicate wells. (C) IFN-y production was 
determined by ELISA and depicted as mean±SD of triplicate measurements. (D) Specific cytotoxicity of another 
CD56+ NK cell product (95% purity) against the myeloid leukemia cell lines K562, Lama, Kasumi and KG1a, and 
the melanoma cell lines BLM and FM3. Specific lysis was determined after 18 hours of co-culture in a FCM-based 
cytotoxicity assay at an E:T ratio of 1:1. Data are displayed as mean±SD of triplicate samples. (E) Degranulation of 
CD56+ NK cells was determined by FCM as the percentage of CD107a+ cells after overnight stimulation with different 
targets. Data are depicted as mean±SD of triplicate samples. (F) IFN-y production was determined by ELISA and 
depicted as mean±SD of triplicate measurements. (G) Specific cytotoxicity of a third CD56+ NK cell product (97% 
purity) against primary AML cells from 5 different patients. Specific lysis was determined after 24, 48 and 72 hours 
of co-culture in a FCM-based cytotoxicity assay at an E:T ratio of 3:1. Data are displayed as mean±SD of triplicate 
samples
Expansion UCB-derived NK cells
Finally, we investigated whether primary leukemia cells are susceptible to killing by the ex 
vivo-generated NK cells. Therefore, we performed cytotoxicity assays with AML cells from five 
different patients. Primary AML cells from three patients (Pt 2, 4 and 5) were substantially killed 
within 3 days of co-culture at a low E:T ratio of 3:1 albeit less potent than K562 cells (Figure 6G). 
These results indicate that UCB-derived NK cells generated by our efficient culture method have 
the ability to kill myeloid leukemia and solid tumor cells.
Ex vivo generation of NK cell products from frozen CD34+ UCB cells
To investigate whether our NK cell expansion protocol could be adapted to a clinically applicable 
procedure, we have performed experiments using GBGM® medium in which we left out LIF 
and MIP-1a in the low-dose cytokine mixture because these cytokines are not available clinical 
grade. Furthermore, we performed these experiments using CD34+ cells selected from thawed 
UCB according to Method III depicted in Figure 1. Thawing and CD34+ cell selection resulted in 
obtaining 1.30±0.61x106 (range 0.84-2.50x106) CD34+ UCB cells from six donors (Table 2). Ex 
vivo generation using Method III resulted in a calculated NK cell yield of 4.6±2.4x109 (range 1.9- 
7.8x109) NK cells with a purity of >95% after 6 weeks of culture (Table 2). The expansion rate 
ranged between 1,500 and 6,500 fold starting with CD34+ cells from cryopreserved UCB. These 
data demonstrate that the transfer of our described procedure to clinical applicable conditions is 
feasible, and generates pure NK cell products with a more than 3-log expansion potential.
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Table 2. Overview of CD34+ cell selection s and NK cell culturing procedures.
Method I - H3000 Method I - Stemline I Method I - Stemline II
C D 3 4 (%) CD34 cells 
(x106)
CD56 (%) CD56
cells
(x109)
C D 5 6 (%) CD56
cells
(x109)
C D 5 6 (%) CD56
cells
(x109)
UCB1 78 1.10 50 0.57 74 1.20 87 2.20
UCB2 55 0.32 88 0.68 65 0.15 82 0.15
UCB3 93 0.52 94 3.10 43 0.55 71 0.50
UCB4 69 0.45 ND ND 99 3.50 57 0.12
UCB5 87 0.20 ND ND 75 0.40 48 0.02
UCB6 83 0.94 ND ND 97 10.0 49 0.12
Mean 78 0.59 77 1.50 75 2.70 66 0.51
SD 14 0.36 24 0.14 21 4.00 17 0.82
Range 55-93 0.20-1.10 50-94 0.57-3.10 43-99 0.15-10.0 48-87 0.02-2.20
Median 81 0.49 88 0.68 75 0.90 64 0.14
Method II - H3000 Method II Stemline I Method II - GBGM
C D 3 4 (%) CD34 cells 
(x106)
CD56 (%) CD56
cells
(x109)
C D 5 6 (%) CD56
cells
(x109)
C D 5 6 (%) CD56
cells
(x109)
UCB7 68 0.50 91 11.0 40 0.69 98 7.70
UCB8 79 0.20 89 6.1 60 0.66 99 8.50
UCB9 96 0.24 85 3.4 88 3.20 100 18.0
Mean 81 0.31 88 6.9 63 1.53 99 11.0
SD 14 0.16 3 4.0 24 1.50 1 5.50
Range 68-96 0.20-0.50 85-91 3.4-11.0 40-88 0.69-3.20 98-100 7.70-18.0
Median 79 0.24 89 6.1 60 0.69 99 8.50
Method III -GBGM
C D 3 4 (%) CD34 cells 
(x106)
C D 5 6 (%) CD56
cells
(x109)
UCB10 98 0.84 99 5.50
UCB11 96 1.20 96 1.90
UCB12 95 1.00 97 2.00
UCB13 88 0.92 95 4.00
UCB14 98 1.30 97 6.60
UCB15 98 2.50 97 7.80
Mean 96 1.30 97 4.60
SD 4 0.61 1 2.40
Range 88-98 0.84-2.50 95-99 1.90-7.80
Median 97 1.10 97 4.70
A summary of all different experiments and the corresponding UCB donors using the different culture methods I-III 
and media (Figure 1). The purity and the total number of CD34+ cells after immunomagnetic selection determined 
by FCM are depicted for each UCB donor. The CD56 content after 5 weeks (Method I and II) or 6 weeks (Method 
III) of culture was analyzed by FCM as described in the Materials and Methods. Numbers of NK cells represent a 
theoretical calculation based on the actual expansion rates of CD56+ NK cells and were calculated using the initial 
numbers of CD34+ cells from each UCB multiplied by the NK cell expansion rate from each culture procedure.
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Discussion
Here, we report a novel and highly potent two-step culture method for the ex vivo generation 
of functional NK cells for clinical application in the treatment of patients with AML and other 
malignancies. We implemented a new clinical grade basal medium, designated GBGM®, which 
facilitates efficient ex vivo HPC and NK cell expansions. Our method enables the generation of 
functional human NK cells more than 4-logs from CD34+ cells enriched from freshly collected 
UCB units and more than 3-log from frozen UCB. To the best of our knowledge, this is the first 
demonstration that human CD56+ NK cells can be efficiently generated ex vivo at such high log­
scale magnitude.
Similar studies have been reported previously using different combinations of cytokines with 
or without feeder cell lines and use of animal and human sera.15-17;20-24 For instance, a recent 
study by Kao et al.16showed that serum-free expanded CD34+ cells could be differentiated into 
a NK cell product with an average purity of 40%-60% after 5-7 weeks of culture. They reached 
a calculated mean expansion rate of 300-fold, but used fetal bovine serum during the NK cell 
generation phase.Compared to these recently published data, our novel culture system holds 
great promise, resulting in more than 3-log-scale ex vivo generation of NK cell products with 
nearly 100% purity using clinical grade medium, human serum, and cytokines. The only cytokines 
that are currently or in the near future not available as clinical grade reagents are LIF and MIP- 
1a, which are part of the low-dose supporting cytokine cocktail. However, experiments using 
CD34+ selected cells from cryopreserved UCB revealed that these two factors can be discarded 
without the loss of the NK cell differentiation potential of our refined protocol (Table 2). Taking 
the high expansion potential, our system allows the generation of an average number of 4.6x109 
highly pure NK cells from frozen CD34+ UCB cells (Table 2). Moreover, preliminary upscaling 
experiments in cell culture bags revealed that the established culture procedure generates up 
to 2x109 NK cells with the same phenotype and function as shown for the NK cell populations 
generated in tissue culture plates (data not shown). These findings indicate that our refined ex 
vivo expansion protocol has the potential to produce more NK cells (i.e. >2x109 with a purity 
between 95-99%) as compared to purification of mature NK cells from a 15 liter lymphapheresis 
procedure, which yields 0.25x109±0.14x109 (range 0.01-0.47x109) NK cells according to the 
published data of McKenna et al. in 2007.7-12
The NK cell product generated by our method displayed reproducibly an activated phenotype 
with a high expression of CD56 and various activating receptors, such as NKG2D, NKp30, 
NKp44 and NKp46. In line with earlier observations, our ex vivo-generated NK cells cultured in 
the presence of IL-2 and IL-15 showed a CD56bright phenotype of which only a subset expressed 
CD16.20;21;25;26 The resulting NK cell products contained 40-60% CD56+NKG2A+ NK cells and up 
to 10% of the CD56+ population expressed various KIRs, though there was considerable variation 
in the frequency of KIR+ NK cell subsets between the different UCB donors. According to the 
NK cell differentiation model of Freud and Caligiuri27, our ex vivo-generated NK cell products 
predominantly contain developmentally mature NK cells expressing high CD94/NKG2A, CD117
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and/or KIR mediating potent cytolytic activity against K562 cells. A minority of the CD56+ NK cells 
in our products are phenotypically immature lacking NKG2A and KIR. However, these immature 
NK cells may have the potential to maturate in vivo following adoptive transfer. Interestingly, 
Cooley et al.28 have shown that CD56+NKG2A"KIR" NK cells are able to mature in vitro upon 
culture with IL-15 and a stromal feeder cell line. Phenotypic analysis have revealed that UCB- 
derived NK cells generated with our protocol display expression of cytokine receptors including 
IL-2/IL-15Rß (CD122), which may promote in vivo survival, expansion and maturation upon 
transfer following immunosuppressive therapy.
The strong cytotoxic activity of our UCB-derived NK cells against various tumor cell lines as 
well as the cytolysis of primary AML cells were displayed by specific lysis, CD107a-mediated 
degranulation and the production of IFN-y. Most experiments were done with AML cell lines 
and primary AML cells, which has been shown to be an attractive target for NK cell-mediated 
immunotherapy.5;6 Interestingly, we also observed efficient lysis of melanoma cell lines, which 
strengthens the therapeutic potential of our NK cells product also towards non-hematological 
cancers. Most recently, several studies demonstrated, that NK cell-mediated cytotoxicity and 
the use of NK cell-based immunotherapy could be an efficient approach for the treatment of 
melanoma, which was also demonstrated in a phase I trial using the NK-92 cell line.29-31 
In conclusion, the method presented here provides an important advance for generating clinically 
relevant NK cell products from hematopoietic stem and progenitor cells with high cell numbers, 
high purity and functionality for use in NK cell-based immunotherapy. These ex vivo-generated 
NK cell products can be exploited for adoptive immunotherapy either following haploidentical 
SCT for boosting NK cell-mediated graft-versus-leukemia reactivity or in the non-transplant 
setting following lymphodepleting immunosuppressive regimens. Our current NK cell generation 
protocol has been optimized for the use of CD34+ cells from UCB, which can be readily obtained 
from cord blood banks. Furthermore, the described modifications of our protocol and use 
of the GBGM® medium have also enabled the generation of NK cells from bone marrow or 
mobilized peripheral blood CD34+ cells (preliminary data not shown). Currently, our first aim is to 
explore the feasibility of adoptive transfer of ex vivo-generated NK cell products from KIR-ligand 
mismatched UCB donors in elderly patients with AML following an intensive immunosuppressive 
regimen. Important aspects to study in this trial are whether ex vivo-generated NK cell products 
are able to survive, migrate and expand in vivo following infusion into preconditioned patients.
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Figure S1. Expansion o f CD34-enriched UCB cells using a cytokine-based culture method. CD34+ UCB cells 
were selected by immunomagnetic beads and cultured for 2 weeks in three different basal media supplemented 
with 10% HS, a low-dose cell supporting cytokine cocktail, a high-dose cell expansion cocktail and clinical grade low 
molecular weight heparin (see details in Materials and Methods and Figure 1). Absolute CD34+ cell numbers (A), fold 
expansion of total cells (B) and CD34 content (C) were determined by FCM after one and two weeks of culture using 
Method I. CD34+ cell numbers and fold expansion of total cells using Method II (D,E). Data are depicted as mean±SD 
for the different media, which have been tested in parallel experiments with CD34+ cells from 3-6 UCB donors.
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Figure S2. Phenotypical profile o f ex v/Vo-generated NK cells using Method II w ith  GBGM. Flow cytometric 
analysis of a second NK cell product generated from CD34+ UCB progenitor cells. Cells at 5 weeks of culture were 
analyzed for expression of CD56, CD3, CD94 and CD16. (A) Expression of a repertoire of receptors important for 
regulating NK cell activity, including C-type lectin receptors, natural cytotoxicity receptors and cytokine receptors. 
Histograms show expression of the antigen of interest (black histogram) compared to the specific isotype control 
(grey histogram). (B) Acquisition of KIR+ NK cell subsets during ex vivo NK cell generation from expanded CD34+ 
UCB cells. KIR expression was determined at week 4 and 5 during the differentiation step by FCM.
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KIR2DL2/3"
CD107a
Figure S3. Responsiveness o f ex v/Vo-generated KIR+ NK cells generated using Method II w ith GBGM to 
MHC class I-deficient target cells. Ex vivo-generated NK cells were incubated alone, or 18 hours with MHC class 
I-negative K562 or MHC class I-expressing KG1a cells at an E:T ratio of 1:1. Cells were then stained for CD56, CD3, 
KIR, and the degranulation antigen CD107a. Shown are the degranulation of total CD56+CD3- NK cells and KIR2DL2/ 
DL3+ NK cell subset expanded for 5 weeks from CD34+ UCB cells. Density plots are gated on CD56+CD3- NK cells 
and the histogram plots show the CD107a degranulation of the KIR2DL2/DL3+ NK cells.
Figure S4. Responsiveness o f ex v/Vo-generated KIR+ NK cells generated by Method II to  target cells 
expressing different KIR ligands. Activity of UCB-derived NK cells derived from two different donors (A and B) 
were tested in a 2 hour CD107a degranulation assay against K562 cells transfected with empty vector (EV), HLA- 
Cw3 cDNA, HLA-Cw4 cDNA or both.
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Figure S5. Functional ac tiv ity  o f ex wVo-generated CD56+ NK cells using Method II. (A) Specific cytotoxicity of 
two CD56+ NK cell products from the same UCB donor but cultured either in H3000 or GBGM against the myeloid 
leukemia cell lines K562 and KG1a. Specific lysis was determined after 24 hours of co-culture in a FCM-based 
cytotoxicity assay at an E:T ratio of 2:1. Data are displayed as mean±SD of triplicate wells. (B) Degranulation of 
CD56+ NK cells was determined by FCM as the percentage of CD107a+ cells. Results are depicted as mean±SD of 
triplicate wells. (C) IFN-y production was determined by ELISA and depicted as mean±SD of triplicate measurements. 
(D) Expression of activating receptors important for NK cell activity. Histograms show antigen expression of GBGM- 
derived NK cells (black histogram) compared to H3000-derived NK cells (grey histogram) and the specific isotype 
control (white histogram).
Movie S1. Movie showing the strong killing potential of ex vVo-generated NK cells (bright spots) towards the 
adherent growing melanoma cell line FM3 within one hour of co-culture. NK cells were added to the melanoma tumor 
cell layer at an E:T ratio of 1:1. The movie can be found at: doi:10.1371/journal.pone.0009221.s006 (1.43 MB AVI).
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Abstract
A better understanding of human NK cell development in vivo is crucial to exploit NK cells for 
immunotherapy. Here, we identified seven distinctive NK cell developmental stages in bone 
marrow of single donors using 10-color flow cytometry and found that NK cell development 
is accompanied by early expression of stimulatory co-receptor CD244 (2B4) in vivo. Further 
analysis of cord blood (CB), peripheral blood (PB), inguinal LN (inLN), liver LN (liLN) and spleen 
(SPL) samples showed diverse distributions of the NK cell developmental stages. In addition, 
distinctive expression profiles of early development marker CD33 and C-type lectin receptor 
NKG2A between the tissues, suggest that differential NK cell differentiation may take place at 
different anatomical locations. Differential expression of NKG2A and stimulatory receptors (e.g. 
NCR, NKG2D) within the different subsets of committed NK cells demonstrated the heterogeneity 
of the CD56brightCD16+/- and CD56dimCD16+ subsets within the different compartments and 
suggests that microenvironment may play a role in differential in situ development of the NK cell 
receptor repertoire of committed NK cells. Overall, differential in situ NK cell development and 
trafficking towards multiple tissues may as a whole give rise to a broad spectrum of mature NK 
cell subsets found within the human body.
Redefining human NK cell developmental stages in vivo
Introduction
Natural killer (NK) cells are large CD56+CD3- granular lymphocytes and are considered part 
of the innate immune system. NK cells can kill infected or malignant-transformed cells without 
prior sensitization, and through the production of cytokines, such as IFN-y, they form a bridge 
between innate and adaptive immune responses.12 NK cell reactivity is tightly regulated through 
a balance of signals between stimulatory and inhibitory receptors, a feature that is being exploited 
today for NK cell-based immunotherapy against cancer.3 For this, a thorough understanding of 
human NK cell development in vivo is crucial.
Bone marrow (BM) is generally considered as the primary site for human NK cell development.4-7 
However, a complete pathway for NK cell development and maturation in BM has not been 
described and it may be possible that precursor NK cells traffic from BM to other tissues for 
terminal differentiation in situ.8 In 2005, Freud et al.9 identified a BM-derived CD34+ hematopoietic 
precursor cell (HPC) residing in lymph nodes (LN) where further differentiation into CD56bright could 
take place. Subsequently, they identified four discrete stages for human NK cell development 
within secondary lymphoid tissues (SLT) based on cell surface expression of CD34, CD117 and 
CD94: stage 1; CD34+CD117-CD94-, stage 2; CD34+CD117+CD94-, stage 3; CD34-CD117+CD94-, 
and stage 4; CD34-CD117+/-CD94+.10 Following NK cell development, commitment to the NK cell 
lineage takes place at stage 3, in which CD56 appears on the cell surface and gives rise to 
CD56bright NK cells in stage 4. These data confirmed previous research describing the abundant 
presence of CD56bright NK cells in SLT.11;12 In addition, we and others have shown that CD56bright 
cells are the first mature NK cells to arise after hematopoietic stem cell transplantation (SCT).13;14 
Overall, these data support a model of in vivo human NK cell development in which CD34+ NK 
cell precursors traffic from BM to SLT where further differentiation into CD56bright NK cells can 
take place. However, how these NK cell developmental stages correlate with NK cell subsets 
in other compartments of the human body (e.g. peripheral blood (PB), spleen (SPL)) remains 
unclear.
In this study, we identified seven distinctive NK cell developmental stages in bone marrow 
using 10-color flow cytometry and found that NK cell development is accompanied by early 
expression of stimulatory co-receptor CD244 (2B4) in vivo. Furthermore, distinctive expression 
profiles of early development marker CD33 and the C-type lectin receptor NKG2A between the 
different tissues, suggest that differential in situ NK cell differentiation may take place at different 
anatomical locations. Thus, differential in situ NK cell development and trafficking towards 
multiple tissues may as a whole give rise to a broad spectrum of mature NK cell subsets found 
within the human body.
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Materials and methods
T issue  c o lle c tio n  and  m on o n u c le a r ce ll iso la tion
Bone marrow (BM), peripheral blood (PB), spleen (SPL) and cord blood (CB) samples were 
obtained at the Radboud University Nijmegen Medical Centre (RUNMC; Nijmegen, The 
Netherlands). BM and PB samples were obtained from healthy stem cell transplantation donors 
before mobilization treatment with G-CSF. SPL samples were obtained from deceased liver 
or kidney transplantation donors. CB samples, obtained at birth after normal full-term delivery, 
were provided by the cord blood bank of RUNMC. At the Erasmus Medical Centre (Rotterdam, 
The Netherlands), liver draining lymph node (LiLN) samples were obtained from deceased 
liver transplantation donors and inguinal lymph node (inLN) samples from kidney transplant 
recipients (not treated with immunosuppressive drugs prior to lymph node excision). After 
collection, each tissue sample was stored at room temperature and processed within 24h. 
Lymph node and spleen samples were first forced through 74 |jm netwell filters (Costar, Corning 
International, NY, and USA) to obtain single cell suspensions. Mononuclear cells (MNC) were 
isolated by density gradient centrifugation (Lymphoprep; Nycomed Pharma, Roskilde, Denmark) 
and cryopreserved in liquid nitrogen until further use. At least 5 independent samples of each 
tissue were collected. This study was performed in accordance with the regulations as set by 
the Medical Ethical Committees for human research of the RUNMC and the Erasmus MC, and 
written informed consent with regard of scientific use was obtained from all study participants or 
their representatives.
M u lti-c o lo r f lo w  cy to m e try
For detailed flow cytometric (FCM) analysis of the different developmental stages and 
phenotype of NK cells, we designed three different 10-color FCM panels using conjugated 
mAbs kindly provided by Beckman Coulter (Marseille, France) with the exception of CD16-FITC 
(Dako, Glostrup, Denmark) and CD159c-PE (R&D Systems, Minneapolis, CA, USA). Detailed 
description of the panels is shown in Table 1.
Table 1. Panels used for flow cytometry.
FITC PE ECD PC5.5 PC7 APC APC-A700
APC-
A750 PB PO
1 CD34 CD133 CD3 CD159a CD117 CD33 CD244 CD56 CD94 CD45
581 AC133 UCHT1 Z199.1.10 104D2D1 D3HL60.251 C1.7.1 N901 HP-3B1 J33
2 CD16 CD 159c CD3 CD158b CD158e1 CD158a CD56 CD159a CD45
DJ130C 134522 UCHT1 GL183 Z27.3.7 EB6.B.3.1.1 N901
Z199.1.
10 J33
3 CD16 CD336 CD3 CD337 CD335 CD314 CD244 CD56 CD45
DJ130C Z231 UCHT1 Z25 BAB281 ON72 C l.7.1 N901 J33
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^  Displayed are the combinations of conjugated monoclonal antibodies (mAb) against specific antigens within each 
panel. In addition, the clone for each specific mAb is shown. Each panel was used for flow cytometric (FCM) analysis 
of bone marrow, cord blood, peripheral blood, inguinal LN, liver LN, and spleen samples of human donors (all 
n=5). Thawed MNC fractions of the human tissue samples were assessed on a Navios™ 10-color flow cytometer 
and analyzed using Kaluza Software® 1.0 (Beckman coulter). Panel 1 was used to identify different NK cell 
developmental stages based on CD34, CD117, CD94 and CD56 expression profiles.10 Additionally, expression of 
early development markers CD133 and CD33, stimulatory co-receptor 2B4 (CD244), and C-type lectin NKG2A were 
analyzed to refine the definition of the different NK cell developmental stages. Panel 2 and 3 were used to analyze 
the NK cell receptor repertoire of CD45+CD56bn9htCD16+/-CD3- and CD45+CD56dimCD16+CD3- NK cells consisting 
of inhibitory and stimulatory receptors. Inhibitory receptors contain KIR (CD158a, CD158b, CD158e1) and NKG2A 
(CD159a). Stimulatory receptors contain NCR (CD335/336/337), NKG2C (CD159c), NKG2D (CD314), and CD244 
(2B4).
For 10-color FCM, combinations of mAb-fluorochrome were balanced to avoid antibody 
interactions, sterical hindrance and to detect also dimly expressing populations. Before multi­
color analyses, all conjugates were titrated and individually tested for sensitivity, resolution and 
compensation of spectral overlap. Isotype controls were used to define marker settings. Thawed 
MNC fractions of collected human tissues were assessed on a Navios™ 10-color flow cytometer 
and analyzed using Kaluza Software® 1.0 (Beckman coulter). To define NK cell developmental 
stages, samples were gated on the CD45+CD3- population within CD45+/SS gated cells to 
exclude T cells and endothelial cells (which may express CD34 but are CD45 negative15) from 
analysis. To analyze the NK cell receptor repertoire (Table 1) of committed NK cells expressing 
CD56, cells were further gated on CD56+ cells within the CD45+CD3- population. Cell populations 
> 0.1% of the CD45+CD3- population with a threshold of more than 50 cells were considered
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reliable. Cell populations were considered to be present in a specific tissue when at least 3 out 
of 5 samples showed reliable results. Cell populations that did not suffice to these criteria were 
excluded from further (statistical) analysis. An overview of analyzed sample sizes is shown in 
Table S1.
S ta tis tica l ana lys is
To compare percentages of cells positive for single markers between the different tissues, a 
random effect logistic regression model was used that accounted for the biological diversity 
between samples of each tissue and for the fact that several samples of each tissue type were 
taken. Mean fluorescence (MFI) of specific markers between the different tissues were analyzed 
using ANOVA analysis with Tukey post testing. P-values <.05 were considered significant.
Results
To identify human NK cell developmental stages within the different tissues and to analyze 
the distribution of different NK cell subsets and their NK cell receptor repertoire, we designed 
three 10-color flow cytometry (FCM) panels (Table 1). As BM is considered the origin of NK cell 
development4-7, we first analyzed BM for the presence of NK cell developmental stages.
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Ide n tif ica tio n  o f seven N K  ce ll d e ve lopm en ta l s tages  in BM
Distinct NK cell developmental stages can be characterized through expression analysis 
of CD34, CD117, CD94 and CD56 antigens.10 Based on that, we gated our samples on the 
CD45+CD3' population within CD45+/SS gated cells to exclude T cells and endothelial cells 
from analysis. Subsequently, cell subsets were first divided based on the expression of CD34 
and CD117. From there, in a second step, each subset was analyzed for CD56 and CD94 
expression. Using this gating strategy, we were able to identify seven distinctive developmental 
stages in BM (Figure 1).
Bone Marrow
CD94 CD94
Figure 1. Identification o f seven NK cell developmental stages in bone marrow (BM). Based on the stages 
defined in Table 1, we analyzed the presence of the different NK cell developmental stages in BM. Shown is one 
representative example (n=5). Cells were gated on the CD45*CD3- population within CD457SS gated cells to exclude 
T cells and endothelial cells from analysis. Subsequently, cell subsets were divided based on the expression of CD34 
and CD117. From there, each subset was analyzed for CD56 and CD94 expression, leading to the identification of 
seven NK cell developmental stages: 1, 2, 3a, 3b, 4, 5a, 5b.
On this basis and in concert with NK cell developmental stages as identified in secondary 
lymphoid tissues (SLT)10, we now propose the following model of NK development, starting 
from CD34+CD117'CD56'CD94' cells (stage 1), followed by the gain of CD117 (stage 2; 
CD34+CD117+CD56'CD94'). Subsequently, CD34 expression is lost in stage 3a (CD34- 
CD117+CD56'CD94‘) followed by NK cell lineage commitment through CD56 acquisition in stage 
3b (CD34'CD117+CD56+CD94‘). After NK cell lineage commitment, cells gain CD94 expression
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and develop into immature CD56bright NK cells (stage 4; CD34-CD117+CD56+CD94+). Through 
loss of CD117 expression, CD56dim cells start to develop (stage 5a; CD34'CD117'CD56+CD94+), 
followed by loss of CD94 expression in stage 5b (CD34'CD117'CD56+CD94'). The acquisition/ 
loss of the different antigens and the presence of CD56bright/dim cells within each stage in BM are 
summarized in Table 2.
Table 2. Developmental stages o f NK cells in BM.
CD34 CD117 CD56 CD94
CD56: 
bright or dim
Stage 1 + - - -
Stage 2 + + - - -
Stage 3a - + - - -
Stage 3b - + + - CD56dim
Stage 4 - + + + CD56bright
Stage 5a - - + + CD56bri9ht<dim
Stage 5b - - + CD56bright<<dim
Main stages of NK cell development in BM based on expression profiles of CD34, CD117, CD56 and CD94.
Early and susta ined  C D 244 exp ress ion  du ring  in vivo  N K  cell d e ve lopm en t
By using 10-color FCM, we were able to further specify the identified NK cell developmental 
stages in BM by analyzing additional antigen expression. For this purpose, we analyzed the cell 
surface expression of CD133, CD33, CD244 and NKG2A within each defined stage (Figure 2). 
CD133 is known as a stem cell antigen that may provide an alternative to CD34 for the selection 
and expansion of hematopoietic cells for transplantation.16 Together with CD34, this antigen was 
only expressed within stages 1 and 2. CD33 has been described as an antigen for early NK cell 
development17 and was expressed in stages 2 and 3a. The CD244 receptor is suggested to be 
a co-receptor in activation of mature NK cells.18 Interestingly, we found that CD244 was already 
expressed on CD34+CD117+ stage 2 cells in BM. During stages 3a and 3b, CD244 expression 
remained present and the amount of CD244+ cells was increased to more than 98% in stages 
4 to 5b. Until now, CD244 expression was only shown to be present at early stages of NK 
cell differentiation during in vitro-induced human NK cell maturation.19 The inhibitory NKG2A 
receptor, shown to be expressed early during NK cell maturation13, was detected starting from 
stage 4 just after NK cell commitment (stage 3b) till stage 5b. In summary, as the different 
assessed antigens showed different expression profiles during NK cell development, we were 
able to further define the NK cell developmental stages (Table 3), in which CD133 expression 
is specific for stages 1 and 2, followed by CD33 expression in stages 2 and 3. From stage 2, 
CD244 is continuously expressed and NKG2A is found in stages 4 to 5b on part of the cells.
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Figure 2. Expression o f CD133, CD33, CD244 and NKG2A w ith in  the NK cell developmental stages in bone 
marrow (BM). Cells were gated on the CD45+CD3- population within CD45+/SS gated cells to exclude T cells and 
endothelial cells from analysis. Next, cell subsets were divided based on the expression of CD34 and CD117. From 
there, each subset was analyzed for CD56 and CD94 expression. Subsequently, the expression of CD133, CD33, 
CD244 and NKG2A was analyzed within the different NK cell developmental stages in BM (n=5). Left panels show 
the percentages of cells positive for the specific markers. Right panels show the mean fluorescence (MFI) of each 
specific marker. Cell populations > 0.1% of the CD45+CD3- population with a threshold of more than 50 cells were 
considered reliable. Cell populations were considered tissue specific when at least 3 out of 5 samples showed 
reliable results. Cell populations that did not suffice to these criteria were excluded from further (statistical) analysis. 
Shown in this figure are all NK cell developmental stages within each tissue.
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Table 3. Developmental s ta g e s  of NK cells in BM (continued).
CD133 CD34 CD33 CD117 CD244 CD56 CD94 NKG2A
CD56: 
bright or dim
Stage 1 +/- + - - - - -
Stage 2 + + +/- + +/- ■ ■ - -
Stage 3a +/- + +/- - - -
Stage 3b - - + + + ■ - CD56dim
Stage 4 + + + + + CD56bright
Stage 5a - - ■ + + + +/- CD56blight < dim
Stage 5b - + + - +/- CD56bright <<c c*'m
Further identification of developmental NK cell stages in BM based on expression of CD133, CD34, CD33, CD177, 
CD244, NKG2A, CD56 and CD94. Indicated is the presence of each specified marker within each stage (based on 
the percentage of positive cells present): + = 100-80%; +/- < 80%; - = below reliable detection limits.
N K cell de ve lop m e n t s ta rts  in BM , fo llo w e d  by fu rth e r m a tu ra tion  in LN, SPL and 
PB
To assess whether the NK developmental stages can be found in other human tissues besides 
BM, we further analyzed samples of cord blood (CB), peripheral blood (PB), inguinal LN (inLN), 
liver LN (liLN) and spleen (SPL) (Figure 3). 135
Redefining human NK cell developmental stages in vivo
CHAPTER 
6
Figure 3. D istribution o f the NK cell developmental stages w ith in different human tissues. The distribution 
of the seven NK cell developmental stages was analyzed within samples of bone marrow (BM), cord blood (CB), 
peripheral blood (PB), inguinal LN (inLN), liver LN (liLN) and spleen (SPL) (all n=5). For identification of the NK 
cell developmental stages, cells were gated on the CD45+CD3- population within CD45+/SS gated cells to exclude 
T cells and endothelial cells from analysis. Subsequently, cell subsets were divided based on the expression of 
CD34 and CD117. From there, each subset was analyzed for CD56 and CD94 expression. Cell populations > 0.1% 
of the CD45+CD3- population with a threshold of more than 50 cells were considered reliable. Cell populations 
were considered tissue specific when at least 3 out of 5 samples showed reliable results. Cell populations that 
did not suffice to these criteria were excluded from further (statistical) analysis. Shown in this figure are all NK cell 
developmental stages within each tissue. Comparison between the different tissues was analyzed using a random 
effect logistic regression model; *P<.05, **P<.01, ***P<.0001.
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Results showed a differential distribution of the NK cell developmental stages within the different 
tissues. The NK cell developmental stages in BM mainly consisted of stage 5a and 5b cells. 
In addition, stages 1 and 2 were only detected in BM, confirming BM as the origin of NK cell 
development. In CB, stage 2 cells were found, but not in PB, showing that blood of fetal origin 
contains more early NK progenitor cells as compared with adult blood. However, the main 
NK cell developmental stages in CB were stage 5a followed by stage 5b. In PB, the NK cell 
developmental stages mainly consisted of stage 5a and 5b cells. In contrast to other tissues, 
the distribution of NK cell developmental stages in inLN primarily contained stage 3a and stage 
3b cells, and showed lower, but similar, frequencies of stages 4 to 5b. In contrast, NK cell 
developmental stages in liLN and SPL consisted primarily of stages 4, 5a and 5b cells. Following 
the presence of the different NK developmental stages within the different tissues analyzed, 
these results suggest that early NK progenitor cells migrate from BM to SLT, after which pre-NK 
cells (stage 3a) may further develop in LN leadings to NK cell commitment (stage 3b), followed 
by further maturation in splenic tissue and the release of mature NK cells into the blood stream. 
The presence of different stages within one tissue, for instance stages other than stage 1 and 2 
in BM or stage 3 in LN, indicates that in situ differentiation of remaining cells also occurs besides 
trafficking of developmental stages towards other tissues.
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S usta ined  C D 33 exp ress ion  in liLN du ring  in  vivo  N K  ce ll deve lopm en t
To asses potential differences of the NK cell developmental stages within the human tissues, we 
further analyzed the expression of CD133, CD33, CD244 and NKG2A within the stages present 
in the human tissues (Figure 4).
Figure 4. Expression o f CD133, CD33, CD244 and NKG2A w ith in  the NK cell developmental stages present 
in different human tissues. Cells were gated on the CD45+CD3- population within CD45+/SS gated cells to exclude 
T cells and endothelial cells from analysis. Next, cell subsets were divided based on the expression of CD34 and 
CD117. From there, each subset was analyzed for CD56 and CD94 expression. Subsequently, the expression (%) of 
CD133, CD33, CD244 and NKG2A was analyzed within the different NK cell developmental stages in bone marrow 
(BM), cord blood (CB), peripheral blood (PB), inguinal LN (inLN), liver LN (liLN) and spleen (SPL) (all n=5). Cell 
populations > 0.1% of the CD45+CD3- population with a threshold of more than 50 cells were considered reliable. 
Cell populations were considered tissue specific when at least 3 out of 5 samples showed reliable results. Cell 
populations that did not suffice to these criteria were excluded from further (statistical) analysis. Comparison between 
the different tissues was analyzed using a random effect logistic regression model; *P<.05, **P<.01, ***P<.0001.
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Between BM and CB, there were no significant differences in expression of CD133, CD33 and 
CD244 within stage 2. The subsequent trend of CD244 acquisition was the same for each tissue 
and all tissues showed more than 98% CD244+ cells in stages 4 and 5a/b. Significant differences 
were seen in the expression profile of the early CD33 antigen within the different human tissues. 
As we previously characterized CD33 expression to be specific for stage 2 and 3a cells in BM 
(Table 3), CD33 expression was prolonged in CB, PB, and SPL until stage 3b. Furthermore, 
in liLN, CD33 expression was even sustained after NK cell commitment until stage 4. The 
prolonged expression of CD33 in some distinct stages and tissues suggests tissue specific NK 
cell developmental subsets in situ.
N KG 2A  exp ress ion  revealed an im pa ired  N K  ce ll m a tu ra tion  p ro file  in lym pho id  
tissues
Having described tissue specific NK cell subsets, by the expression profile of CD33, we further 
analyzed if there are also tissue specific differences in the NK cell maturation pattern. As the level 
of NKG2A expression may be representative for the level of NK cell maturation2021, we analyzed 
the NKG2A expression profile on “committed” NK cells. Besides the significant differences in the 
CD33 expression profile, the expression profile of NKG2A also showed a distinction between the 
different human tissues (Figure 4). In stage 4, all tissues contained more than 95% NKG2A+ cells. 
Following NK cell developmental stages, BM, CB and PB showed a decrease in the percentage 
of NKG2A+ cells up to approximately 25% NKG2A+ cells in stage 5b, whereas in inLN and liLN 
a median of 75-80% remained NKG2A+ and SPL kept a median of 50% NKG2A+ cells. The 
stronger decrease of cells expressing NKG2A in BM, CB and PB as compared with other tissues 
was also reflected in the mean fluorescence intensity of NKG2A expression following stage 4 to 
5b (Figure S1). Overall, these data suggest that the committed NK cells in LN and SPL have a 
more immature phenotype as compared with cells present in BM, PB and CB.
In order to better define NK cell maturation, we extended our analyses with regard to “committed” 
NK cells. Therefore, we subsequently analyzed the expression of additional NK cell receptors to 
further asses the maturity status of the committed NK cells within the different human tissues.
D iffe rences in th e  N K  ce ll re ce p to r repe rto ire  su g g e s ts  d is tin c t in s itu  N K  cell 
de ve lop m e n t w ith in  LN and C B
Phenotypically committed NK cells (CD45+CD3-CD56+) can generally be divided into two 
distinguishable subsets: the CD56brighlCD16+/- and the CD56dimCD16+ subset.22 Our data, 
confirmed the heterogeneity of the CD56brighlCD16+/- and CD56dimCD16+ subsets within BM, CB, 
PB, and LN, showing balances of CD56brighl>>CD56dim in LN, and CD56brighl<<CD56dim in BM, CB 
and PB (Figure S2). Additionally, we identified a CD56brigh,“ CD56dim balance in SPL.
To further assess the maturity of the committed NK cell subsets, we analyzed the expression of 
various inhibitory and stimulatory NK cell receptors by using FCM panels 2 and 3 (Table 1). For
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analysis of the committed NK cell population, we gated on CD56+ cells within the CD45+CD3" 
population and subsequently analyzed the expression of killer immunoglobulin-like receptors 
(KIR), NKG2A/C, NKG2D, CD244 and natural cytotoxicity receptors (NCR; NKp30, NKp44, 
NKp46). These receptors trigger and modulate mature NK cell effector function through a 
balance between inhibitory (KIR, NKG2A) and stimulatory signals (NKG2C, NKG2D, CD244, 
NCR).2;23
We first analyzed the NK cell receptor repertoire of the CD56brighlCD16+/- subset within the 
committed NK cell population of each tissue (Figure 5). Results showed that there was no 
difference in the amount of KIR+ cells between the tissues. Nevertheless, the mean fluorescence 
of KIR2DL/S2/3 and KIR3DL1 was lower in both LN and SPL, suggesting a more immature 
phenotype of CD56brighl cells as compared with BM, CB and PB. Surprisingly, the proportion 
of NKG2A+ cells was significantly lower in liLN as compared to other tissues. This may be 
explained by a different NK cell development in situ, as suggested by the prolonged expression 
of CD33 (Figure 4). Furthermore, the amount of activating receptor positive cells, with the 
exception of NKp44, was also lower in liLN as compared with other tissues (Figure 6). This 
was also reflected within the CD56dimCD16+ subset of liLN, showing lower amounts of NKG2D+, 
CD244+ and NKp30+ cells as compared with other tissues. Thus, these results show that NK cell 
development in lymphnodes may differ in situ between LN at different anatomical locations and 
also other tissues.
Analysis of CB showed that both the CD56brightCD16+/- (Figure 5) and the CD56dimCD16+ (Figure 
6) subset contained significantly more NKG2A+ cells as compared with other tissues. In addition, 
the level of NKG2A expression (MFI) in the CD56brightCD16+/- subset was also significantly higher, 
which confirmed previous results.24 NKG2C, which is the stimulatory lectin-like counterpart of 
NKG2A, also showed elevated expression within the CD56brightCD16+/- subset of committed NK 
cells in CB (Figure 5). Together, these data suggest that the fetal micro-environment of CB may 
provide prevalence for the expression of lectin-like antigens as compared with other human 
tissues.
Overall, the data on the NK cell receptor repertoire within the different subsets of the committed 
NK cells demonstrates the heterogeneity of the CD56brightCD16+/- and CD56dimCD16+ within the 
different compartments and suggests that microenvironment may play a role in differential in situ 
development of the NK cell receptor repertoire of committed NK cells.
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Figure 5. Expression o f KIR, NKG2A/C, NCR, NKG2D and CD244 w ithin the CD56briahtCD16+/- NK cell subset 
of different human tissues. Cells were gated on the CD45+CD56+CD3- population within CD45+/SS gated cells to 
exclude T cells and endothelial cells from analysis. Subsequently, the expression of KIR, NKG2A/C, NCR (NKp30, 
44, 46), NKG2D and CD244 was analyzed within the CD56bri9htCD16+/- NK cell subset present in the committed NK cell 
population of bone marrow (BM), cord blood (CB), peripheral blood (PB), inguinal LN (inLN), liver LN (liLN) and spleen 
(SPL) (all n=5). (A) Shown are the percentages of CD56bnghtCD16+/- cells positive for each specific receptor within each 
tissue. (B) Shown is the mean fluorescence intensity (MFI) for each specific receptor expressed by CD56b^9htCD16+^ 
cells. Cell populations > 0.1% of the CD45+CD3- population with a threshold of more than 50 cells were considered 
reliable. Cell populations were considered tissue specific when at least 3 out of 5 samples showed reliable results. 
Comparison of percentages of positive cells between the different tissues was analyzed using a random effect logistic 
regression model. Comparison of MFI of positive cells between the different tissues was analyzed using ANOVA; 
*P<.05, **P<.01, ***P<.0001.
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Figure 6. Expression o f KIR, NKG2A/C, NCR, NKG2D and CD244 w ith in  the CD56dimCD16+ NK cell subset of 
different human tissues. Cells were gated on the CD45+CD56+CD3- population within CD45+/SS gated cells to 
exclude T cells and endothelial cells from analysis. Subsequently, the expression of KIR, NKG2A/C, NCR (NKp30, 
44, 46), NKG2D and CD244 was analyzed within the CD56dimCD16+ NK cell subset present in the committed NK 
cell population of bone marrow (BM), cord blood (CB), peripheral blood (PB), inguinal LN (inLN), liver LN (liLN) and 
spleen (SPL) (all n=5). (A) Shown are the percentages of CD56dimCD16+ cells positive for each specific receptor 
within each tissue. (B) Shown is the mean fluorescence intensity (MFI) for each specific receptor expressed by 
CD56dimCD16+ cells. Cell populations > 0.1% of the CD45+CD3- population with a threshold of more than 50 cells 
were considered reliable. Cell populations were considered tissue specific when at least 3 out of 5 samples showed 
reliable results. Comparison of percentages of positive cells between the different tissues was analyzed using a 
random effect logistic regression model. Comparison of MFI of positive cells between the different tissues was 
analyzed using ANOVA; *P<.05, **P<.01.
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Discussion
In contrast to T and B cells, the developmental pathways and locations for human NK cell 
development are currently less well defined. Results of this study suggest that this is partly due 
to the heterogeneity of NK cell subsets and their diverse anatomical distribution over the different 
compartments within the human body. Using 10-color FCM, we were now able to establish 
seven NK cell developmental stages, which are numbered in line with the initial 4 stages as 
described by Freud et a/.10, based on expression profiles of CD34, CD117, CD56 and CD94, 
which were further specified by the expression profiles of CD133, CD33, CD244 and NKG2A. 
Our results showed that NK cell development is accompanied by early expression of CD244 and 
that there is a diverse distribution of the NK cell developmental stages among different human 
tissues. In addition, we provided a detailed phenotypical characterization of the committed NK 
cell population revealing different NK cell maturation stages (i.e. CD56bright:CD56dim ratio and 
heterogeneity in the NK cell receptor repertoire) within the tissues.
Our data pointed BM to be the origin for NK cell development as stage 1 and 2 cells (CD34+CD117' 
CD56-CD94- and CD34+CD117+CD56-CD94-, respectively) were only found in BM and not in LN, 
SPL or PB. This is in contrast to research done by Freud et a/., who identified stage 1 and 2 cells 
in secondary lymphoid tissues (SLT).10 This may be due to differences in sample preparations 
before analysis. In the previous study, for each donor's tissue, cells from multiple tonsil pieces or 
multiple LN were pooled in order to obtain sufficient numbers within each NK cell developmental 
stage. In contrast, with the use of 10-color flow cytometry, we were able to study small sample 
sizes of tissues obtained from single donors. Due to biological variation between donors, pooled 
samples of each tissue may cause a non-representative view of NK cell subset numbers present 
within the different tissues analyzed. However, due to the detection limits that we set for our 
analysis, we cannot rule out that very small populations remained undetected within our samples. 
Nevertheless, without pooling samples, we believe that this unique collection of tissue samples 
provides a genuine view on the distribution of the different NK cell developmental stages within 
the different anatomical locations as they are in vivo.
Upon acquiring CD56 expression (NK cell commitment), the cells acquired CD94 expression. 
Simultaneously, NKG2A positive cells appeared. Later, following NK cell development, CD94 
expression decreased during the final maturation steps towards a CD56dim phenotype together 
with a decrease in NKG2A expression.17;25 The concomitant downregulation of NKG2A with 
CD94 may be explained by heterodimer formation that gives rise to a functional inhibitory CD94/ 
NKG2A complex.2627 This complex is used for broad immune surveillance as it recognizes the 
ubiquitously expressed HLA-E molecule. Notably, we also observed a mature in vivo NK cell 
developmental stage, that primarily consisted of CD56dim cells, expressing low levels of NKG2A 
without CD94 (stage 5b: CD133-CD34-CD117-CD244+CD56+CD94-NKG2A+). The low expression 
level of NKG2A in combination with the fact that NKG2A only contributes to the binding affinity 
of the heterodimeric complex and HLA-E solely interacts with CD9427, suggests that in this 
case NKG2A is non-functional. Recently, the functional CD94/NKG2A receptor complex was
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described to be endocytosed by a macropinocytic-like process, which may be related to the 
maintenance of its surface expression.28 However, as it is not clear whether the CD94/NKG2A 
complex is internalized as a whole or may be first uncoupled before internalization, it may be 
possible that for a brief period NKG2A may exist on the cell surface without CD94. Together, this 
suggests that inhibition of cells in stage 5b largely depends on KIR signaling, and that stage 5b 
is one of the final stages in NK cell development.
Remarkably, the phenotype of committed NK cells (stage 3b-5b) differed between both LN 
(liver and inguinal sites). The NK cell receptor repertoire in liLN showed significantly less cells 
expressing NKG2A/C, NKp30, CD244 and NKG2D. All together, these results suggest that 
committed NK cells in liLN reside in an even more immature state as compared with committed 
NK cells in inLN. This was confirmed by the expression of CD33, a marker for early NK cell 
development, which is expressed significantly longer by committed NK progenitor cells in 
liLN as compared with committed NK progenitors in inLN and other tissues following NK cell 
development. Similarly, CD56bright NK cells in the liver itself show a more immature phenotype as 
compared to their counterpart in PB.29 The differences in NK cell differentiation in situ after NK 
cell commitment may be due to the regional immune system of the liver, which is characterized 
by relatively weak cellular immune responses and hyporesponsiveness.3031 As NK cells form a 
bridge between innate and adaptive immune responses, the immature state of committed NK 
cells in liver and its draining LN may play a role in this. However, as we were not able to perform 
functional analysis due to small sample sizes, this remains subjected to further study.
Our findings confirm results from previous studies showing that the CD56brighlCD16+/- and 
CD56dimCD16+ subsets are present in the same proportions in both CB and PB.32;33 Nevertheless, 
these studies also reported that CB NK cells have a natural reduced killing ability as compared 
with PB NK cells. We postulate that this may be due to differences in NKG2A expression as our 
results showed that NKG2A is significantly more expressed in CB as compared with committed 
NK cells in PB and also other tissues. Nevertheless, the reduced killing ability of CB NK cells 
can be reversed after cytokine stimulation.3233 Thus, as CB is a source for ex vivo generation of 
NK cell-based immunotherapeutics34, the high expression of NKG2A and its inhibition on NK cell 
activity of CB NK cells may not necessarily form a problem for NK cell-based immunotherapeutic 
strategies.
Although our analysis of the committed NK cells could not distinguish NK cell subsets between 
stages 3b to 5b, the ratio between the CD56brighlCD16+/- and CD56dimCD16+ subsets and the 
overall expression of KIR and NKG2A provided a clear overview on the maturation status of 
committed NK cells within the different tissues. Committed NK cells in LN represented the most 
immature status as the NK cells profoundly consisted of CD56brighlCD16+/- cells, followed by SPL 
showing an equal balance of both subsets. BM, CB and PB held the most mature status of 
NK cells as they abundantly contained the CD56dimCD16+ subset. After allogeneic stem cell 
transplantation (SCT), in vivo maturation of the NK cell receptor repertoire is characterized by 
fast upregulation of NKG2A followed by the acquisition of KIR together with a slow decrease in 
NKG2A expression.13;14;20;35 The maturation status of the committed NK cells within the different
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tissues analyzed confirm these findings as the overall KIR expression was highest in BM, CB 
and PB, followed by SPL and was lowest in LN. With the exception of CB, ranges of NKG2A 
expression were lowest in BM and PB, followed by a higher range of NKG2A expression in LN 
and SPL.
In summary, these data support a model for in vivo NK cell development indicating BM as the 
origin of NK cell development (Figure 7). Through trafficking of precursor NK cells from BM 
to LN, commitment to the NK cell lineage takes place in LN followed by in situ differentiation 
and maturation of NK cells with restricted maturation of the NK cell receptor repertoire. For 
further differentiation of committed NK cells, stage 3b or stage 4 CD56low/brighl cells may traffic 
towards splenic tissue in which CD56dim cells may develop and further maturation of the NK cell 
receptor repertoire takes place. Final maturation of NK cells occurs through trafficking of cells 
(stage 4 to 5) towards the periphery from which NK cells may be further distributed to different 
compartments in the human body. Further functional analyses of committed NK cells within the 
different NK cell developmental stages are warranted to obtain a complete view on the NK cell 
developmental pathway that includes the acquisition of the cytolytic and cytokine producing 
functions during NK cell development.
Trafficking o f Distribution o f mature CD56b"aht
stage 3a cells and 0056®" NK cells towards
Figure 7. Proposed model fo r human NK cell development in  vivo. Based on our data, we propose that precur­
sor NK cells (stage 2) traffic from BM to LN, where commitment to the NK cell lineage takes place (stage 3a ^  3b) 
followed by in situ differentiation of NK cells with restricted maturation of the NK cell receptor repertoire. For further 
differentiation of committed NK cells, 0056“ ** cells (stage 4) may traffic towards splenic tissue in which CD56dim 
cells may develop and further maturation of the NK cell receptor repertoire takes place. Final maturation of NK cells 
occurs through trafficking of cells towards the periphery from which NK cells may be further distributed to different 
compartments in the human body.
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supplemental material
Table S1. Cell numbers in analyzed samples.
Total cell number1 
(x104)
Gated CD45+CD3' cells2 
(x104)
Progenitor cells3 
(x104)
BM 16.9 (8.9-34.9) 2.8(1.9-3.3) 0.98 (0.7-1.2)
CB 39.9 (27.5-99.9) 12.2 (7.1-31.4) 1.88 (0.6-5.0)
PB 37.8 (35.7-38.9) 8.8(5.4-11.0) 4.15(1.1-7.7)
inLN 10.0(21.3-61.9) 6.3 (1.2- 34.4) 2.2 (0.4-5.4)
liLN 4.0 (2.5-39-6) 7.8(1.5-29.7) 1.1 (0.1-3.0)
SPL 40.8 (27.4-45.8) 25.2 (13-29.8) 3.03 (2.1-4.1 )
To define NK cell developmental stages, samples were gated on the CD45+CD3' population within CD45+/SS gated 
cells to exclude T cells and endothelial cells from analysis. For each tissue, the following items are indicated: 1Total 
cell number within the CD45+/SS gate; 2the amount of cells within the CD45+CD3- gate and; 3the total amount o f cells 
covering all NK cell developmental stages. All cell numbers are shown in median (range).
Figure S1. NKG2A expression levels in stages 4, 5a, and 5b in d ifferent human tissues. Cells were gated on 
the CD45+CD3' population within CD45+/SS gated cells to exclude T cells and endothelial cells from analysis. Next, 
cell subsets were divided based on the expression of CD34 and CD117. From there, each subset was analyzed for 
CD56 and CD94 expression. Subsequently, the NKG2A expression level was analyzed within the different NK cell 
developmental stages in bone marrow (BM), cord blood (CB), peripheral blood (PB), inguinal LN (inLN), liver LN 
(liLN) and spleen (SPL) (all n=5). Reliable NKG2A expression was seen in stages 4, 5a, and 5b. Cell populations > 
0.1% of the CD45+CD3' population with a threshold of more than 50 cells were considered reliable. Cell populations 
were considered tissue specific when at least 3 out of 5 samples showed reliable results. Cell populations that did not 
suffice to these criteria were excluded from further (statistical) analysis. Comparison of MFI of positive cells between 
the different tissues was analyzed using ANOVA; *P<.05, **P<.01, ***P<.0001.
Redefining human NK cell developmental stages in vivo
151
Figure S2. CD56 and CD16 expression patterns o f com mitted NK cells (stage 3b-5b) w ith in  different human 
tissues. Cells were gated on the CD45+CD56+CD3- population within CD45+/SS gated cells to exclude T cells and 
endothelial cells from analysis. Based on the CD56 and CD16 expression within the committed NK cell population 
(stage 3b-5b), NK cells subsets were divided into the major CD56bri9htCD16+/- and CD56dimCD16+ subset. BM=bone 
marrow, CB=cord blood, PB=peripheral blood, inLN=inguinal LN, liLN=liver LN, SPL=spleen (all n=5). (A) Shown are 
representative examples (one of each tissue) for CD56 and CD16 expression patterns within the committed NK cell 
population. (B) Shown are the distribution of the CD56bnghtCD16+/- subset (left panel) and the CD56dimCD16+ subset 
within the different human tissues. Cell populations > 0.1% of the CD45+CD3- lymphocyte population with a threshold 
of more than 50 cells were considered reliable. Cell populations were considered tissue specific when at least 3 
out of 5 samples showed reliable results. Cell populations that did not suffice to these criteria were excluded from 
further (statistical) analysis. Comparison between the different tissues was analyzed using a random effect logistic 
regression model; *P<.05, **P<.01, ***P<.0001.
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Summary and Discussion
7.1 General
Allogeneic stem cell transplantation (SCT) is often the final treatment modality for patients with 
leukemia or other hematological malignancies.12 However, relapse of the underlying malignancy 
is still a major complication post SCT. To prevent the occurrence of relapse post SCT, patients 
are treated with pre-emptive donor lymphocyte infusions (DLI) consisting of donor-derived T 
cells from the same donor used for allogeneic SCT in order to boost the donor-derived immune 
system to terminally eradicate residual tumor cells.3-5 Unfortunately, DLI treatment using donor- 
derived T cells does not only provoke graft-versus-leukemia (GVL) reactivity, but also increases 
the risk for GVHD development. Thus, post allogeneic SCT, long-term remission is still greatly 
dependent on effective graft-versus-leukemia (GVL) reactivity, while strictly controlling GVHD. 
Therefore, the development of treatment strategies augmenting GVL reactivity while reducing 
GVHD is of clinical importance.
In allogeneic SCT, natural killer (NK) cells have shown to play an important role in GVL reactivity 
within the first months after transplantation.6-9 Ruggeri et a/.10 showed that alloreactive donor 
NK cells were able to lyse recipient tumor cells in vitro, implying that these NK cells may be 
able to provide immune reactivity by targeting residual tumor cells still present in the recipient. 
Moreover, fast recovery of NK cells and predicted GVL reactivity towards host tumor cells has 
been associated with reduced GVHD, decreased relapse rates, and better overall survival of the 
patient.11-13 Altogether, this makes NK cells important candidates for immunotherapeutic use in 
the treatment of leukemia and other malignancies.
In this thesis, we studied the alloreactive potential of mature donor-derived NK cells when given 
as part of the graft in HLA-matched allogeneic SCT (chapter 2) and studied the feasibility of 
skewing NK cell alloreactivity of mature donor NK cells towards leukemic target cells prior to 
transplantation (chapter 3). Bearing in mind that donor NK cells need to exert optimal GVL reactivity 
after allogeneic SCT, we additionally studied the effects of commonly used immunosuppressive 
drugs (ISDs), such as CsA, MPA, and rapamycin (chapter 4). For exploitation of NK cells for 
future adoptive cancer immunotherapy, we further developed a cytokine-based culture system 
for ex vivo expansion of NK cells from hematopoietic stem and progenitor cells from umbilical 
cord blood (chapter 5). Additionally, as thorough knowledge of human NK cell development in 
vivo is essential for the development of NK cell-based immunotherapies, we finally studied NK 
cell development in various human tissues using 10-color flow cytometry (chapter 6).
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7.2 F ac ilita tion  o f m a tu re  a llo reac tive  d o n o r N K  ce lls  in a llogene ic  SCT
7,2,1 Infusion o f mature donor NK cells as part o f the graft
Immediately after stem cell transplantation, alloreactive NK cells have been shown to be 
beneficial not only for boosting the anti-tumor response, but also for the prevention of GVHD 
as well as infections. In these cases, optimal functional activity of NK cells already in the early 
phase after SCT is essential, and therefore the presence of NK cells in the graft appears to be 
beneficial for transplant outcome.14;15
In chapter 2, as part of a prospective randomized phase III study, we directly compared the 
alloreactive potential of allogeneic donor NK cells between patients having either received a 
CD3+/CD19+ cell depleted graft (containing substantial NK cell numbers) or a conventional CD34+ 
selected graft (devoid of NK cells) in the setting of in HLA-matched SCT. Results demonstrate that 
patients having received a CD3+/CD19+ cell depleted graft, exhibited a faster recovery of NK cells 
and a functional NK cell receptor repertoire of inhibitory and stimulatory receptors as compared 
with patients having received a conventional CD34+ graft. Furthermore, transplantation with a 
CD3+/CD19+ cell depleted graft resulted in the development of a functionally different NK cell 
population that was more prone to activation via the CD94/NKG2C receptor complex and less 
sensitive to inhibition via the CD94/NKG2C receptor complex. Although it was demonstrated that 
human cytomegalovirus (CMV) infection may result in increased CD94/NKG2C expression levels 
and subsequent loss of CD94/NKG2A expression16"18, this phenomenon remained present in the 
CD3/19 depletion group after exclusion of CMV positive patients from analysis. Unfortunately,
157later interim analysis on 25 patients per group showed that the primary objectives of this clinical 
study could not be reached resulting in early termination of the study. Thus, the alternative 
reconstitution of the NK cell receptor repertoire using CD3+/19+ depleted grafts, characterized 
by the change in balance of CD94/NKG2A+ NK cells to more CD94/NKG2C+ NK cells, and its 
impact on clinical outcomes after HLA-matched SCT remains a subject for further study.
Recently, the reconstitution of allogeneic donor NK cells was evaluated in haploidentical SCT 
after reduced intensity conditioning (RIC) using CD3+/19+ depleted grafts.19 Data showed similar 
results as compared with our study, including fast recovery of NK cells and immune reconstitution 
of the NK cell receptor repertoire. In addition, a similar decrease of NKG2A+ NK cells was seen 
post SCT. However, the expression of NKG2C was not evaluated. Nevertheless, this study 
confirms our findings that different graft manipulation methods may trigger differential NK cell 
reconstitution, which may be beneficial for transplant outcome. Previously, Gentilini et a/.20 even 
showed a significant faster and sustained recovery of NK cells in a group of patients after RIC 
allogeneic SCT with CD3+/CD19+ depleted grafts in comparison with patients with myeloablative 
allogeneic SCT with CD34+ selected grafts combined with adoptive NK cell infusion two days 
post SCT.
Overall, these studies suggest that the use of NK cell rich grafts is favorable for the facilitation 
of fast and sustained NK cell recovery and differential reconstitution of the NK cell receptor 
repertoire, which may lead to improved donor NK cell alloreactivity in the GVL direction (suggested 
by results in chapter 2). Further prospective comparisons of the different graft manipulation
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methods for allogeneic SCT in the HLA-matched or haploidentical setting are warranted for more 
detailed analysis of the impact of graft composition on immune reconstitution. Subsequently, the 
impact of adoptive NK cell infusions after allogeneic SCT for boosting GVL reactivity needs to 
be studied in further detail.
7.2.2 Skewing donor NK cell alloreactivity before SCT
In allogeneic SCT, donor NK cell alloreactivity can be facilitated by allowing mismatches for specific 
HLA molecules (e.g. HLA-C) between donor and recipient. This is referred to as the “ligand-ligand” 
model. The introduction of certain HLA mismatches has been shown to induce NK cell-mediated 
GVL reactivity, without inducing severe GVHD, and to contribute to decreased relapse, better 
engraftment and improved overall survival.10;13;21 However, others state that the induction of NK 
cell alloreactivity is not dependent on HLA mismatching, but is rather induced by the presence 
of an inhibitory KIR in the donor's genotype with the absence of the corresponding KIR-ligand in 
the recipient's HLA repertoire (“receptor-ligand” model).22-24 This makes the exploitation of NK cell 
alloreactivity not only feasible for HLA-mismatched settings, but may also be promising for HLA- 
matched settings.
In chapter 3, we examined the plasticity of the KIR repertoire and the cytolytic response of mature 
human peripheral blood NK cells in an in vitro culture system based on the “receptor-ligand” model. 
Results demonstrate that the presence of a specific KIR-ligand (HLA-C) present on feeder cells 
skews the response of healthy donor NK cells by favoring the outgrowth of NK cells expressing the 
KIR that lacks its cognate ligand. Subsequently, this resulted in an oligoclonal increase of specific 
alloreactive NK cells bearing improved cytolytic ability. The results of this study fully support the 
“receptor-ligand” model, as skewing of the KIR repertoire was seen in both the HLA-C mismatched 
setting as in the HLA-C matched setting; the NK cell population from HLA-C1 donors showed an 
increase in the frequency of KIR2DL/S2/3+ NK cells in the presence of HLA-C2 feeder cells and of 
KIR2DL/S1+ NK cells when cultured in the presence of HLA-C1 feeder cells.
Overall, the results of this study hold promise for the exploitation of target-specific alloreactive 
donor NK cells in both HLA-matched and -mismatched allogeneic SCT settings or adoptive NK 
cell immunotherapy based on the “receptor-ligand” model. For further exploitation, however, the 
“licensing/education” model needs to be considered as well. Upon maturation, NK cells obtain 
their “license to kill” through interactions of inhibitory KIRs with self-HLA class I molecules.25-27 
NK cells that fail to interact with self-HLA class I molecules remain functionally immature and 
will reside in a hyporesponsive state. Recently, it was shown that the strength of response by 
an individual NK cell is even quantitatively controlled by the extent of inhibitory signals that are 
received from HLA class I molecules during NK cell education.28 Concerning adoptive transfer of 
mature NK cells for immunotherapeutic purposes, this suggests that the presence of inhibitory 
KIR on donor NK cells in absence of its cognate ligand in the recipient (“receptor-ligand” model) 
as well as the HLA-background of the donor NK cells (“licensing/education” model) are two key 
factors that need to be taken into account for the successful exploitation of alloreactive donor NK 
cell responses.
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7.2.3 Interference by immunosuppressive drugs
For optimal NK cell-mediated GVL reactivity, NK cells need to be fully functional in the early m
DJphase after SCT, despite that at this stage a high level of immunosuppressive treatment is 
given. Among the various ISDs, cyclosporin A (CsA), rapamycin (Rapa) and mycophenolate 
mofetil (MMF) have successfully been applied for the prevention of GVHD.29-33 In chapter 2, 
patients received CsA as GVHD prophylaxis after transplantation. In chapter 4, we studied 
the influence of CsA, Rapa and mycophenolic acid (MPA; the active metabolite of MMF) on 
NK cell phenotype and function in an in vitro cytokine-based culture system. Results showed 
that the modulation of the NK cell receptor repertoire during culture was arrested by Rapa 
and MPA treatment. This was reflected in the cytolytic activity, as MPA- and Rapa-treated NK 
cells, in contrast to CsA-treated NK cells, lost their cytotoxicity against leukemic target cells. In 
contrast, IFN-y production was not only impaired by MPA and Rapa, but also by CsA upon target 
encounter. A recent study, however, suggested that IFN-y production upon target encounter 
may be limited to the CD56dim NK cell subset, whereas the CD56bright NK cell subset produces 
IFN-y upon cytokine-stimulation.34 Thus, as CD56bright NK cells were still abundantly present in 
the CsA-treated cultures, in contrast to MPA- and Rapa-treated cultures, the IFN-y production 
upon cytokine-stimulation may largely be preserved after CsA treatment. This was confirmed in a 
study showing sustained IFN-y production by CsA-treated NK cell cultures upon IL-12 and IL-18 
stimulation35, suggesting that IFN-Y-mediated GVL reactivity after allogeneic SCT should remain 
intact when using CsA as GVHD prophylaxis.
Our findings on the effect of CsA and MPA on the cytolytic response by in vitro cytokine-stimulated 
NK cells are in concert with previous findings on this subject.36 Besides CsA and MPA, they also 
evaluated the effect of tacrolimus (TAC) and methotrexate (MTX), which are also successfully 
used as GVHD prophylaxis after allogeneic SCT.31;37;38 Both ISDs did not interfere with NK cell- 
mediated cytolytic activity against different leukemic cell lines. However, a dose range of each 
ISD is lacking in this study, which would be more appropriate when studying the effect of ISDs 
on NK cell functionality.
Overall, these in vitro studies clearly suggest that the choice of immunosuppressive treatment 
might affect the outcome of NK cell therapy in vivo after transplantation. Additional studies on NK 
cell phenotype and function of patients after allogeneic SCT using different immunosuppressive 
strategies are warranted to survey the in vivo effect of the different immunosuppressive regimens 
in more detail.
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7.3 C lin ica l g ra d e  N K  ce ll p ro d u c ts  fo r  a d o p tive  ca n ce r im m u n o th e ra p y
7.3.1 Development of clinical grade NK cell products
The facilitation of donor NK cell alloreactivity is not restricted to HLA-matched/mismatched 
allogeneic SCT, but may also be exploited for adoptive immunotherapy in non-transplantation 
settings. Previously, several clinical studies have examined the feasibility of allogeneic NK cells 
for adoptive immunotherapy using allogeneic NK cells selected from leukapheresis products 
by immunomagnetic beads selection protocols.39-44 In all these studies, the adoptive transfer of 
allogeneic NK cells proved to be safe and well tolerated by patients. Nevertheless, for optimal 
exploitation of NK cell adoptive immunotherapy, the development of innovative strategies 
producing allogeneic NK cell products with high cell numbers, high purity and functionality are 
needed. In this respect, recent studies have developed culture systems for large scale ex vivo 
expansion of allogeneic NK cells using either hematopoietic progenitor cells from bone marrow 
or UCB.45-47 However, most of these culture systems are unsuitable for clinical application due to 
the use of animal sera, animal-derived proteins, and/or supportive feeder cells.
In chapter 5, we developed a cytokine-based method for high log-scale ex vivo expansion of 
functional allogeneic NK cells from hematopoietic stem and progenitor cells from umbilical cord 
blood (UCB) using a novel clinical grade medium. The ex vivo-generated NK cell products are 
of high purity and contain developmentally mature NK cell populations expressing inhibitory 
NKG2A and KIRs, and a variety of stimulatory receptors. Furthermore, these NK cell products 
show the ability to efficiently kill myeloid leukemia and melanoma tumor cell lines. The findings in 
this study provide an important advance for the clinical application of ex vivo-generated NK cell 
products to be exploited for adoptive immunotherapy either following allogeneic SCT for boosting 
NK cell-mediated GVL reactivity or in the non-transplant setting following lymphodepleting 
immunosuppressive regimens. In addition, human in vitro studies and in vivo evidence in mice 
suggest that NK cell-based immunotherapy may also be beneficial for patients with melanoma or 
renal cell carcinoma when applied in the in the setting of the “receptor-ligand” model.48-50 Overall, 
further exploitation of this culture system may provide a broad clinical application for NK cell- 
based immunotherapy against hematological and non-hematological malignancies.
7.3.2 Clinical feasibility o f ex vivo-generated NK cells: a phase I trial
Recently, the NK cell generation protocol, described in chapter 5, was transferred to clinical 
applicable conditions and medical ethical approval was given to study the feasibility of adoptive 
transfer of ex vivo-generated NK cell products in elderly patients diagnosed with poor prognosis 
AML. In the second quartile of 2011, a phase I dose-escalating study will start for a group of 12 AML 
patients (age >65 years), not eligible for allogeneic SCT, who have achieved clinical remission 
after standard remission-induction chemotherapy and who have completed consolidation 
chemotherapy. Patients will receive allogeneic NK cells generated ex vivo from CD34+ UCB cells 
in a single escalating dose up to 10x107 donor NK cells/kg body weight after completing standard 
chemotherapy and preparative immunosuppressive conditioning consisting of fludarabine and 
cyclophosphamide in order to prevent rejection. The primary goal is to evaluate the safety and
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dose-limiting toxicity of adoptive transfer of the allogeneic ex vivo-generated NK cells. Secondly, 
the in vivo lifespan of the adoptively transferred allogeneic NK cells will be evaluated together 
with an assessment of NK cell-mediated GVL reactivity in study participants.
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7.4 M on ito r in g  N K  ce ll deve lopm en t
To exploit NK cells for immunotherapy, a better understanding of human NK cell development 
in vivo is essential. Freud et al.5152 were the first to define distinct NK cell developmental stages 
in secondary lymphoid tissues (SLT) based on expression profiles of CD34, CD117, CD94 and 
CD5, and provided evidence that supported a model of in vivo human NK cell development in 
which CD34+ NK cell precursors traffic from BM to SLT where further differentiation into mature 
CD56bright NK cells can take place. We (chapter 2) and others have shown that CD56bright cells 
are also the first mature NK cells to arise after allogeneic SCT followed by further differentiation 
towards CD56dim NK cells.53 However, the specific route of NK cell development and how the 
distinct NK cell developmental stages in SLT correlate with the different NK cell subsets found 
in other compartments of the human body (e.g. peripheral blood (PB), spleen (SPL)) remains 
unclear.
In chapter 6, we identified seven distinctive NK cell developmental stages in bone marrow using 
newly developed 10-color flow cytometry panels. We are the first to find that NK cell development 
is accompanied by early expression of CD244 in vivo, which is an important stimulatory co­
receptor. Furthermore, distinctive expression profiles of early development antigen CD33 and 
NKG2A between liver lymph nodes (LN) and inguinal LN, suggest that differential in situ NK cell 
differentiation may take place in common tissues. Overall, the results of this study support a 
model of in vivo human NK cell development indicating BM as the origin of NK cell development. 
Commitment to the NK cell lineage takes place in LN followed by in situ differentiation and 
maturation of NK cells (CD56bright) with restricted maturation of the NK cell receptor repertoire. 
Further differentiation of committed NK cells may take place in SPL (CD56bright towards CD56dim) 
followed by trafficking towards the periphery and other anatomical locations of the human body. 
In contrast to previous NK cell development studies51;52, we were able to study small sample 
sizes of tissues obtained from single donors with the use of 10-color flow cytometry. Given the 
biological variation within human tissues, this creates an improved and more reliable view on 
human NK cell development within the different locations of the human body. However, further 
functional analyses of committed NK cells within the different NK cell developmental stages and 
trafficking studies exploring chemokine and cytokine profiles are warranted to obtain a complete 
view on the human NK cell developmental pathway. In addition, the use of 10-color flow 
cytometry should be further exploited for these purposes and may also serve as an important 
monitoring tool of human NK cell development and functionality in vivo after allogeneic SCT or 
after adoptive NK cell-based immunotherapy.
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7.5 Tow ards N K  ce ll im m uno the rapy
Within the last decade, different NK cell-based immunotherapy strategies have successfully 
been developed. They have either already been proved safe in clinical phase I/II trials or 
are currently under clinical evaluation. Today, applications for NK cell-based immunotherapy 
can generally be divided into three main categories: (1) the use of enriched NK cell grafts for 
allogeneic SCT; (2) administering NK-DLI after allogeneic SCT and; (3) adoptive NK cell transfer 
in non-transplantation settings (Figure 1).
Transplantation setting
Figure 1. A pplications fo r NK cell-based immunotherapy. In the allogeneic SCT setting, patients are first treated 
with a conditioning regimen to eradicate healthy hematopoietic recipient cells and to minimize the tumor burden 
within the recipient. Subsequently, enriched NK cell grafts (1) and/or NK-DLI (2) may be applied in the further course 
of allogeneic SCT in order to facilitate alloreactive donor NK cell-mediated GVL reactivity. In the non-transplant set­
ting (e.g. patients no longer eligible for allogeneic SCT or with solid tumors), adoptive NK cell transfer can be used 
as a NK cell-based immunotherapeutic strategy in patients after completing standard chemotherapy and preparative 
immunosuppressive conditioning in order to prevent rejection.
7.5.1 Allogeneic SCT setting
The use of enriched NK cell grafts for allogeneic SCT has shown to be beneficial for transplant 
outcome and provides enhanced GVL reactivity directly after transplantation as compared with 
conventional grafts that lack NK cells.11;15;chapler 2 In addition, the head start in GVL reactivity 
may lead to better outcomes in terms of infectious events and overall survival after allogeneic 
SCT.14 Altogether, this indicates the immunotherapeutic value of the exploitation of donor NK 
cells in the allogeneic SCT setting. In order to further increase the beneficial effects of such 
NK cell-based immunotherapy strategies in the setting of allogeneic SCT, donor NK cells can 
also be administered as part of the conditioning regimen prior to transplantation instead of, or 
in combination with, the use of enriched NK cell grafts. This can have three potential beneficial 
effects. First, NK cell-mediated GVL reactivity could provide anti-tumor activity prior to allogeneic
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SCT.6;54 Second, NK cell-mediated depletion of host dendritic cells before transplantation could X  
prevent the development of acute GVHD allowing for a less stringent depletion of T cells in pp 
the graft.6;54 Third, NK cells may facilitate better engraftment through eradication of host T cells, 
thereby reducing the need for toxic myeloablative regimens and shortening the neutropenic ^  
period.6 However, to be able to implement the combinatorial strategy of NK cell infusions as 
part of the conditioning regimen together with the use of enriched NK cell grafts in the clinic, the 
necessary amount of NK cells used for infusion prior to allogeneic SCT to provoke beneficial 
immunotherapeutic effects still needs to be established. Insufficient numbers may cause the 
necessity to choose between the use of NK cell infusions as part of the conditioning regimen and 
the use of enriched NK cell grafts. In this respect, also in case of the combinatorial strategy, it is 
important that more research is performed on the effects of conditioning and immunosuppressive 
regimens on NK cells in exploiting NK cell-mediated (GVL) reactivity in the allogeneic SCT setting.
The use donor T cells for DLI after allogeneic SCT has developed into an effective treatment of 
recurrent hematological malignancy as well as prophylactic treatment in high-risk leukemia and 
lymphoma.55 Still, the main risk of T-DLI is the induction of life-threatening GVHD. To minimize 
the risk of GVHD, studies have been initiated to modify conventional DLI by using donor NK cells 
instead of donor T cells.41;56 Additionally, the administration of NK-DLI may facilitate engraftment 
and induce NK cell-mediated GVL reactivity.41;56 Although no firm conclusions can be drawn 
on the clinical efficacy of NK-DLI after allogeneic SCT at this point, data indicate that NK-DLI 
is safe and well tolerated, and can generate GVL reactivity and long-term remission in some 
patients after leukemia relapse. As non-malignant tissues generally do not overexpress ligands 
for activating NK cell receptors, NK-DLI should not cause GVHD.5758 Until now, NK-DLI has been 
tested in the haploidentical SCT setting. Thus, further research on the efficacy of NK-DLI in the 
HLA-matched SCT setting is warranted.
7.5.2 Non-transplant settings
In non-transplant settings, donor NK cells can be exploited for immunotherapeutic strategies 
for the treatment of hematological and non-hematological malignancies. Previously, Miller et 
al.59 showed that haploidentical donor NK cell infusions after high-dose cyclophosphamide and 
fludarabine treatment resulted in long-term survival and in vivo expansion of donor NK cells in 
patients with metastatic melanoma (n=10), metastatic renal cell carcinoma (n=13), refractory 
non-Hodgkin's disease (n=1), and poor-prognosis AML (n=19). The in vivo NK cell expansion 
was associated with an increased levels of endogenous IL-15, which were possibly responsible 
for driving the survival and proliferation of donor NK cells. In general, the donor NK cell infusions 
were well tolerated without evidence for the induction of GVHD. Furthermore, 5 out of 19 
patients with poor-prognosis AML achieved complete remission. Only 4 of the 19 AML patients 
were KIR-ligand (HLA) mismatched in the graft-versus-host direction. Interestingly, out of these 
4 patients, 3 achieved complete remission. These findings indicate that haploidentical donor NK 
cells can persist and expand in vivo and may have a role in the treatment of (non-)hematological 
malignancies in non-transplant settings or in combination with allogeneic SCT. In addition, when
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using haploidentical donors the choice of a KIR-ligand mismatched donor, based on the “ligand­
ligand” model, may be needed to obtain successful results in future clinical trials.59 In case of 
HLA-matched donors, the choice of a “receptor-ligand” mismatched donor is preferred.
In parallel, adoptive transfers are currently also being performed with the NK cell line NK-92. 
This cell line can be cultured under good manufacturing practice (GMP) conditions and shows 
significant cytotoxicity against several tumor cell lines.60 Infusions of NK-92 cells have been 
administered to more than 20 patients with advanced renal-cell carcinoma and malignant 
melanoma. This proved to be safe and generated antitumor effects in some cases.61 Furthermore, 
NK-92 cells can easily be obtained in high numbers during GMP culture providing sufficient 
amounts of cells for adoptive immunotherapeutic strategies. An obvious drawback of relying on 
a cell line for adoptive immunotherapy is that it may only be successful for certain malignancies 
or patient groups. Thus, recent studies have developed culture systems for large scale ex vivo 
expansion of allogeneic donor NK cells using either hematopoietic progenitor cells from bone 
marrow or UCB.45-47;chapler 5 As mentioned above, our culture system is now being transferred to 
GMP conditions and will be tested in a clinical phase I trial in the near future.
7.5.3 Crucial issues for NK cell-based immunotherapy
Several issues remain crucial for the development and implementation of successful NK cell- 
based immunotherapy in the future. In the non-transplant setting , these include issues relating 
to the type of NK cell preparation to be used (activation, degree of enrichment and possible 
selection or skewing of specific subpopulations), criteria for donor selection (“ligand-ligand” 
versus “receptor-ligand” model, KIR genotyping and phenotyping, and size of the alloreactive 
subset), conditioning of patients prior to immunotherapy, clinical context of therapy, and criteria 
for patient selection and strategies for the identification of susceptible tumors within patient 
groups. Besides these issues, the effects of immunosuppressive regimens given after allogeneic 
SCT are also important when implementing NK cell-based immunotherapy in the setting of 
allogeneic SCT.
The research described in this thesis focused on the facilitation of alloreactive donor NK cells 
in HLA-matched allogeneic SCT and elaborated on potential skewing of NK cell alloreactivity 
towards specific malignant cells. Furthermore, we gave more insight on potential side-effects 
of immunosuppressive regimens and contributed to the development of a clinical grade NK cell 
product, which is to be evaluated within the clinic in the near future. The 10-color flow cytometry 
panels that we developed for our research provided better insight in human NK cell development 
in vivo and may serve as an important and valuable NK cell analysis/monitoring tool for future 
studies. Altogether, the research described in this thesis contributes to the exploitation of 
allogeneic NK cells towards NK cell immunotherapy for the treatment hematological and non- 
hematological malignancies.
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A llogene  s ta m ce ltra n sp la n ta tie
Allogene (niet lichaamseigen) stamceltransplantatie (SCT) is vaak de laatste stap in het 
behandeltraject voor patiënten met hematologische aandoeningen zoals leukemie. Het is een 
intensieve en zware behandelmethode met als doel het ontspoorde hematopoïetische systeem 
van de patiënt te vervangen met hematopoïetische stamcellen van een donor. Na transplantatie 
nestelen donor stamcellen zich in het beenmerg van de patiënt (‘engraftment') en vormen 
ze de basis voor de ontwikkeling van een nieuw en gezond hematopoïetisch systeem. In het 
transplantaat bevinden zich naast donor stamcellen ook een kleine hoeveelheid volwassen 
witte bloedcellen van de donor, namelijk T-cellen. Deze cellen voorkomen afstoting van het 
transplantaat en bestrijden daarnaast de resterende tumorcellen van de patiënt na allogene 
SCT. Dit laatste wordt ook wel het ‘graft-versus-tumor' (GVT) of het ‘graft-versus-leukemia' (GVL) 
effect genoemd. Na allogene SCT kunnen deze alloreactieve T-cellen van de donor echter ook 
gezond weefsel van de patiënt aantasten, wat resulteert in acute ‘graft-versus-host disease' 
(GVHD). Ter voorkoming dat acute GVHD de overhand neemt en tot ernstige complicaties 
leidt, wordt de balans tussen GVHD en GVL-reactiviteit direct na transplantatie nauwkeurig 
onder controle gehouden door toediening van immunosuppressieve medicijnen. Wanneer 
‘engraftment' van de donor stamcellen in de patiënt heeft plaatsgevonden en zich geen ernstige 
GVHD heeft voorgedaan, worden de hoeveelheden immunosuppressiva langzaam afgebouwd. 
Om de kans op terugkeer van de ziekte (‘relapse') te verkleinen kan de patiënt vervolgens 
behandeld worden met een donor lymfocyten infuus (DLI). Dit infuus bevat T-cellen van dezelfde 
donor en dient als een extra ‘boost' aan GVL-reactiviteit. Deze additionele behandeling brengt 
echter een verhoogd risico op de ontwikkeling van GVHD met zich mee.
GVHD ve rsus  GVL
Om de kans op GVHD zo gering mogelijk te houden is het van essentieel belang dat het 
weefseltype (HLA klasse I en klasse II: ‘humane leukocyten antigenen type I en type II') van de 
donor niet teveel afwijkt van die van de patiënt. Wanneer in de familie geen passende donor 
gevonden is, kan eventueel een niet-verwante donor met de juiste HLA-typering gevonden 
worden. Wereldwijd zijn databases van mogelijke stamceldonoren met hun HLA-typering 
beschikbaar, waarin gezocht kan worden naar een potentieel geschikte donor.
Hoewel het zoveel mogelijk ‘matchen' van HLA het risico op GVHD behoorlijk reduceert, is de 
ontwikkeling van GVHD na allogene SCT niet uitgesloten. Medisch onderzoek richt zich dan ook 
op de ontwikkeling van nieuwe ‘immunotherapeutische' behandelmethoden die vanuit zichzelf 
voldoende GVL-reactiviteit teweeg brengen zonder overmatige inductie (of zelfs reductie) van 
GVHD. In dit kader heeft het gebruik van natural killer (NK) cellen grote interesse gekregen.
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NK-cellen zijn witte bloedcellen die tumorcellen en virusgeïnfecteerde cellen bestrijden. Direct 
na allogene SCT maken NK-cellen deel uit van de eerste defensielinie tegen opportunistische 
infecties en zijn ze, in tegenstelling tot T-cellen, middels een ‘license to kill' in staat om 
tumorcellen te bestrijden zonder voorafgaande sensitisatie. NK-cellen scannen andere cellen op 
de aanwezigheid van HLA klasse I met behulp van ‘killer immunoglobulin-like' receptoren (KIR), 
die zich op het oppervlak van hun celmembraan bevinden. Indien deze herkenning tussen NK- 
cel en potentiële ‘targetcel' niet of niet voldoende plaatsvindt, doordat de NK-cel het HLA klasse 
I als lichaamsvreemd herkent of door verminderde aanwezigheid van het HLA klasse I, kunnen 
activerende eiwitten (aanwezig op het celmembraan van de targetcel) de NK-cel stimuleren tot 
het lyseren van de targetcel. In vergelijking met gezonde lichaamscellen hebben tumorcellen 
en virusgeïnfecteerde cellen vaak een verminderde expressie van HLA klasse I en een hogere 
expressie van activerende eiwitten. Op deze manier kunnen donor NK-cellen na allogene SCT 
onderscheid maken tussen de tumorcellen en gezonde lichaamscellen van de patiënt en dus 
GVL-reactiviteit teweeg brengen zonder inductie van GVHD.
Het uitbuiten van NK-cel gemedieërde GVL-reactiviteit binnen allogene SCT is de focus van
dit proefschrift. In hoofdstuk 1 wordt een algemene inleiding gegeven over allogene SCT en
de mogelijke toepassing van donor NK-cellen in het bewerkstelligen van GVL-reactiviteit in
afwezigheid van GVHD.
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In hoofdstuk 2 wordt het effect van ‘NK-cel rijke' stamceltransplantaten vergeleken met het 
effect van conventionele stamceltransplantaten, die geen NK-cellen bevatten, op de repopulatie 
en de GVL-reactiviteit van donor NK-cellen na allogene SCT. Wanneer donor NK-cellen worden 
meegegeven met het stamceltransplantaat vindt direct na allogene SCT een snelle repopulatie 
van deze NK-cellen plaats met vroege GVL-reactiviteit in vergelijking met conventionele 
stamceltransplantaten. Tevens lijkt het gebruik van ‘NK-cel rijke' stamceltransplantaten tot een 
meer geactiveerde NK-cel populatie te leiden, wat een gunstig effect kan hebben op de gehele 
GVL-reactiviteit na allogene SCT
Vervolgens wordt in hoofdstuk 3 beschreven dat NK-cel gemedieërde GVL-reactiviteit specifiek 
‘gestuurd' kan worden in de richting van tumorcellen. De totale NK-cel populatie kan op basis 
van expressie van verschillende KIR receptoren onderverdeeld worden in verschillende 
subpopulaties. De NK-cel subpopulaties zullen afhankelijk van de herkenning tussen de 
specifieke KIR receptoren op NK-cellen en specifieke HLA klasse I eiwitten op de tumorcellen 
wel of geen GVL-reactiviteit vertonen. Door de gehele donor NK-cel populatie gedurende korte 
tijd te kweken in aanwezigheid van specifieke HLA klasse I+ tumorcellen vindt er binnen de 
totale NK-cel populatie een toename plaats van specifieke KIR+ NK-cellen die het HLA klasse 
I op deze tumorcellen niet herkennen. Naast de toename van deze specifieke KIR+ NK-cellen
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zijn deze NK-cellen ook reactiever tegen tumorcellen met dezelfde specifieke HLA klasse I+ 
expressie waarmee ze gekweekt zijn in vergelijking met ‘controle' NK-cellen (specifieke KIR+ 
NK-cellen die niet gekweekt zijn of die gekweekt zijn in afwezigheid van de specifieke HLA 
klasse I+ tumorcellen). De resultaten van dit onderzoek geven aan dat de gehele donor NK- 
cel populatie specifieker gericht kan worden tegen tumorcellen van de patiënt. Dit kan worden 
gebruikt in de verdere ontwikkeling van specifieke NK-cel immunotherapie.
Voor de toepassing van NK-cel immunotherapie in de setting van allogene SCT is het belangrijk 
dat NK-cellen hun GVL-reactiviteit behouden onder druk van de immunosuppressieve 
medicijnen die na allogene SCT worden toegediend aan de patiënt. Hoofdstuk 4 beschrijft de 
invloed van verschillende immunosuppressiva, die veelal gebruikt worden na allogene SCT, op 
het functioneren van donor NK-cellen. Uit de resultaten van deze studie blijkt dat het gebruik 
van mycofenolaat (MPA; het actieve derivaat van mycofenolaat mofetil (MMF)) en rapamycine 
(Rapa) de activatie van donor NK-cellen remt, wat resulteert in een verminderde GVL-reactiviteit. 
Dit in tegenstelling tot het gebruik van cyclosporine A (CsA), dat geen effect lijkt te hebben op de 
activatie en GVL-reactiviteit van donor NK-cellen. Voor het succes van NK-cel immunotherapie 
in de setting van allogene SCT is een zorgvuldige keuze uit de beschikbare immunosuppressiva 
dan ook van essentieel belang voor zover de situatie binnen de kliniek dit toestaat.
O n tw ikke ling  van k lin ische  N K -ce l p roducten
In hoofdstuk 5 wordt de ontwikkeling van een immunotherapeutisch NK-cel product beschreven. 
In deze studie wordt aangetoond dat ruime hoeveelheden donor NK-cellen met GVL-reactiviteit 
ontwikkeld kunnen worden vanuit hematopoïetische stamcellen uit navelstrengbloed. In een 
eerste kweekfase zorgt een cocktail van signaalstoffen voor de toename (‘expansie') van het 
beperkte aantal donor stamcellen dat in het navelstrengbloed aanwezig is. Vervolgens worden 
de geëxpandeerde stamcellen door een andere cocktail van signaalstoffen in een tweede 
kweekfase ‘gedwongen' om zich verder te ontwikkelen tot NK-cellen, welke een sterke GVL- 
reactiviteit vertonen richting diverse tumorcellijnen en primaire tumoren. Dit proces van het 
vermeerderen en uitrijpen van hematopoïetische stamcellen tot NK-cellen met voldoende 
GVL-reactiviteit is een belangrijke stap in het toegankelijk maken van NK-cel immunotherapie. 
De op deze wijze gegenereerde NK-cel producten zijn niet alleen veelbelovend voor klinische 
toepassingen binnen de setting van allogene SCT, maar zouden ook toegepast kunnen worden 
als ‘stand alone' immunotherapie voor patiënten die niet (meer) in aanmerking komen voor 
allogene SCT.
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Voor de ontwikkeling en toepassing van NK-cel immunotherapie is voldoende kennis van de 
normale NK-cel ontwikkeling in het menselijk lichaam noodzakelijk. Eerder onderzoek heeft 
laten zien dat NK-cel ontwikkeling onderverdeeld kan worden in vijf stadia. Tot nu toe zijn 
deze stadia echter alleen in humane secundaire lymfeknopen aangetoond op basis van de 
detectie van 4 verschillende antigenen (4-kleuren fluorescentieanalyse). In hoofdstuk 6 zijn 
de NK-cel ontwikkelingsstadia met behulp van 10-kleuren fluorescentieanalyse in meerdere 
humane (lymfoïde) weefsels geanalyseerd. Resultaten van deze studie tonen aan dat de 
NK-cel ontwikkeling onderverdeeld kan worden in acht verschillende stadia. De verspreiding 
van deze NK-cel ontwikkelingsstadia ondersteunen een NK-cel ontwikkelingsmodel dat start 
in het beenmerg, waarna voorlopercellen zich tot onvolwassen NK-cellen ontwikkelen in de 
lymfeknopen. Na deze gedeeltelijke NK-cel rijping differentiëren de onvolwassen NK-cellen zich 
verder in de milt en vindt via het perifere bloed verspreiding plaats van de verschillende typen 
volwassen NK-cellen. In de afzonderlijke weefsels zijn tevens weefselspecifieke NK-cel typen te 
zien. Dit toont aan dat humane weefsels niet alleen ruimte bieden aan NK-cellen in verschillende 
ontwikkelingsstadia die op doorreis zijn naar het volgende weefsel, maar ook dat NK-cellen 
weefselspecifieke differentiatie kunnen ondergaan zonder verdere verspreiding naar andere 
weefsels. Deze combinatie van factoren verklaart de grote hoeveelheid aan verschillende typen 
NK-cellen, die aanwezig zijn in het menselijke lichaam.
De hierboven beschreven resultaten leveren een belangrijke bijdrage aan het NK-cel 
ontwikkelingsvraagstuk. Tevens vormt de binnen deze studie ontwikkelde 10-kleuren 
fluorescentieanalyse een waardevol analyse-instrument voor het monitoren van alloreactieve 
donor NK-cellen en de verdere ontwikkeling van NK-cel immunotherapie.
N K -ce l im m uno the rap ie
In hoofdstuk 7 wordt tot slot een algemene beschouwing gegeven over de verschillende 
onderwerpen die in dit proefschrift beschreven staan. In de laatste vijf jaren zijn internationaal 
verschillende strategieën voor de toepassing van alloreactive donor NK-cellen succesvol 
ontwikkeld. Deze strategieën zijn inmiddels succesvol toegepast in klinische trials of staan 
op het punt om klinisch geëvalueerd te worden. Momenteel wordt NK-cel immunotherapie 
toegepast in drie verschillende en onderling te combineren strategieën: 1) als onderdeel van het 
stamceltransplantaat; 2) als donor NK-DLI in plaats van donor T-DLI na allogene SCT; en 3) als 
‘stand alone' NK-cel immunotherapie, los van allogene SCT. Het in dit proefschrift beschreven 
onderzoek draagt bij aan de ontwikkeling van deze strategieën en aan de succesvolle toepassing 
van NK-cel immunotherapie voor de behandeling van kanker.
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Dankwoord
Na al het andere geschreven te hebben, is het nu dan toch echt tijd voor het laatste en 
waarschijnlijk meest gelezen gedeelte van dit boekje: het dankwoord! Met als kleine toevoeging 
dat de rest van het boekje ook de moeite waard is om te lezen...
Op de eerste plaats wil ik graag iedereen bedanken die direct dan wel indirect hebben bijgedragen 
aan het tot stand komen van dit proefschrift. Een aantal mensen wil ik in het bijzonder bedanken:
Mijn promotor en copromotor: prof. dr. Irma Joosten en dr. Arnold van de Meer. Irma en 
Arnold, dank jullie wel voor jullie vertrouwen en steun gedurende deze periode. De prettige en 
constructieve samenwerking tijdens de snelle eindsprint van dit manuscript is hierbij memorabel 
te noemen! Irma, jouw nuchtere kijk op het geheel hield me met beide benen op de grond en 
op belangrijke momenten wist je de zaken feilloos in perspectief te plaatsen. Arnold, het zal 
niet altijd makkelijk zijn geweest om mij als promovenda te begeleiden in combinatie met de 
opleiding tot medisch immunoloog, maar beiden zijn tot een goed einde gebracht. Bedankt voor 
je altijd optimistische blik en bemoedigende woorden wanneer ik weer eens donderwolken zag 
naderen.
Een woord van dank aan mijn paranimfen: Bram van Cranenbroek en Jorieke Peters. Bram, 
vanaf de eerste dag ben jij mijn rechterhand op het lab geweest en vormden we samen een 
goed team. Het spreekwoord ‘met iemand kunnen lezen en schrijven' is bij jou zeker van 
toepassing. Ik ben je erg dankbaar voor je enorme inzet en betrokkenheid bij dit project en voor 
je vriendschap. Jorieke, mijn medepromovenda vanaf het eerste uur. We hebben de afgelopen 
jaren mooie (aio-)momenten, maar ook minder leuke (aio-)momenten, met elkaar gedeeld (wat 
kunnen de ‘PhD comics' toch altijd de spijker op hun kop doen slaan!) en door de jaren heen heb 
je altijd voor me klaar gestaan. We zijn dan wel niet zo goed in het ‘samen visjes houden', maar 
ik hoop dat onze vriendschap vrolijk doorzwemt. Ik wens je heel veel succes met het afronden 
van jouw promotie!
Mijn (oud) collega's van het kweeklab: Jorieke, Bram, Esther F., Esther v. R., Ronald, Jos, 
Marina, Elena, Sip, Claire, Xuehui, Vivian, Hans, Jeroen, Ellen (en Kjeld, ook al ben je meer van 
het DNA...). Dank jullie wel voor de warme gezelligheid, waaronder ook de ‘vrijdagochtendpraat' 
(soms al op de maandag), tijdens en/of naast het werk.
De studenten die ik heb mogen begeleiden tijdens mijn promotieonderzoek: Wouter de Munter 
en Talia Latuhihin. Wouter, de resultaten van jouw werk aan de ‘CFSE tox' hebben bijgedragen 
aan de basis voor andere functionele testen in dit proefschrift. Talia, de resultaten van jouw 
onderzoek aan immunosuppressiva hebben de basis gevormd voor één van de publicaties 
beschreven in dit proefschrift. Dank jullie wel voor jullie inzet.
Dankwoord
CHAPTER 
8
Ook wil ik graag alle (oud) collega’s van het LMI (voormalig ABTI) bedanken voor hun bijdrage 
aan een goede tijd en voor de ondersteuning bij dit proefschrift. Het DNA lab wil ik bedanken 
voor het uitvoeren van de vele KIR en DNA typeringen, die gedaan zijn voor hoofdstuk 2 en 3. 
Graag wil ik van het DNA lab in het bijzonder Sylvie en Kjeld bedanken voor hun ondersteuning 
tijdens het ontwikkelen van de transfectanten voor hoofdstuk 3. Willy en Bep, bedankt voor het 
aanmelden van al die buffycoats! Chris, ontzettend bedankt voor je hulp bij bestellingen en de 
soms nodige ‘troubleshooting’ daarbij (‘51Cr’ doet je vast wel een vaag belletje rinkelen.). 
André, zonder jouw IT hulp zou de inhoud van dit proefschrift een heel stuk lastiger op papier 
verschenen zijn: mijn dank is groot!
Collega’s van de BMT unit van het laboratorium Hematologie (LH, voormalig CHL) wil ik graag 
bedanken voor hun enorme inzet bij het opwerken en opslaan van alle patiëntensamples, die 
beschreven staan in hoofdstuk 2. Jos, Carel, Bennie, Marianne, Eugenie en Sandra: bedankt! 
Frank en Paul, dank voor de coördinatie van het geheel.
Daarnaast wil ik graag de collega’s van de FCM unit van het LH bedanken voor de gezellige 
momenten tijdens de vele analyses op de XLA en FC500. In het bijzonder wil ik graag Eugenie, 
Marij, Bijan, Erik en Edith bedanken voor hun bijdrage aan de FCM analyses voor hoofdstuk
2. Rob en Jeroen, bedankt voor alle ‘sorts’ die jullie hebben uitgevoerd voor hoofdstuk 3 en 4.
Graag wil ik alle medeauteurs, die in dit proefschrift staan, bedanken voor de goede samenwerking 
en uitwisseling van kennis. Jan, ik wens jou en alle andere betrokken collega’s heel veel succes 
met de aankomende klinische studie en met het verdere NK-cel onderzoek. Frank, bedankt voor 
je support. Harry, je was er als mijn mentor op het juiste moment.
Ik wil ook alle stamceltransplantatie patiënten en donoren bedanken. Uw medewerking aan dit 
onderzoek is van essentieel belang geweest.
Tijdens het promoveren zijn goede vrienden minstens zo belangrijk als de collega’s op het werk. 
Graag wil ik dan ook alle vrienden bedanken voor hun vriendschap en steun.
Martijn, Nicole, Rob, Linda, Johan, Josien, Maarten, Ellis, Ronald, Nathalja, Peter en Marloes; ik 
kom dan wel niet uit Limburg en de taalcursus van Ronald staat nog steeds op het programma, 
maar het is altijd goed als we elkaar zien en jullie vriendschap is mij heel dierbaar. Dank jullie 
wel voor de interesse in mijn werk en voor de vele gezellige momenten, maar ook jullie support, 
de laatste jaren. Linda, je hebt me ongelooflijk veel werk uit handen genomen met het design en 
de lay-out van dit boekje: ontzettend bedankt!
Dankwoord
Lieve “Bioloogjes”: de weekendjes weg, de stapavondjes in Utrecht, een etentje hier of daar, 
of gewoon een leuke middag op het water, we hebben al meer dan tien jaar lol met z’n allen. 
Thanks! Remko, Frank, Mijntje en Michiel: ik kijk met plezier terug naar de gezellige (kerst) 
avondjes bij elkaar in het Utrechtse en de sportieve uurtjes op de squashbaan. Daarnaast staan 
jullie altijd klaar voor Peter en mij, ook als het wat minder gaat, dank jullie wel. Chantal: of we 
nu samen bij jou in Nijmegen zijn of bij ons in Utrecht, beiden voelen als thuis en zelfs op lange 
afstand is onze vriendschap altijd heel dichtbij, dank je wel voor wie je bent. Ik wens je heel veel 
succes met de laatste loodjes van je eigen boekje: je weet ons te vinden hè?! Saskia: bij onze 
eerste ontmoeting konden we meteen goed praten en lachen samen. Dit, en onze liefde voor 
lekker eten, vormt de basis van onze dierbare vriendschap.
Mijn oud studiegenootjes, Shakti, Jeroen (“Jef”), Paula, Eva, Suzanne, Jurgen, Jessica, Jeroen 
(“Jack”), Iris, Sylvia en alle anderen, oftewel de “Biotechnologen”: na de studie zijn we verspreid 
over ’t land gaan wonen en werken, maar als we elkaar zien dan is het altijd goed. Het jaarlijkse 
weekendje in de Ardennen is daarbij inmiddels een mooie en gezellige “traditie” geworden en het 
is heerlijk om dan weer bij te praten of gewoon lekker oude studieverhalen op te halen. Shakti, 
Paula en Eva: de etentjes samen zijn altijd erg gezellig en wat is het fijn om onze aioverhalen 
met zoveel herkenning samen te kunnen delen (Shakti, als niet-aio ga je hier altijd goed in 
mee!). Bedankt allemaal voor jullie vriendschap en support. En voor degenen die nog gaan 
promoveren: heel veel succes met de afronding van je eigen boekje.
David Faustin: Beste David, het Aruba avontuur is voor mijn ouders helaas anders afgelopen 
als we gedacht hadden, maar we hebben er een waardevolle vriend aan over gehouden. Uit het 
niets stond je voor ons klaar. Dank je wel! Ook voor je enorme hulp met onze thuiscomputer, 
waar een groot gedeelte van dit proefschrift op geschreven is.
Graag wil ik iedereen binnen onze beiden families bedanken voor alle steun, liefde, vriendschap 
en gezelligheid. Jullie zijn mij allemaal heel erg dierbaar. Lieve Jan en Nel, jullie hebben mij in 
Limburg een tweede thuis gegeven. Ik ben heel erg blij met jullie als mijn schoonouders, het is 
altijd heerlijk thuiskomen bij jullie. Heidy, je staat altijd voor ons klaar met een glimlach.
Ome Geert en tante Marolien: Dank jullie wel voor jullie warmte en gastvrijheid of het nu in 
Meijel is of in Servië op “the hill”. Gerard, het is een genot om de een-tweetjes met je broer te 
aanschouwen. Ik hoop dat we met de gehele familie samen nog veel mogen genieten van het 
goede leven!
Lieve Frans en Annemiek, voor Peter en mij zijn jullie uitgegroeid tot een extra paar ouders. Bij 
jullie staat de deur altijd open voor een goed gesprek of gewoon een gezellig avondje, waarbij we 
lekker tafelen. Dank jullie wel voor jullie warmte en steun de afgelopen jaren.
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Patrick en Axel, mijn ‘kleine' broertjes, jullie zijn in mijn leven altijd erg belangrijk voor mij geweest 
en dit zullen jullie ook altijd blijven. Johanne en Sanne, ik ben blij dat jullie deze twee gelukkig 
maken.
Pap en mam, alles wat ik ben en alles wat ik doe heb ik aan jullie onvoorwaardelijke liefde en 
steun te danken. Dank jullie wel voor jullie rotsvaste vertrouwen in mij en voor de vrijheid om 
datgene te doen waar ik zelf voor wil gaan (al is het dan meestal niet de makkelijkste weg om te 
bewandelen). Ik hoop dat we met z’n allen nog heel lang van elkaar mogen genieten.
Lieve Peter, samen vormen we ons eigen thuis en één blik naar elkaar zegt vaak meer dan vele 
woorden kunnen uitdrukken. Met deze paar simpele, maar allesomvattende, woorden snap je 
dan ook precies wat ik je eigenlijk allemaal wil zeggen: Ik hou van je!
Tokyo, maart 2011
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